СТАБИЛЬНЫЕ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ

Изобретение относится к области медицины и фармацевтики, а именно к фармацевтической композиции, содержащей по меньшей мере 95% этилэйкозапентаеноата (этил-EPA) от общего количества жирных кислот, присутствующих в композиции, заключенного в оболочку капсулы, содержащую желатин в количестве от 50% до 70% от массы неводных компонентов, но не содержащую химически модифицированный желатин, глицерин в количестве от 5% до 15% от массы неводных компонентов, сорбит в количестве от 15% до 25% от массы неводных компонентов, мальтит в количестве от 3% до 10% от массы неводных компонентов и очищенную воду. Технический результат заключается в ослаблении или предотвращении окисления этил-EPA в составе фармацевтической композиции, заключенной в оболочку капсулы по изобретению, в большей степени, чем это обеспечивает стандартная оболочка капсулы типа IIa. 12 з.п. ф-лы, 3 ил., 4 табл., 4 пр.

КОМПОЗИЦИИ НА ОСНОВЕ ЧАСТИЧНО ФТОРИРОВАННЫХ АЛКАНОВ, СОДЕРЖАЩИЕ ЭТИЛОВЫЕ ЭФИРЫ ОМЕГА-3 ЖИРНЫХ КИСЛОТ

Группа изобретений относиться к области медицины, а именно к офтальмологии, и предназначена для приготовления офтальмологического лекарственного средства. Стабильная жидкая офтальмологическая фармацевтическая композиция содержит a) по меньшей мере один этиловый эфир омега-3 жирной кислоты в общем количестве до 5 масс. % включительно от общей массы композиции; b) жидкий парафин в общем количестве до 1 масс. % включительно от общей массы композиции; где указанные по меньшей мере один этиловый эфир омега-3 жирной кислоты и жидкий парафин растворены в жидком носителе, содержащем частично фторированный алкан, выбранный из 1-перфторгексил-октана (F6H8) или 1-перфторбутил-пентана (F4H5). Указанный жидкий парафин представляет собой легкий жидкий парафин. Также представлено применение указанной композиции в качестве лекарственного средства. В другом воплощении обеспечивается набор, включающий контейнер, содержащий указанную офтальмологическую композицию, средство для дозирования и, необязательно ...

ПРОИЗВОДНЫЕ ИНГЕНОЛА ДЛЯ РЕАКТИВАЦИИ ЛАТЕНТНОГО ВИРУСА ВИЧ

Настоящее изобретение относится к применению некоторых производных ингенола в качестве реактиваторов латентного ВИЧ в вирусных резервуарах. В другом аспекте настоящее изобретение относится к комбинации, включающей указанные производные ингенола и антиретровирусные средства, которые проявляют значительную активность против активно реплицирующегося вируса. В частности, изобретение относится к применению одного или более производных ингенола формулы I в получении продукта для реактивации латентного вируса ВИЧ в вирусных резервуарах организма человека, где Z представляет собой Z1 или Z2так, что когда Z=Z1, x и y представляют собой целые числа, x варьирует от 2 до 10 и y варьирует от 2 до 7; и когда Z=Z2, А представляет собой фенил, CH- или CH=СН- и В представляет собой -СН=СН-, [-CH-]или [-CH-], где q представляет собой целое число в диапазоне от 1 до 10 и w представляет собой целое число в диапазоне от 1 до 10, при условии, что: если А представляет собой фенил, В представляет собой -СН=СН- ...

АЛЬФА-ЗАМЕЩЕННЫЕ ОМЕГА-3 ЛИПИДЫ, КОТОРЫЕ ЯВЛЯЮТСЯ АКТИВАТОРАМИ ИЛИ МОДУЛЯТОРАМИ РЕЦЕПТОРА, АКТИВИРУЕМОГО ПРОЛИФЕРАТОРАМИ ПЕРОКСИСОМ (PPAR)

Изобретение относится к новым омега-3 липидным соединениям общей формулы (I) или к их любой фармацевтически приемлемой соли, где в формуле (I): Rи Rявляются одинаковыми или разными и могут быть выбраны из группы заместителей, состоящей из атома водорода, гидроксигруппы, С-Салкильной группы, атома галогена, C-Салкоксигруппы, С-Салкилтиогруппы, С-Салкоксикарбонильной группы, карбоксигруппы, аминогруппы и С-Салкиламиногруппы; Х представляет собой карбоновую кислоту или ее карбоксилат, выбранный из этилкарбоксилата, метилкарбоксилата, н-пропилкарбоксилата, изопропилкарбоксилата, н-бутилкарбоксилата, втор-бутилкарбоксилата или н-гексилкарбоксилата, карбоновую кислоту в форме триглицерида, диглицерида, 1-моноглицерида или 2-моноглицерида, или карбоксамид, выбранный из первичного карбоксамида, N-метилкарбоксамида, N,N-диметилкарбоксамида, N-этилкарбоксамида или N,N-диэтилкарбоксамида; и Y является С-Салкеном с двумя или более двойными связями, имеющими Е- и/или Z-конфигурацию. Также описаны фармацевтические ...

СПОСОБ ИММУНОСТИМУЛЯЦИИ В ЭКСПЕРИМЕНТЕ

Изобретение относится к области медицине, а именно к иммунологии. Предлагаемые средства - СТЕАРОКС-920 и ОС-20 /неионогенные поверхностно-активные вещества/ позволяют стимулировать иммунную систему, супрессированную змеиными ядами или другими зоотоксинами. Это позволяет рекомендовать их как средства для корригирования показателей иммунного статуса лиц, подвергшихся укусам змей, каракурта, скорпиона и т.д.

СПОСОБ ПОЛУЧЕНИЯ МАСЛА, СОДЕРЖАЩЕГО АРАХИДОНОВУЮ КИСЛОТУ, НЕМОДИФИЦИРОВАННОЕ МИКРОБНОЕ МАСЛО, СПОСОБ ОБЕСПЕЧЕНИЯ АРАХИДОНОВОЙ КИСЛОТОЙ СМЕСИ ДЛЯ ДЕТСКОГО ПИТАНИЯ, КОСМЕТИЧЕСКАЯ КОМПОЗИЦИЯ, ПИТАНИЕ ИЛИ ПИТАТЕЛЬНАЯ ДОБАВКА, СПОСОБ ЛЕЧЕНИЯ ЛЮДЕЙ И СМЕСЬ ДЛЯ ДЕТСКОГО ПИТАНИЯ

Немодифицированное микробное масло, содержащее по крайней мере 10 мас.% арахидоновой кислоты, а также эйкозапентаеновую кислоту в количестве не более 20 мас. % от содержания арахидоновой кислоты получают методом микробиологического синтеза с использованием штамма культуры Pythium insidiossum. Масло вводят в детское питание в количестве, обеспечивающем содержание арахидоновой кислоты в количестве, эквивалентном женскому грудному молоку. Масло вводят также в косметическую композицию. При лечении людей, страдающих от недостатка арахидоновой кислоты, масло вводят в фармакологически приемлемом количестве. Использование изобретения позволяет ликвидировать дефицит арахидоновой кислоты в организме. 7 с. и 20 з.п.ф-лы, 2 табл.

СПОСОБ ПРОФИЛАКТИКИ НЕАЛКОГОЛЬНОЙ ЖИРОВОЙ БОЛЕЗНИ ПЕЧЕНИ У ПАЦИЕНТОВ С ЖЕЛЧНОКАМЕННОЙ БОЛЕЗНЬЮ ПОСЛЕ ЛАПАРОСКОПИЧЕСКОЙ ХОЛЕЦИСТЭКТОМИИ

Изобретение относится к медицине и предназначено для профилактики неалкогольной жировой болезни печени у пациентов с желчнокаменной болезнью (ЖКБ) после лапароскопической холецистэктомии. Проводят лечение, включающее Урсофальк, Мукофальк и Хофитол. Урсофальк принимают по 10 мг/кг массы тела на ночь, Мукофальк - 1 пакетик по 5 г 3 раза в день за 15 мин до еды, длительность приема и Урсофалька, и Мукофалька - 2 месяца после операции, затем принимают Хофитол по 2 таблетки 3 раза в день в течение месяца. Курс профилактики повторяют через 3 месяца. Способ позволяет снизить частоту развития жировой болезни печени у пациентов с ЖКБ после лапароскопической холецистэктомии. 1 пр.

ФАРМАЦЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ ПОЛИЦИКЛИЧЕСКИХ СОЕДИНЕНИЙ В КАЧЕСТВЕ СРЕДСТВ ПРОТИВ СПИДа

... 1. Применение полициклических соединений, выбранных из ингенолов, ланоста-8,24-диен-3-олов и их смесей для получения фармацевтических композиций для профилактики или лечения вызванных ВИЧ инфекций.2. Применение по п.1, где указанными ингенольными соединениями являются одно или более из 3-(2,4,6-додекатриеноил)ингенола, 3-(2,4,6,8-тетрадекатетраноил)ингенола, их фармацевтически приемлемых солей, изомеров, полиморфов, сольватов или гидратов, пролекарств или их метаболитов.3. Применение по п.1, где указанные ланоста-8,24-диен-3-олы представлены одним или более из эуфорбола, трикаллола и ланостерола, их фармацевтически приемлемых солей, изомеров, кристаллов и полиморфов, сольватов и гидратов, пролекарств или их метаболитов.4. Применение по п.1 смесей ингенолов и ланоста-8,24-диен-3-олов в соотношении в интервале от 1:100 до 100:1, в частности от 1:50 до 50:1, более конкретно от 1:10 до 10:1, еще конкретнее от 1:4 до 4:1.5. Способ лечения инфекций, вызванных ВИЧ, где указанный способ включает ...

КОМПОЗИЦИЯ ОМЕГА-3 ЖИРНЫХ КИСЛОТ ДЛЯ ПРОФИЛАКТИКИ И /ИЛИ ЛЕЧЕНИЯ КАХЕКСИИ

СЛОЖНЫЕ ЭФИРЫ ДЛЯ ЛЕЧЕНИЯ ОФТАЛЬМОЛОГИЧЕСКИХ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ

КОМПОЗИЦИЯ ДЛЯ ЛЕЧЕНИЯ ГЛАЗ, СОДЕРЖАЩАЯ ОМЕГА-3 ЖИРНЫЕ КИСЛОТЫ И ОМЕГА-6 ЖИРНЫЕ КИСЛОТЫ

... 1. Композиция для лечения глаз, содержащая омега-3 жирные кислоты, омега-6 жирные кислоты и соединения цинка, предпочтительно в виде сульфата цинка. 2. Композиция по п.1, отличающаяся тем, что дополнительно содержит по меньшей мере один витамин, выбранный из группы, включающей витамин Е, витамин С, витамин В, предпочтительно витамин В6 и/или витамин В 12. 3. Композиция по п.1, отличающаяся тем, что омега-3 жирные кислоты содержатся в виде триглицеридов рыбьего жира. 4. Композиция по п.1, отличающаяся тем, что омега-3 жирная кислота представляет собой эйкозапентановую кислоту, предпочтительно полученную из пищевых масел, рапсового масла, льняного масла и/или рыбьего жира. 5. Композиция по п.1, отличающаяся тем, что омега-3 жирная кислота представляет собой докозагексановую кислоту. 6. Композиция по п.1, отличающаяся тем, что омега-6 жирная кислота представляет собой гамма - линоленовую кислоту, предпочтительно получаемую из масла семян бурачника, масла семян энотеры и/или масла из косточек ...

СПОСОБ УМЕНЬШЕНИЯ ТОКСИЧЕСКОГО ПОВРЕЖДЕНИЯ ПЕЧЕНИ

Способ уменьшения токсического повреждения печени, заключающийся во внутрижелудочном введении в организм комбинации полиена - 1,0 мл/кг и нейрозима 250 мг/кг.

LIPOXINVERBINDUNGEN MIT VERLÄNGERTER HALBWERTSZEIT

Kosmetische und/oder dermatologische Wirkstoffkombination

Kosmetische und/oder dermatologische O/W-Emulsion mit einem Gehalt an Retinoiden, Glycerylstearat und Cyclodextrinen.

Zusammensetzung zur Linderung von Gelenkschmerzen

Nahrungsergänzungsmittel in Form eines Nahrungsmittels oder eines Getränks umfassend ein Krillöl in Kombination mit Astaxanthin und Polymeren von Hyaluronsäure oder Natriumhyaluronat (Hyaluronan) mit geringem Molekulargewicht.

Presentation of Polyunsaturated Fatty Acids

A non-aqueous formulation of a fatty acid anhydride conforming to the general formula R1-O-R2, where R1 and R2 are polyunsaturated (C 16 -C 26 ) fatty acid acyl groups, is particularly efficacious for the presentation of the corresponding acids in therapy or as food additives. Ordinary or mixed acid anhydrides are chosen from a group of acids including octa(poly)enoic, eicosa(poly)enoic and docosa(poly)enoic acids. Preferred acids are those with two to six cis double bonds.

Treatment of neurodegenerative conditions

The use of a defined structure lipid glyceride comprising a glycerol moiety esterifed with one or more fatty acid moieties, characterised in that the lipid has a fatty acid moiety at the sn-2 position selected from the group consisting of q -linolenic acid and dihomo- q -linolenic acid for the manufacture of a medicament for the treatment of a neurodegenerative disease is provided characterised in that it is a lipid of formula II ```wherein

R<1> and R<3>

are the same and are selected from H, -C(O)(CH2)nCH3 wherein n is selected from 4 to 16, and

R<2>

is selected from q -linolenoyl and dihomo- q -linolenoyl-residues.

Nutritional or pharmaceutical compositions

Arachidonic acid and methods for the production and use thereof.

IMPROVED FORMULATIONS OF POWDER FOR INHALATION

ANALOGUES OF OMEGA-3-PUFAS DERIVATIVE LIPIDMEDIATOREN AND OPERATING TECHNIQUE

RETINSÄUREDERIVATE

METHOD OF POWER PRODUCTION FROM WIND-POWER PLANTS WITH SEVERAL ROTORS

OLIGOMERE GERADKETTIGER AND NORMAL ONES FETTSAÜREN AND THESE CONTAINING DRUGS

OMEGA-3-FETTSÄUREN AND OMEGA-6-FETTSÄUREN CONTAINING COMPOSITION

POLYMERIZED PEPTID MODIFYING LIPIDE AS BIOLOGICAL TRANSPORT SYSTEMS FOR MIKRONUTRIENTS

OMEGA-3 FATTY ACID ABSTENTION PHARMACEUTICAL COMPOSITIONS

MODIFIED INSULIN WITH MORE REDUCE IMMUNOGENITÄT

OF CONDITIONS OR ILLNESSES, THE BY SUBFUNCTION OF THE BRAIN CAUSES COMPOSITIONS FOR PREVENTION OR ALLEVIATION

ISOTONES FAT EMULSIONS

USE FROM RETINOIDEN TO THE REVERSAL OF GLUCOCORTICOID INDUCING HAUTATROPHIE

MEANS FOR MODULATING OF PROCEDURES THROUGH RETINOID RECEPTORS AND BUT USEFUL CONNECTIONS

PROCEDURE AND COMPOSITIONS FOR THE SYNTHESIS OF LANGKETTIGEN, REPEATED INSATIATED FATTY ACIDS

NATURAL PHENOLIC PRODUCTS AND THEIR DERIVATIVES TO THE PROTECTION FROM NEURODEGENERATIVE ILLNESSES

ARACHIDONSÄURE AND PROCEDURE FOR YOUR PRODUCTION AS WELL AS USE THE SAME

USE FROM POLYUNGESÄTTIGTEN FATTY ACIDS TO THE PRIMARY PREVENTION OF CARDIOVASCULAR ACCUMULATIONS

PROCEDURE FOR EXTRACTING STEROL WITH A POLAR SOLVENT FOR THE PRODUCTION OF A MIKROBIELLEN OIL WITH LOW ONE STEROLGEHALT

HETEROATOMICINTERRUPTED SIMILAR VON15 HYDROXYEICOSATETRAENSÄURE AND PROCEDURE FOR THEIR USE

IBUPROFEN SOLUTIONS AS CAP FILLING AND CAP PREPARATIONS

ARACHIDONSAURE AND PROCEDURE FOR YOUR PRODUCTION AS WELL AS USE THE SAME

Lipid comprising docosapentaenoic acid

The present invention relates to extracted plant lipid or microbial lipid comprising docosapentaenoic acid, and processes for producing the extracted lipid.

Increasing the hdl level and the hdl/ldl ratio in human seru m by balancing saturated and polyunsaturated dietary fatty a cids

Use of triglyceride oils containing gamma-linolenic acid residues and linoleic acid residues for the treatment of neurodegenerative disease

Use of pinolenic acid

Preventive or ameliorating agent for liver disease involving hepatopathy

Preventive or ameliorating agent for liver disease involving hepatopathy

Compositions containing hydroperoxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders

Supplements containing annatto extracts and carotenoids and methods for using the same

SUPPLEMENTS CONTAINING ANNATTO EXTRACTS AND CAROTENOIDS AND METHODS FOR USING THE SAME

USE OF EPA AND DHA IN SECONDARY PREVENTION

Lipid mixtures and their use

Growth stimulating factors

Arachidonic acid and methods for the production and use thereof

FATTY ALCOHOLS AND FATTY ACID ESTERS USEFUL FOR TREATMENT OF INFLAMMATION

Immunomodulators selected from: (a) a saturated or cis-unsaturated C10 - C20 fatty alcohol or an ester thereof with a C1 - C6 alkanoic acid; (b) a monoester of a C2 - C8 alkanediol or of Glycerol with a saturated or cis- unsaturated C10 - C20 fatty acid; and (c) a diester of glycerol with a saturated or cis-unsaturated C10- C20 fatty acid, are useful for treatment of inflammation, particularly immunologically-mediated inflammation such as it occurs in autoimmune diseases.

DESATURASE GENES AND USES THEREOF

The subject invention relates to the identification of genes involved in the desaturation of polyunsaturated fatty acids at carbon 5 (i.e., .DELTA.5-desaturase") and at carbon 6 (i.e., ".DELTA.6-desaturase") and to uses thereof. In particular, ..DELTA.5-desaturase may be utilized, for example, in the conversion of dihomo-g-linolenic acid (DGLA) to arachidonic acid (AA) and in the conversion of 20: 4n-3 to eicosapentaenoic acid (EPA). Delta-6 desaturase may be used, for example, in the conversion of linoleic (LA) to g-linolenic acid (GLA). AA or polyunsaturated fatty acids produced therefrom may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.

DIACYLGLYCEROL ACYLTRANSFERASE GENES AND USE THEREOF

Disclosed are a diacylglycerole acyltranferase, and a polynucleotide which codes for same. Provided are: a polynucleotide containing a base sequence represented by SEQ ID NO: 1 or 4; a polynucleotide which codes for a protein comprising an amino acid sequence represented by SEQ ID NO: 2; an expression vector and transformant containing said polynucleotide; a method for producing an aliphatic acid or a lipid using said transformant; and food containing the aliphatic acid or lipid which were produced by means of said method.

OIL COMPOSITION, FORMULATIONS COMPRISING THE OIL COMPOSITION, AND THE USE THEREOF TO REDUCE ACCUMULATION OF VISCERAL FAT, IMPROVE GLUCOSE TOLERANCE, AND PREVENT OR TREAT OBESITY RELATED DISEASES AND DISORDERS

This invention relates to an oil composition, preferably obtained from a copepod, and the use thereof to reduce accumulation of visceral fat and counteract impairment of heart function caused by obesity inducing Western diets. The oil composition of the present invention can thus be used to reduce abdominal obesity and improve glucose tolerance and thus to reduce the risk of obesity related diseases such as but not limited to type 2 diabetes or cardiovascular disease, or to prevent or treat such diseases.

COMPOSITION FOR PREVENTING ONSET OF CARDIOVASCULAR EVENTS

PHARMACEUTICAL AND NUTRITIONAL COMPOSITIONS CONTAINING ESSENTIAL FATTY ACIDS AND HOMOCYSTEINE-LOWERING AGENTS

The combined application of at least one essential fatty acid of the n-6 or n- 3 series, optionally together with further essential fatty acid(s) of the n-6 or n-3 series, together with one or more homocysteine lowering agent. The homocysteine lowering agent is selected from vitamin B12, folic acid, a compound related to folic acid with similar biological activity and vitamin B6.

FAT COMPOSITION FOR ORAL OR ENTERAL ADMINISTRATION AND HEXACOSANOIC ACID DEPRESSANT

A fat composition for oral or enteral administration which contains eicosapentaenoic acid and/or a derivative thereof, docosahexaenoic acid and/or a derivative thereof, and a C20 or higher monoenoic acid and/or a derivative thereof and functions to diminish hexacosanoic acid; and a hexacosanoic acid depressant which comprises as active ingredients eicosapentaenoic acid and/or a derivative thereof, docosahexaenoic acid and/or a derivative thereof, and a C20 or higher monoenoic acid and/or a derivative thereof. They can be prepared by extraction from a fish oil or the like, purification, blending, etc. Based on the function of diminishing hexacosanoic acid, the composition and the depressant produce an aging-inhibitory effect on cell membranes, which is effective in the prevention and treatment of life style-related diseases.

DIHOMO-.GAMMA.-LINOLENIC ACID-CONTAINING MICROBIAL OIL/LIPID WITH REDUCED ARACHIDONIC ACID CONTENT

The purpose of the present invention is to provide an oil that contains dihomo-?-linolenic acid at a higher purity. Provided is a microbial oil that is specified by a high content of dihomo-?-linolenic acid contained therein and/or a reduced content of undesirable constituting fatty acid(s).

METHODS OF REDUCING THE RISK OF A CARDIOVASCULAR EVENT IN A STATIN-TREATED SUBJECT BY INCREASING SERUM AND PLASMA EPA AND DPA LEVELS

In various embodiments, the present disclosure provides methods reducing the risk of a cardiovascular event in a subject on statin therapy by administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof by increasing the subject's plasma and serum EPA levels.

METHODS OF REDUCING THE NEED FOR PERIPHERAL ARTERIAL REVASCULARIZATION IN A STATIN-TREATED SUBJECT

In various embodiments, the present disclosure provides methods of diagnosing a need for peripheral arterial revascularization and/or reducing a need for peripheral arterial revascularization in a subject by administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof.

VERY-LONG-CHAIN POLYUNSATURATED FATTY ACIDS, ELOVANOID HYDROXYLATED DERIVATIVES, AND METHODS OF USE

Provided are methods of using compounds, pharmaceutical compositions, cosmetic and dermatological compositions or nutritional supplement compositions, comprising omega-3 very-long-chain polyunsaturated fatty acids (n-3 VLC-PUFAs) and/or their endogenous hydroxylated derivatives thereof, known as elovanoids for promoting the protection, prevention, and treatment of disturbances of the eye surface, such as dry eye and inflammatory conditions of the eye surface.

IBUPROFEN SOLUTIONS FOR CAPSULE-FILLING AND CAPSULE PREPARTIONS

Capsule preparations are produced by using solutions for capsule-filling which contain ibuprofen, polyethylene glycol, water and terpenes (menthol, limonene, borneol, dl-camphor, mentha oil, etc.) optionally together with one or more drugs selected from among antipyretic analgesics, antihistamines, antitussives, expectorants, sympathetic stimulant, analeptics, hypnotic sedatives and anti-inflammatory agents, solubilizers, thickeners, pH controlling agents, colorants, etc. Thus, it is attempted to relieve the bitterness of ibuprofen and establish an immediate action at the same time.

ESSENTIAL FATTY ACIDS IN THE PREVENTION OF CARDIOVASCULAR EVENTS

The invention concerns the use of essential fatty acids with a high content in eicosapentaenoic acid ethyl ester (EPA) or docosahexaenoic acid ethyl ester (DHA) or a high concentration mixture thereof in the preparation of a medicament useful for preventing mortality, in particular due to sudden death, in patients who have suffered from a myocardial infarction.

FILL LIQUID COMPOSITION FOR IBUPROFEN CAPSULE AND CAPSULE PREPARATION

A fill liquid composition for capsules is produced by mixing ibuprofen, polyethylene glycol, water and terpenoid selected from menthol, limonene, borneol, dl-camphor, peppermint oil and so forth, and optionally one or more agents selected from antipyretic analgesic, anti-histamine, antitussive, expectorant, sympathetic nerve stimulant, central stimulant, hypnotic sedative and antiphlogistic, and solubilizing agent, viscous agent, pH adjuster, coloring agent, and the like, in order to exhibit the effects that the prevention of bitterness of ibuprofen and the quick-activeness of ibuprofen are consistently achieved.

ARACHIDONIC ACID AND METHODS FOR THE PRODUCTION AND USE THEREOF

POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES, AND USES THEREOF

The invention emcompasses polyunsaturated fatty acid monoglycerides and d erivatives thereof, having the formulae (I), (II), (III) and (IV), pharmaceu tically acceptable salts thereof, compositions thereof and processes of prep aring said compounds. These compounds can be useful as cancer chemopreventiv e agents, cancer treating agents, or radioenhencers for radiotherapy of canc er, or for inhibiting tumor growth or cell proliferation, or reducing tumor growth.

PREVENTIVE/THERAPEUTIC AGENT FOR ALZHEIMER'S DEMENTIA

It is intended to provide a preventive/therapeutic agent for Alzheimer's dementia, characterized in that a .omega.-3 polyunsaturated fatty acid and thyroid hormone are used in combination. The preventive/therapeutic agent ca n be an alternative to a therapeutic method currently performed for Alzheimer' s dementia or can achieve a high therapeutic effect by using the therapeutic method in combination and is excellent in safety.

LIPID COMPRISING DOCOSAPENTAENOIC ACID

The present invention relates to extracted plant lipid or microbial lipid comprising docosapentaenoic acid, and processes for producing the extracted lipid.

MONOACYLGLYCEROLS FOR USE IN CONJUNCTION WITH A LIPASE INHIBITOR AND/OR DIETS LOW IN FAT AND/OR CALORIES

In an embodiment, compositions comprising monoacylglycerols (MAG), such as sn-1(3) MAG, are administered with a lipase inhibitor, such as tetrahydrolipstatin, and/or with a diet low in fat and/or calories. In another embodiment, compositions comprising MAG, such as sn-1(3) MAG, are administered concurrently with a lipase inhibitor, such as tetrahydrolipstatin, and/or with fat-soluble nutrients. The compositions and the methods of using the compositions enhance absorption of fatty acids and fat-soluble nutrients such as fat-soluble vitamins and carotenoids to address nutritional deficiencies due to a weight loss diet used in association with a lipase inhibitor.

COMPOSITIONS USEFUL IN THE PREVENTION OR TREATMENT OF SKIN CANCER

The invention relates to compounds of general formula (I): CH3-(CH=CH)n-R (I) wherein n = 3, 5, 7; R is selected from -CO-OR', -CO-O(-), or -CH2-O-CO-R', R' being selected from H, C1-C22 alkyl or alkenyl.aryl or aralkyl, or sugars; with the proviso that when R is -CH2-O-CO-R' and R' alkyl, said alkyl being selected from C1 to C11; and pharmaceutically acceptable salts thereof, preferably such as sodium, potassium, lysine salts, each compound of general formula (I) being used as such or in admixture with one or more of the other ones, for use in the prevention or treatment of skin cancer resulting from DNA damage produced by UV radiation.

COMPOSITIONS COMPRISING PEMAFIBRATE AND AN OMEGA-3 FATTY ACID USEFUL IN THE TREATMENT OF DYSLIPIDEMIA

This invention provides a combination-drug composition and a combination use of pharmaceuticals for preventing and/or treating dyslipidemia states, such as hyper-LDL cholesterolemia, in mammals, including humans. This invention pertains to a drug composition for preventing and/or treating dyslipidemia and the like, said drug composition comprising the following: (R)-2-[3-[[N-(benzoxazole-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy] butyric acid, a salt thereof, or a solvate of either; and an omega-3 fatty acid or an ester derivative of an omega-3 fatty acid.

DESATURASE GENES AND USES THEREOF

The subject invention relates to the identification of genes involved in the desaturation of polyunsaturated fatty acids at carbon 5 (i.e., .DELTA.5-desaturase") and at carbon 6 (i.e., ".DELTA.6-desaturase") and to uses thereof. In particular, .DELTA.5-desaturase may be utilized, for example, in the conversion of dihomo-g-linolenic acid (DGLA) to arachidonic acid (AA) and in the conversion of 20: 4n-3 to eicosapentaenoic acid (EPA). Delta-6 desaturase may be used, for example, in the conversion of linoleic (LA) to g-linolenic acid (GLA). AA or polyunsaturated fatty acids produced therefrom may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.

BIOLOGICAL OIL COMPOSITION, FORMULATIONS COMPRISING THE OIL COMPOSITION, AND USE THEREOF TO PREVENT OR TREAT CARDIOVASCULAR DISEASE

This invention relates to a biological oil composition, preferably obtained from a copepod, most preferably the copepod Calanus finmarchicus and the use thereof to prevent or treat formation of atherosclerotic plaques and hence development of coronary heart disease. The composition comprises the same marine n-3 polyunsaturated fatty acids (PUFAs) generally regarded as being responsible for the anti-atherosclerotic effect of marine oils, namely EPA (C20:5n-3 eicosapentaenoic acid) and DHA (C22:6n-3 docosahexaenoic acid). However, quite unexpectedly, it has been found that the oil composition of the present invention has a remarkably higher ability to prevent formation of atherosclerotic plaques than what can be attributed to EPA and DHA alone, and moreover, unlike EPA and DHA alone it has a notable blood cholesterol lowering effect.

THE USE OF COMPOUNDS TO INHIBIT 5A-REDUCTASE ENZYME ACTIVITY, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM

The object of the present invention is the use of compounds designed to inhibit the activity of the enzyme 5a-reductase. This is a novel use of compounds of general Formula (I): CH3 (-CH=CH)n-R (I) where n = from 2 to 7, and R is chosen from among: CHO, CH2OH, CH2O-CO-R', CO-O(-), where R' is chosen from among H, and the alky from C1 to C22, each compound of general Formula (I) being used as such or in mixtures with other compounds, as the active principle in a pharmaceutical or cosmetic composition designed to inhibit the action of the enzyme 5a-reductase, and of the pharmaceutical or cosmetic compositions deriving therefrom.

METHODS OF TREATING GIARDIASIS

Compounds useful for the treatment of giardiasis are described.

COMPOSITION FOR PREVENTING RECURRENCE OF STROKE

Provided is a composition effective for preventing onset and/or recurrence of stroke, in particular, which is expected to be effective for preventing onset and/or recurrence of stroke in a hyperlipidemia patient who has been treated with HMG-CoA RI, or in particular, recurrence of stroke in a patient who is beyond six months after the onset of stroke; i.e., a composition for preventing onset and/or recurrence of stroke, containing ethyl icosapentate as its effective component.

COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASE

In various embodiments, the present invention provides pharmaceutical compositions comprising fatty acids and methods for treating subjects using same.

?3 FATTY ACID COMPOUND PREPARATION

Provided is a compound preparation which comprises at least one selected from the group consisting of ?3 polyvalent unsaturated fatty acids and pharmaceutically acceptable salts and esters thereof, and comprises at least one selected from the group consisting of statin compounds and pharmaceutically acceptable salts thereof. The compound preparation has a capsule film pH of 7.0 to 9.5 and is in the form of a soft capsule. The compound preparation inhibits decomposition of the statin compounds and/or degeneration/insolubilization of the capsule film. A medical use for the compound preparation, a method for producing the compound preparation, and a method for using the compound preparation are also provided.

METHODS OF REDUCING THE RISK OF A CARDIOVASCULAR EVENT IN A SUBJECT ON STATIN THERAPY

In various embodiments, the present invention provides methods of reducing the risk of a cardiovascular event in a subject on statin therapy and, in particular, a method of reducing the risk of a cardiovascular event in a subject on statin therapy having a fasting baseline triglyceride level of about 135 mg/dL to about 500 mg/dL, and administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof.

SEMIFLUORINATED ALKANE COMPOSITIONS

The invention provides novel compositions comprising semifluorinated alkanes and at least one compound sensitive or prone to oxidation. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue. The invention further provides kits comprising such compositions.

HIGHLY UNSATURATED FATTY ACID OR HIGHLY UNSATURATED FATTY ACID ETHYL ESTER WITH REDUCED ENVIRONMENTAL POLLUTANTS, AND METHOD FOR PRODUCING SAME

A highly unsaturated fatty acid or a highly unsaturated fatty acid ethyl ester produced using, as feedstock oil, an oil containing a highly unsaturated fatty acid as a constituent fatty acid. The highly unsaturated fatty acid or highly unsaturated fatty acid ethyl ester has a reduced content of environmental pollutants. The highly unsaturated fatty acid or highly unsaturated fatty acid ethyl ester contains, among the dioxins contained, polychlorinated dibenzo-p-dioxin (PCDD) and polychlorinated dibenzofuran (PCDF) in an amount of less than 0.05 pg-TEQ/g, and coplanar PCB (Co-PCB) in an amount of less than 0.03 pg-TEQ/g. A method for producing the highly unsaturated fatty acid or highly unsaturated fatty acid ethyl ester, wherein free fatty acids and environmental pollutants are removed from feedstock oil by thin-film distillation, and the oil obtained is made into an ethyl ester and refined by rectification and column chromatography.

USE OF LIPOXIN A4 AND ITS DERIVATIVES AS ANTAGONISTS FOR SLOW-REACTING SUBSTANCES OF ANAPHYLAXIS

Composition and methods are disclosed for antagonizing SRS-A; and especially LTD4, comprising the administration of LXA4 or an active derivative thereof to an animal. These compositions and methods are useful in the control of hemostasis, vascular reactivity, and especially vasoconstriction, and, anaphylactic and allergic reactions in animals.

PREVENTION AND IMPROVEMENT OF MEDICAL SYMPTOMS CAUSED BY LEUCOTRIENE B4

A composition such as foods, drinks, pharmaceutical composition, for prevention or improvement of medical symptoms such as inflammation such as chronic inflammation, or allergy etc., comprising an omega 9 series unsaturated fatty acid such as 6,9--octadecadienoic acid, 8,11-eicosadienoic acid, 5,8,11--eicosatrienoic acid etc.

STRUCTURED LIPIDS

There is disclosed structured lipid containing either a gamma-linolenic acid or a dihomogamma linolenic acid residue, together with an n-3 fatty acid residue and a medium chain fatty acid residue on the same glycerol backbone. This structured lipid is particularly well adapted to the treatment of disease or stress states. The gamma-linolenic or dihomogamma-linolenic acid residues modify the prostanoid synthesis pathway, reducing the level of series "2" prostanoids and elevating the levels of series "1" and "3" prostanoids. The n-3 fatty acid residue enhances the level of series "1" prostanoids as well as increases the production of series "3" prostanoids. The medium chain fatty acid residues enhances the absorption of the structured lipid. There is also disclosed enteral and parentetal diets as well as nutritional supplements containing the structured lipids of the invention.

Structured Lipids

ANGIOGENIC LIPID FORMULATIONS

There is disclosed an aqueous formulation for vascularizing ischemic or grafted tissue, comprising an alk-1-enyl glycerol derivative having formula (I) wherein R is a straight or branched C1-24 saturated or unsaturated alkyl or a straight or branched C1-24 aryl and X and Y each is H or an saturated or unsaturated alkyl group having from 2 to 26 carbon atoms, or a monoglyceride having a C8-24 ether-linked saturated alkyl in an aqueous buffered pharmaceutical carrier.

RETINOYLOXY(SUBSTITUTED)ALKYLENE BUTYRATES USEFUL FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES

This invention relates to the novel retinoyloxy(substituted)alkylene butyrate compounds and pharmaceutical compositions containing same, to methods of treating, preventing or ameliorating cancer and other proliferative diseases in a subject in need of such treatment by comprising administering those compounds, pharmaceutically-acceptable salts or prodrugs thereof to a patient. The compounds of the invention are also useful in methods of inhibiting histone deacetylase, ameliorating wrinkles, treating or ameliorating dermatological disorders, inducing wound healing, treating cutaneous ulcers and treating gastrointestinal disorders.

Connections with insatiated fatty acid remainders to the production from medicines to the treatment of multiple sclerosis.

Ein Fettsäureglycerid wird verwendet zur Herstellung eines Medikamentes. Dieses Fettsäureglyderid enthält einen Glycerinrest und einen Fettsäurerest, der an die sn-2-Position des Glycerins gebunden ist. Der Fettsäurerest ist entweder gamma-Linolensäure oder dihomo-gamma-linolensäure. Das Medikament ist bestimmt für die Behandlung von multipler Sklerose.

Connections with insatiated fatty acid remainders to the production from medicines to the treatment of multiple sclerosis.

Ein Fettsäureglycerid wird verwendet zur Herstellung eines Medikamentes. Dieses Fettsäureglyderid enthält einen Glycerinrest und einen Fettsäurerest, der an die sn-2-Position des Glycerins gebunden ist. Der Fettsäurerest ist entweder gamma-Linolensäure oder dihomo-gamma-linolensäure. Das Medikament ist bestimmt für die Behandlung von multipler Sklerose.

Use of an Triglycerid oil for the production of a medicine for the treatment of multiple sclerosis.

Ein Medikament wird bereitgestellt, das die Behandlung eines Patienten, der an einer neurodegenerativen Erkrankung leidet, erlaubt. Dieses Medikament enthält eine therapeutisch wirksame Dosis an Triglyceridöl, das sowohl -Linolensäure- als auch Linosäurereste als Triglyzeridester enthält, wobei das Verhältnis an -Linolensäure- zu Linolsäureresten an der sn-2-Position des Triglyzerids zumindest 0,8 beträgt; wobei die Menge an -Linolensäureresten an der sn-2-Position zumindest 18% beträgt, und wobei das Öl in einer Dosis verabreicht wird, die ausreicht, den TGF-1-Spiegel des Patienten auf einem therapeutischen Niveau zu halten oder auf ein solches anzuheben. Bevorzugt wird das Medikament so hergestellt, dass ein therapeutisches Niveau von einem TGF-1/TNF--Verhältnis von zumindest 0,5 im Blut des Patienten nach 18-monatiger täglicher Dosierung erhalten werden kann. Bevorzugte Öle sind Borretsch- oder Mucor-Öle, bei denen mindestens 35% der Fettsäurereste an der sn-2-Position -Linolensäurereste ...

COMPOSITION CAPSULE

LIPID, CONTAINING DOKOZAPENTAENOVUYu ACID

ОЧИСТКА СЫРЫХ МАСЕЛ, СОДЕРЖАЩИХ PUFA

Описан способ получения смеси масла, содержащего ω6-PUFA (такую как ARA), с маслом, содержащим ω3-PUFA (такой как DHA и/или EPA), которая может быть включена в съедобные составы, такие как пищевые продукты и, в частности, композиции для младенцев. Сырое масло, содержащее ω6-PUFA (например, ARA), смешивают с сырым маслом, содержащим ω3-PUFA (например, DHA или EPA), с получением смеси (или неразделимой смеси) сырых масел. Данную смесь затем очищают перед добавлением в пищевой продукт. Альтернативно, обрабатывают сырое масло, содержащее ω6-PUFA, и сырое масло, содержащее ω3-PUFA, также обрабатывают, и эти два очищенных масла затем смешивают до получения неразделимой смеси перед проведением дезодорации, а затем добавляют в пищевой продукт. Очистка включает обработку кислотой и/или щелочью, отбеливание, дезодорацию, фильтрацию, осветление или охлаждение. Очистка удаляет микроэлементы-металлы, пигменты, углеводы, белки, серу, стерины, моно- и диглицериды из масел, что делает их пригодными для ...

МАСЛО ИЗ МИКРОБНЫХ КЛЕТОК, КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ МАСЛО, И СПОСОБ ПОЛУЧЕНИЯ МАСЛА

Настоящее изобретение раскрывает способ получения масла из микробных клеток, включающий культивирование микроорганизма в культуральной среде в ферментере, где ферментация разделена по меньшей мере на две стадии, причем на второй или последней стадии источник углерода добавляют со скоростью ≤0,30 М углерода/кг среды в час; и скорость добавления источника углерода находится ниже скорости потребления источника углерода микроорганизмами. Микроорганизмы, таким образом, имеют источник углерода, ограниченный так, что они предпочтительно метаболизируют жиры или липиды иные, чем арахидоновая кислота (ARA), тем самым повышается относительное содержание ARA в клетках. Полученное масло содержит по меньшей мере 50% арахидоновой кислоты (ARA) и обладает по крайней мере одним из следующих свойств: а) имеет содержание триглицеридов по меньшей мере 90%; б) имеет значение перекисного числа (POV) не более 3,0; в) имеет значение анизидинового числа (AnV) не более 1,0; г) имеет содержание фосфолипидов ниже ...

ПОЛУЧЕНИЕ МАСЛА ИЗ МИКРОБНЫХ КЛЕТОК

Настоящее изобретение раскрывает способ получения масла из микробных клеток, включающий культивирование микроорганизма двухстадийной ферментацией, где на последней стадии, которая предшествует окончанию ферментации, источник углерода потребляется микроорганизмами со скоростью выше, чем его добавляют в среду; добавляют со скоростью ≤0,30 M углерода/кг среды; и/или он является фактором, ограничивающим рост микроорганизмов. Микроорганизмы, таким образом, имеют источник углерода, ограниченный так, что они предпочтительно метаболизируют жиры или липиды иные, чем арахидоновая кислота (ARA), тем самым повышается относительное содержание ARA в клетках. Затем извлекают масло из клеток микроорганизма с использованием гексана в качестве растворителя, которое содержит по меньшей мере 50% ARA и по меньшей мере 90% триглицеридов. Отчет о международном поиске был опубликован 2004.04.15.

СОСТАВ КАПСУЛЫ

Изобретение относится к следующему препарату капсул, который обладает превосходной растворимостью и т.п. фармацевтически активного ингредиента и содержит жидкий и твердый фармацевтические ингредиенты: бесшовной капсуле, содержащий жидкие и твердые фармацевтически активные ингредиенты, в которой жидкий фармацевтически активный ингредиент заключен в капсулу в форме жидкой фармацевтической композиции, а твердый фармацевтически активный ингредиент диспергирован в слое оболочки капсулы.

Methods of treating hypertriglyceridemia

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.

Bioavailability Enhancement Delivery System

A composition for increasing the bioavailability of drugs in humans and animals comprising a microemulsion further comprising a first emulsifier, a second emulsifier, and an oil wherein the emulsifiers have individual HLB values of between about 10 and about 30, are in a ratio ranging from about 1:1 to about 4:1; and, the first and second emulsifier combination and oil are in a ratio of about 99:1 to about 9:1. A method for increasing the bioavailability of such a composition is also provided.

Methods of treating hypertriglyceridemia

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.

Composition With Preventive or Improvement Effect on Symptoms or Diseases Associated with Stress-Induced Behavior Disorders

A composition with a preventive or improvement effect on symptoms or diseases associated with stress-induced behavior disorders, comprising arachidonic acid and/or a compound comprising arachidonic acid as a constituent fatty acid.

Marker associated with non-alcoholic steatohepatitis

Disclosed is a novel NASH marker for use in a method for detecting NASH or evaluating the severity of NASH, which utilizes at least one factor selected from the group consisting of an IL-1 receptor antagonist, sCD40, HMGB1, sPLA2 group IIA and an sPLA2 activity as the marker. Also disclosed is a method for detecting NASH or evaluating the severity of NASH in a subject, which utilizes the marker.

Lipoxin compounds and their use in treating cell proliferative disorders

Compounds having the active site of natural lipoxins, but a longer tissue half-life are disclosed. In particular, 15-epi-lipoxins and their use in ameliorating undesired cell proliferation, which characterizes diseases such as cancer, are also disclosed.

Methods and compositions for treating and preventing parenteral nutrition associated liver disease

Methods and compositions for treating or preventing parenteral nutrition associated liver disease are provided. Methods and compositions for advancing enteral tolerance in subjects receiving enteral nutrition are provided. The methods involve the use of omega-3 fatty acid compositions. In some embodiments the omega-3 fatty acid compositions comprise docosahexanoic acid and eicosapentaenoic acid. In some embodiments the omega-3 fatty acid compositions comprise fish oil. In some embodiments the subjects to be treated are receiving parenteral nutrition. In some embodiments the subjects to be treated are infants having a low birth weight, very low birth weight, extremely low birth weight, a low gestational age, short bowel syndrome, necrotizing entercolitis, or any combination thereof.

INFANT NUTRITION FOR IMPROVING FATTY ACID COMPOSITION OF BRAIN MEMBRANES

The present invention relates to infant nutrition, in particular to infant nutrition comprising special lipid globules for improvement of the fatty acid composition in brain membranes. 116-. (canceled)17. A method for altering brain membrane fatty acid composition selected from the group consisting of i) increasing brain membrane fluidity , ii) increasing brain membrane PUFA , iii) increasing brain membrane LC-PUFA , iv) decreasing ratio of brain membrane n6/n3 LC-PUFA , v) decreasing ratio of brain membrane n6/n3 PUFA , vi) increasing brain membrane n3 PUFA , vii) increasing brain membrane n3 LC-PUFA and viii) increasing brain membrane DHA , in a human subject , the method comprising administering to the human subject a nutritional composition comprising b1) 0.5 to 20 wt. % phospholipids based on total lipid and/or', 'b2) 0.6 to 25 wt. % of polar lipids based on total lipids, wherein polar lipids are the sum of phospholipids, glycosphingolipids and cholesterol, and the composition comprising lipid globules with a core comprising the vegetable lipids and a coating comprising the phospholipids or polar lipids., 'a) 10 to 50 wt. % vegetable lipids based on dry weight of the composition, and'}18. The method according to claim 17 , wherein the lipid globules have:(i) a volume-weighted mode diameter above 1.0 μm, and/or(ii) a diameter of 2 to 12 μm in an amount of at least 45 volume % based on total lipid.19. The method according to claim 18 , wherein the lipid globules have:(i) a volume-weighted mode diameter between 1.0 and 10 μm, and/or(ii) a diameter of 2 to 12 μm in an amount of at least 55 volume % based on total lipid.20. The method according to claim 17 , wherein the composition comprises n3 LC-PUFA in an amount of at least 0.2 wt. % of the total fatty acid content and that does not exceed 15 wt. % of the total fatty acid content.21. The method according to claim 17 , wherein the composition comprises DHA in an amount of 0.1 to 0.6 wt. % based on total fatty acid ...

STABLE PHARMACEUTICAL COMPOSITION AND METHODS OF USING SAME

The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases. 1. A method of lowering triglycerides in a subject with triglycerides of at least 500 mg/dl comprising , administering to the subject daily a pharmaceutical composition comprising an amount of eicosapentaenoic acid selected from the group consisting of about 1100 mg , about 1650 mg and about 2200 mg , and not more than about 30% , by weight of total fatty acids , docosahexaenoic acid , for a period effective to reduce triglycerides in the subject.2. The method of comprising claim 1 , administering to the subject the pharmaceutical composition daily for a period effective to reduce triglycerides by at least 10% in the subject.3. The method of comprising claim 1 , administering to the subject the pharmaceutical composition daily for a period effective to reduce triglycerides by at least 20% in the subject.4. The method of comprising claim 1 , administering to the subject the pharmaceutical composition daily for a period effective to reduce non-HDL-C in the subject.5. The method of comprising claim 1 , administering to the subject the pharmaceutical composition daily for a period effective to reduce non-HDL-C by 5% in the subject.6. The method of comprising claim 1 , administering to the subject the pharmaceutical composition daily for a period effective to increase HDL-C in the subject.7. The method of comprising claim 1 , administering to the subject the pharmaceutical composition daily for a period effective to increase HDL-C by 5% in the subject.8. The method of wherein the effective amount of eicosapentaenoic acid is about 1100 mg.9. The method of wherein administration of about 1100 mg of eicosapentaenoic acid per day results in an increase in plasma eicosapentaenoic acid levels of at least 200% in the subject.10. The method of wherein the effective amount of ...

STABLE PHARMACEUTICAL COMPOSITION AND METHODS OF USING SAME

The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases. 1. A method of treating high triglycerides in a subject receiving statin therapy comprising , administering to the subject daily a pharmaceutical composition comprising an amount of eicosapentaenoic acid selected from the group consisting of about 1100 mg , about 1650 mg and about 2200 mg and not more than about 30% , by weight of total fatty acids , docosahexaenoic acid , for a period effective to reduce triglycerides in the subject.2. The method of comprising claim 1 , administering to the subject the pharmaceutical composition for a period effective to reduce triglycerides by at least 10% in the subject.3. The method of comprising claim 1 , administering to the subject the pharmaceutical composition for a period effective to reduce triglycerides by at least 15% in the subject.4. The method of comprising claim 1 , administering to the subject the pharmaceutical composition for a period effective to reduce non-HDL-C in the subject.5. The method of comprising claim 1 , administering to the subject the pharmaceutical composition for a period effective to reduce non-HDL-C by at least about 5% in the subject.6. The method of comprising claim 1 , administering to the subject the pharmaceutical composition for a period effective to increase HDL-C in the subject.7. The method of comprising claim 1 , administering to the subject the pharmaceutical composition for a period effective to reduce lipoprotein associated phospholipase A2 in the subject.8. The method of comprising claim 1 , administering to the subject the pharmaceutical composition for a period effective to reduce lipoprotein associated phospholipase A2 by at least 5% in the subject.9. The method of wherein the effective amount of eicosapentaenoic acid is about 1100 mg.10. The method of wherein said administration ...

PHARMACEUTICAL COMPOSITION COMPRISING EICOSAPENTAENOIC ACID AND NICOTINIC ACID AND METHODS OF USING SAME

The present invention relates to, inter alia, pharmaceutical compositions comprising eicosapentaenoic acid and/or derivatives thereof and nicotinic acid, to methods of manufacturing such compositions, and to therapeutic methods for treating carious diseases and disorders. 1. A pharmaceutical composition comprising nicotinic acid in an amount of not more than about 1200 mg and eicosapentaenoic acid or a derivative thereof , wherein the composition contains not more than 10% , by weight , docosahexaenoic acid , if any.2. The composition of wherein the composition contains substantially no docosahexaenoic acid.3. The composition of wherein the eicosapentaenoic acid or derivative thereof is present in an amount of about 100 mg to about 5000 mg.4. The composition of wherein the eicosapentaenoic acid or derivative thereof is present in an amount of about 100 mg to about 1000 mg.5. The composition of wherein the eicosapentaenoic acid or derivative thereof comprises an eicosapentaenoic acid ethyl ester.6. The composition of wherein the nicotinic acid is suspended in the eicosapentaenoic acid or derivative thereof to form a suspension.7. The composition of wherein the suspension is present in a capsule.8. The composition of wherein the composition further comprises a statin.9. A pharmaceutical composition comprising nicotinic acid in an amount of not more than about 800 mg and eicosapentaenoic acid ethyl ester claim 1 , wherein the composition contains substantially no amount of docosahexaenoic acid or derivative thereof.10. A pharmaceutical composition comprising nicotinic acid in an amount of not more than about 500 mg and about 100 mg to about 1000 mg of eicosapentaenoic acid ethyl ester claim 1 , wherein the composition contains no docosahexaenoic acid claim 1 , the nicotinic acid is suspended in the eicosapentaenoic acid ethyl ester claim 1 , and the composition is present in a capsule.11. The composition of wherein the nicotinic acid is present in an amount of about 50 ...

METHODS AND COMPOSITIONS FOR TREATING, REVERSING, INHIBITING OR PREVENTING RESISTANCE TO ANTIPLATELET THERAPY

Methods of identifying subjects who are resistant to antiplatelet therapy, such as therapy with clopidogrel, are presented. The methods comprise determining is whether the subject is an efficient converter of medium chain polyunsaturated fatty acids to long-chain polyunsaturated fatty acids. Also provided are methods of treating resistance to antiplatelet therapy in subjects who are efficient converters of medium chain polyunsaturated fatty acids to long-chain polyunsaturated fatty acids, comprising adjunctively administering to the subject an effective amount of a composition comprising omega-3 long chain polyunsaturated fatty acids. Improved methods of antiplatelet therapy are provided, wherein the improvement comprises adjunctive administration of a composition comprising omega-3 long chain polyunsaturated fatty acids in free acid form. Dosage forms comprising at least one antiplatelet agent and compositions comprising omega-3 long chain polyunsaturated fatty acids, including compositions comprising omega-3 long chain polyunsaturated fatty acids in free acid form, are provided. 1. A method for treating , reversing , inhibiting , or preventing resistance to antiplatelet therapy in a subject who is an efficient converter and for whom antiplatelet therapy is clinically indicated , comprising:administering to the subject an effective amount of a composition comprising omega-3 lc-PUFAs (“omega-3 composition”).2. The method of claim 1 , further comprising the prior step of determining whether the subject is an efficient converter.3. The method of claim 2 , wherein determining whether the subject is an efficient converter comprises determining the subject's genotype at one or more polymorphisms associated with one or more genes selected from the group consisting of FADS1 claim 2 , FADS2 claim 2 , and FADS3.4. The method of claim 2 , wherein determining whether the subject is an efficient converter comprises measuring the level of arachidonic acid in a sample from the ...

METHODS OF TREATING HYPERTRIGLYCERIDEMIA

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. 1. A method of reducing triglycerides in a subject having a fasting baseline triglyceride level of 500 mg/dl to about 1500 mg/dl comprising , administering orally to the subject 4 capsules per day , each capsule comprising about 900 mg to about 1 g of ethyl eicosapentaenoate and not more than about 3% docosahexaenoic acid or its esters , by weight of total fatty acids present , for a period of 12 weeks to effect a reduction in triglycerides in the subject.2. The method of wherein the subject has a fasting baseline LDL-C from about 50 mg/dl to about 300 mg/dl.3. The method of claim 1 , wherein the subject has one or more of: a baseline fasting non-HDL-C of about 200 mg/dl to about 400 mg/dl claim 1 , a baseline fasting total cholesterol of about 250 mg/dl to about 400 mg/dl claim 1 , a baseline fasting VLDL-C of about 140 mg/dl to about 200 mg/dl claim 1 , and/or a baseline fasting HDL-C of about 10 mg/dl to about 60 mg/dl.4. The method of claim 1 , wherein said administering effects a reduction in fasting triglycerides of at least about 10% without increasing LDL-C by more than 5% in the subject.5. The method of claim 1 , wherein said administering effects a reduction in apolipoprotein B in the subject.6. The method of claim 1 , wherein said administering effects a reduction in VLDL-C in the subject.7. The method of claim 1 , wherein said administration effects reduction in fasting triglycerides of at least about 20% without increasing LDL-C in the subject.8. The method of claim 1 , wherein each capsule comprises about 950 mg of ethyl eicosapentaenoate.9. The method of claim 1 , wherein each capsule comprises about 975 mg of ethyl eicosapentaenoate.10. ...

PHARMACEUTICAL COMPOSITIONS COMPRISING DGLA AND/OR 15-HETRE AND METHODS OF USE THEREOF

The present disclosure provides compositions comprising fatty acids, or derivatives thereof (e.g., C1-C4 esters) including, for example, DGLA, and/or 15-HETrE, used singly or in combination for the prevention and/or treatment of effects associated with UV radiation such as erythema. 1. A composition for preventing or reducing the occurrence of erythema , the composition comprising a therapeutically effective amount of DGLA and/or 15-HETrE.2. The composition of claim 1 , wherein the composition comprises about 0.1 wt. % DGLA to about 20 wt. % DGLA.3. The composition of claim 2 , wherein the composition comprises about 10 wt. % DGLA claim 2 , about 1.0 wt % DGLA claim 2 , or about 0.1 wt. % DGLA.4. The composition of claim 1 , wherein the composition comprises about 0.01 wt. % to about 50 wt. % 15-HETrE.5. The composition of claim 4 , wherein the composition comprises about 10 wt. % 15-HETrE claim 4 , about 1.0 wt. % 15-HETrE claim 4 , about 0.1 wt. % 15-HETrE claim 4 , or about 0.01 wt. % 15-HETrE.6. The composition of claim 5 , wherein the composition comprise about 0.1 wt. % DGLA to about 20 wt. % DGLA and about 0.01 wt. % to about 50 wt. % 15-HETrE.7. A photoprotective composition for preventing or reducing the occurrence of erythema claim 5 , the composition comprising i.) a therapeutically effective amount of DGLA and/or 15-HETrE; and ii.) a sunscreen active agent.8. The composition of claim 7 , wherein the composition comprises about 0.1 wt. % DGLA to about 20 wt. % DGLA.9. The composition of claim 8 , wherein the composition comprises about 10 wt. % DGLA claim 8 , about 1.0 wt. % DGLA claim 8 , or about 0.1 wt. % DGLA.10. The composition of claim 7 , wherein the composition comprises about 0.1 wt. % to about 50 wt. % 15-HETrE.11. The composition of claim 10 , wherein the composition comprises about 10 wt. % 15-HETrE claim 10 , about 1.0 wt. % 15-HETrE claim 10 , about 0.1 wt. % 15-HETrE claim 10 , or about 0.01 wt. % 15-HETrE.12. The composition of claim 7 , ...

METHODS OF TREATING HYPERTRIGLYCERIDEMIA

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. 1. A method of reducing triglycerides in a subject having a fasting baseline triglyceride level of 500 mg/dl to about 1500 mg/dl comprising , administering orally to the subject about 4 g per day of a pharmaceutical composition comprising at least about 90% ethyl eicosapentaenoate , by weight of total fatty acids present , and not more than about 3% docosahexaenoic acid or its esters , by weight of total fatty acids present , for a period of 12 weeks to effect a reduction in triglycerides in the subject.2. The method of wherein the subject has a fasting baseline LDL-C from about 50 mg/dl to about 300 mg/dl.3. The method of claim 1 , wherein the subject has one or more of: a baseline fasting non-HDL-C of about 200 mg/dl to about 400 mg/dl claim 1 , a baseline fasting total cholesterol of about 250 mg/dl to about 400 mg/dl claim 1 , a baseline fasting VLDL-C of about 140 mg/dl to about 200 mg/dl claim 1 , and/or a baseline fasting HDL-C of about 10 mg/dl to about 60 mg/dl.4. The method of claim 1 , wherein said administering effects a reduction in fasting triglycerides of at least about 10% without increasing LDL-C by more than 5% in the subject.5. The method of claim 1 , wherein said administering effects a reduction in apolipoprotein B in the subject.6. The method of claim 1 , wherein said administering effects a reduction in VLDL-C in the subject.7. The method of claim 1 , wherein said administering effects reduction in fasting triglycerides of at least about 20% without increasing LDL-C in the subject.8. A method of reducing triglycerides in a subject having a fasting baseline triglyceride level of 500 mg/dl to about 1500 mg/dl comprising claim 1 , ...

Compounds with a Skin Pigmenting Activity And Pharmaceutical or Cosmetic Compositions Containing Them

The present invention relates to compounds having general formula (I): 119-. (canceled)20. Compound having general formula (I):{'br': None, 'sub': 3', 'n, 'CH—(CH═CH)—R\u2003\u2003(I)'}{'sub': 2', '1', '22, 'sup': '(−)', 'where: n=3, 5, 7; R is chosen from —CH—O—CO—R′, —CO—OR′ or —CO—O, R′ is chosen from H, C-Calkyl or alkenyl, aryl or aralkyl, or sugars; and their pharmaceutically acceptable salts, such as sodium, potassium and lysine salts, for improving the pigmentation of the human skin.'}211. A composition comprising one or more of the compounds having general formula (I) according to claim as the active ingredient for treating pigmentation disorders.222. A composition according to claim for treating vitiligo , pityriasis alba , idiopathic guttate hypomelanosis , post-inflammatory hypopigmentation , Bourneville's syndrome (tuberous sclerosis) and Tinea versicolor.231. A composition comprising one or more of the compounds having general formula (I) according to claim for improving the tanning of the skin.241. A composition comprising one or more of the compounds having general formula (I) according to claim for improving the photoprotective capacity of the skin by means of the melanin pigmentation of the epidermis.251. A composition comprising a compound according to claim , characterised in that the compound is 2 ,4 ,6-octatrienoic acid.261. A composition comprising a compound according to claim , characterised in that the compound is the sodium or potassium salt of 2 ,4 ,6-octatrienoic acid 2 ,4 ,6-octatrienoic acid.271. A composition comprising a compound according to claim , characterised in that the compound is the L-lysine salt of 2 ,4 ,6-octatrienoic acid.281. A composition comprising a compound according to claim , characterised in that the compound is an ester of 2 ,4 ,6-octatrienoic acid.291. A composition comprising a compound according to claim , characterised in that the compound is the ethyl ester 2 ,4 ,6-octatrienoic acid.301. A composition ...

COATED CAPSULES AND TABLETS OF A FATTY ACID OIL MIXTURE

Compositions comprising a fatty acid oil mixture and at least one free fatty acid in a coated capsule or a coated tablet form suitable for oral administration, and methods of use thereof, are disclosed. Further disclosed are preconcentrates comprising a fatty acid oil mixture, at least one surfactant, and optionally at least one free fatty acid, in a coated capsule or a coated tablet form, and methods of use thereof. The preconcentrates are capable of forming a self-nanoemulsifying drug delivery system (SNEDDS), a self-microemulsifying drug delivery system (SMEDDS), or self-emulsifying drug delivery systems (SEDDS) in an aqueous solution. 167-. (canceled)70. A method of treating at least one health problem in a subject in need thereof comprising administering to the subject a composition according to claim 68 , wherein the at least one health problem is chosen from irregular plasma lipid levels claim 68 , cardiovascular functions claim 68 , immune functions claim 68 , visual functions claim 68 , insulin action claim 68 , neuronal development claim 68 , heart failure claim 68 , hypertriglyceridemia claim 68 , hypercholesterolemia claim 68 , mixed dyslipidemia claim 68 , dyslipidemia claim 68 , and post myocardial infarction.80. The preconcentrate according to claim 79 , wherein the preconcentrate comprises from about 300 mg to about 400 mg of DHA and from about 400 mg to about 500 mg of EPA.8478. A self-nanoemulsifying drug delivery system (SNEDDS) claim 79 , self-microemulsifying drug delivery system (SMEDDS) claim 79 , or self-emulsifying drug delivery system (SEDDS) comprising a preconcentrate according to any one of claim 79 , claim 79 , and claim 79 , wherein the preconcentrate forms an emulsion in an aqueous solution.8578. A method of treating at least one health problem in a subject in need thereof comprising administering to the subject a pharmaceutical preconcentrate according to any one of claim 79 , claim 79 , and claim 79 , wherein the at least one health ...

SN-2-MONOACYLGLYCEROLS AND LIPID MALABSORPTION

The present invention relates generally to the field of lipids and in particular aims at improving lipid absorption, for example under conditions of lipid maldigestion or malabsorption. One embodiment of the present invention relates to a composition comprising a sn-2 monoacylglycerol derivative, wherein the sn-1 and sn-3 positions are blocked by protective groups. The acyl group may be a fatty acid, for example one with anti-inflammatory properties. 1. Composition comprising an sn-2 monoacylglycerol derivative , wherein the sn-1 and sn-3 positions are blocked by protective groups and the acyl group is a fatty acid having anti-inflammatory properties.2. Composition in accordance with claim 1 , wherein the fatty acid having anti-inflammatory properties is selected from the group consisting of eicosapentaenoic acid (EPA) claim 1 , docosahexaenoic acid (DHA) claim 1 , α-linolenic acid (ALA) claim 1 , stearidonic acid (SA) claim 1 , γ-linolenic acid (GLA) claim 1 , dihomo-γ-linolenic acid (DGLA) claim 1 , n-3 docosapentanenoic acid (DPA) claim 1 , sciadonic acid and juniperonic acid.3. Composition in accordance with claim 1 , wherein the protective groups are selected from the group consisting of acetyl groups claim 1 , ethyl groups claim 1 , propyl groups claim 1 , vanillin claim 1 , and other molecules able to form acetals.4. Composition in accordance with claim 1 , wherein the sn-2 monoacylglycerol derivative is selected from the group consisting of 1 claim 1 ,3-diacetyl-2-eicosapentaenoylglycerol claim 1 , 1 claim 1 ,3-diethyl-2-eicosapentaenoylglycerol claim 1 , 1 claim 1 ,3-dipropyl-2-eicosapentaenoylglycerol claim 1 , a vanillin derivative of sn-2 monoeicosapentaenoylglycerol claim 1 , other acetal derivatives of monoeicosapentaenoylglycerol claim 1 , and combinations thereof.5. Composition in accordance with claim 1 , wherein the composition is selected from the group consisting of a food product claim 1 , an animal food product claim 1 , a pharmaceutical ...

Fatty acids and metal ions compositions and uses thereof

Compositions comprising various fatty acids and their variants such as DHA, DHA-lysoPC, and EPA combined with neuro-therapeutic metal ions such as magnesium (Mg), zinc (Zn) or lithium (Li), capable of traversing the blood-brain barrier (“BBB), and blood nerve barrier (“BNB”) and methods of use of such compositions to provide therapeutic concentrations of Mg, Zn, or Li in cerebrospinal fluid over a desired period of time to a subject presenting symptoms of Mg, Zn, or Li deficiency or disease symptoms which are alleviated by supplementation of such ions are provided These symptoms may include, but are not limited to, mild cognitive impairment, bipolar disorder, stroke, and pain. 1. A pharmaceutical composition comprising magnesium complexed with one or more fatty acids selected from a group consisting of DHA , DHA-LysoPC and EPA , and a pharmaceutically acceptable carrier.2. A pharmaceutical composition according to claim 1 , further comprising an antioxidant.3. A method of increasing the concentration of magnesium in cerebrospinal fluid comprising providing the composition of to a mammal claim 1 , wherein the concentration of magnesium in cerebrospinal fluid is increased by at least about 5%.4. A method of enhancing cognitive function comprising administering a composition of to a subject in an amount that is effective to enhance cognitive function.5. A method of ameliorating pain comprising administering a composition of to a subject in an amount effective to ameliorate pain.6. A method of ameliorating depression comprising administering a composition of in an amount effective to ameliorate depression.7. A pharmaceutical composition comprising zinc complexed with one or more fatty acids selected from a group consisting of DHA claim 1 , DHA-lysoPC and EPA claim 1 , and a pharmaceutically acceptable carrier.8. A pharmaceutical composition according to claim 7 , further comprising an antioxidant.9. A method of increasing the concentration of zinc in cerebrospinal fluid ...

TYPE A GELATIN CAPSULE CONTAINING PUFA IN FREE ACID FORM

A pharmaceutical formulation comprising at least one omega-3 polyunsaturated fatty acid in free acid form or a pharmacologically acceptable derivative thereof is contained in a soft gelatin capsule characterised in that the capsule comprises gelatin extracted by an extraction process comprising acid pre-treatment of a collagen source. One advantage of the present invention over a soft to gelatin capsule containing the same formulation but comprising gelatin extracted by an extraction process comprising alkali pre-treatment of the collagen source is that the present invention does not harden significantly over time and thus has a longer shelf life. 134-. (canceled)35. A pharmaceutical dosage form comprising:a soft gelatin capsule comprising Porcine Type A gelatin; anda pharmaceutical formulation inside the capsule comprising at least one omega-3 polyunsaturated fatty acid in free acid form;wherein the capsule comprises sufficient Porcine Type A gelatin such that the capsule disintegrates within a time period of not more than 30 minutes in purified water at 37° C. after storage for at least 3 months at 40° C.36. The pharmaceutical dosage form of claim 35 , wherein the formulation comprises at least about 20 wt % of the at least one omega-3 polyunsaturated fatty acid in free acid form.37. The pharmaceutical dosage form of claim 36 , wherein the formulation comprises at least about 50 wt % of the at least one omega-3 polyunsaturated fatty acid in free acid form.38. The pharmaceutical dosage form of claim 37 , wherein the formulation comprises at least about 90 wt % of the at least one omega-3 polyunsaturated fatty acid in free acid form.39. The pharmaceutical dosage form of claim 35 , wherein the at least one omega-3 polyunsaturated fatty acid in free acid form comprises 5 claim 35 ,8 claim 35 ,11 claim 35 ,14 claim 35 ,17-eicosapentaenoic acid (EPA) in free acid form.40. The pharmaceutical dosage form of claim 39 , wherein the at least one omega-3 polyunsaturated fatty ...

METHODS OF TREATING HYPERTRIGLYCERIDEMIA

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. 1. A method of reducing large vLDL particle concentration in a subject having a fasting baseline triglyceride level of about 500 mg/dl to about 1500 mg/dl comprising administering to the subject about 2 g to about 4 g per day ethyl eicosapentaenoate thereby to produce a reduction in large vLDL particle concentration.2. The method of wherein said reduction is statistically significant.3. The method of wherein administering to the subject about 2 g to about 4 g per day of ethyl eicosapentaenoate produces a reduction in large vLDL particle concentration by comparison with a baseline large vLDL particle concentration prior to initiation of administration.4. The method of wherein the reduction in large vLDL particle concentration is at least a 2.5% reduction.5. The method of wherein the reduction in large vLDL particle concentration is at least a 10% reduction.6. The method of wherein the reduction in large vLDL particle concentration is at least a 20% reduction.7. The method of wherein the reduction in large vLDL particle concentration is at least about 24% reduction.8. The method of wherein the subject is administered about 3.8 g to about 4 g per day of ethyl eicosapentaenoate.9. The method of wherein the subject is administered ethyl eicosapentaenoate for a period of 12 weeks.10. A method of reducing small LDL particle concentration in a subject having a fasting baseline triglyceride level of about 500 mg/dl to about 1500 mg/dl comprising claim 1 , administering to the subject about 2 g to about 4 g per day of ethyl eicosapentaenoate thereby to produce a reduction in small LDL particle concentration by comparison with a baseline small LDL particle ...

COMBINATIONS OF NIACIN COMPOUNDS, OMEGA-3 FATTY ACID COMPOUNDS, AND PHYTOSTEROL COMPOUNDS FOR PREVENTION AND/OR MITIGATION OF ERECTILE DYSFUNCTION

Provided herein are nutritional compositions, regimens and methods for the prevention, mitigation, or treatment of ED. In some embodiments, the invention comprises compositions of at least two (and preferably three) members selected from the group consisting of a niacin compound, an Omega-3 fatty acid compound, and a phytosterol compound. 1. A composition for the prevention , mitigation , or treatment of erectile dysfunction , the composition comprising:at least two members of the group consisting of a niacin compound, an Omega-3 fatty acid compound, and a phytosterol compound.2. The composition of claim 1 , wherein the composition comprises a niacin compound claim 1 , an Omega-3 fatty acid compound claim 1 , and a phytosterol compound.3. The composition of claim 2 , wherein the composition comprises between 100 mg and 500 mg of the niacin compound claim 2 , an Omega-3 fatty acid compound claim 2 , and a phytosterol compound.4. The composition of claim 1 , wherein the composition comprises inositol hexanicotinate.5. The composition of claim 1 , wherein the at least two members consist of a niacin compound and one member of the group consisting of an Omega-3 fatty acid compound and a phytosterol compound.6. The composition of claim 5 , wherein the niacin compound and the one member of the group consisting of an Omega-3 fatty acid compound and a phytosterol are present in the composition in a 1:2 ratio claim 5 , respectively.7. The composition of claim 1 , wherein the composition does not contain any statin or other cholesterol modifying pharmaceutical.8. The composition of claim 1 , wherein the composition does not contain any additional pharmaceutical intended to treat erectile dysfunction.9. The composition of claim 1 , wherein the composition is in an oral delivery form.10. A method of preventing claim 1 , mitigating claim 1 , or treating erectile dysfunction in a human male claim 1 , the method comprising the steps of:preparing a first composition comprising at ...

Methods and Compositions for Treating Arthritis with Docosahexaenoic Acid

The present invention is directed to methods and compositions for treating arthritis in a subject, comprising administering about 430 mg to about 12.4 g of docosahexaenoic acid (DHA) per day in a dosage form to the subject in need thereof, wherein the dosage form is substantially free of eicosapentaenoic acid (EPA) and substantially free of non-alpha tocopherol. 1. A method for treating arthritis in a subject , comprising administering about 430 mg to about 12.4 g of docosahexaenoic acid (DHA) per day in a dosage form to the subject in need thereof , wherein the dosage form is substantially free of eicosapentaenoic acid (EPA) and substantially free of non-alpha tocopherol.2. The method of claim 1 , wherein the EPA is less than about 3% (w/w) of the total fatty acid content of the dosage form.32. The method of any of - claims 1 , wherein the EPA is less than about 0.1% (w/w) of the total fatty acid content of the dosage form.43. The method of any of - claims 1 , wherein the EPA is not detectable in the dosage form.54. The method of any of - claims 1 , wherein the dosage form is substantially free of docosapentaenoic acid 22:5n-6 (DPAn6).65. The method of any of - claims 1 , wherein the DHA is derived from an algal source.7Crypthecodiunium cohnii, ThraustochytriumSchizochytrium. The method of claim 6 , wherein the algal source is claim 6 , or sp.87. The method of any of - claims 1 , wherein about 0.84 g to about 4 g of DHA is administered per day to the subject.9. The method of claim 8 , wherein about 0.84 g to about 1.5 g of DHA is administered per day to the subject.10. The method of claim 8 , wherein about 0.84 mg to about 1 g of DHA is administered per day to the subject.1110. The method of any of - claims 1 , wherein the DHA is administered once per day claims 1 , twice per day claims 1 , three times per day claims 1 , four times per day claims 1 , five times per day claims 1 , six times per day claims 1 , seven times per day claims 1 , eight times per day claims ...

DIENE COMPOUNDS FOR USE IN HUMAN EPIDERMAL CELL REPAIR, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM

The present invention relates to a novel use of compounds having the general formula (I): 113-. (canceled)15. The method according to claim 14 , wherein the said active principle is 2 claim 14 ,4 claim 14 ,6-octatrien-1-ol.16. The method according to claim 14 , wherein the said active principle is 2 claim 14 ,4 claim 14 ,6-octatrienoic acid.17. The method according to claim 14 , wherein the said active principle is a pharmacologically or cosmetically acceptable salt of 2 claim 14 ,4 claim 14 ,6-octatrienoic acid.18. The method according to claim 14 , wherein the said active principle is 2 claim 14 ,4 claim 14 ,6-octatrienoic acid sodium salt.19. The method according to claim 14 , wherein the said active principle is 2 claim 14 ,4 claim 14 ,6-octatrienoic acid L-lysine salt.20. The method according to claim 14 , wherein the said active principle is 2 claim 14 ,4 claim 14 ,6-octatrienoic acid ethylester.21. The method according to claim 14 , wherein the said active principle is 2 claim 14 ,4 claim 14 ,6-octatrien-1-ol claim 14 , acetate.22. The method according to claim 14 , wherein the said active principle is 2 claim 14 ,4 claim 14 ,6-octatrien-1-ol claim 14 , palmitate.23. The method according to claim 14 , wherein the said active principle is a mixture of two or more of the compounds of formula (I).24. The method according to claim 14 , wherein said composition comprises an amount of the said active principle in the range 0.05-0.3% by weight.25. The method according to claim 14 , wherein said composition comprises the said active principle with any suitable excipient for a topical administration onto the skin. Meshes of keratin filaments generally serve as a structural framework, providing mechanical support not only for individual cells, but also for whole epithelial layers. Keratins constitute a family of intermediate filament proteins that are assembled to form heterodimers of keratin type 1 (keratins 9 to 23) and keratin type 2 (keratins 1 to 8). Because of ...

ANTI-INFLAMMATORY ACTIONS OF NEUROPROTECTIN D1/PROTECTIN D1 AND ITS NATURAL STEREOISOMERS

The invention describes novel isolated, purified, 10,17-dihydroxy-docoosahexaenoic acids, esters, derivatives and their preparation. 132-. (canceled)34. The compound of claim 33 , wherein when Pand Pare both hydrogen atoms claim 33 , then R is other than a hydrogen atom.35. The compound of claim 33 , wherein Pand Pare each hydrogen atoms and R is a hydrogen atom.36. A composition comprising a compound of claim 33 , anda pharmaceutically acceptable carrier.37. A method to treat airway inflammation comprising administration of a therapeutically acceptable amount of a compound of .38. The method of claim 37 , wherein Pand Pare each hydrogen atoms and R is a hydrogen atom.39. The method of claim 37 , wherein said airway inflammation is asthma.40. The method of claim 37 , wherein when Pand Pare both hydrogen atoms claim 37 , then R is other than a hydrogen atom.41. A method to treat airway inflammation comprising administration of a therapeutically acceptable amount of a composition of .42. The method of claim 41 , wherein Pand Pare each hydrogen atoms and R is a hydrogen atom.43. The method of claim 41 , wherein said airway inflammation is asthma.44. The method of claim 37 , wherein Pand Pare each hydrogen atoms and R is a hydrogen atom.45. The method of claim 37 , wherein said airway inflammation is asthma. This application is a divisional application of U.S. application Ser. No. 12/089,141, now U.S. Pat. No. 8,273,792, filed Aug. 4, 2008, which is a Section 371 National Stage Application of International No. PCT/US2006/38326, filed Oct. 3, 2006, which claims benefit under 35 U.S.C. §119(e) to provisional U.S. application Ser. Nos. 60/723,052, filed Oct. 3, 2005, entitled “Anti-Inflammatory Actions of Neuroptectin D1/Protectin D1 and Its Natural Stereoisomers” and 60/749,786, filed Dec. 13, 2005, entitled “Anti-Inflammatory Actions of Neuroptectin D1/Protectin D1 and Its Natural Stereoisomers”, the contents of both are incorporated herein by reference in their entirety ...

PHARMACEUTICAL SEMI-SOLID COMPOSITION OF ISOTRETINOIN

Pharmaceutical semi-solid composition of Isotretinoin An oral pharmaceutical composition of isotretinoin containing at least two lipidic excipients, one of them being hydrophilic (i.e. having an HLB value superior or equal to 10), the other being an oily vehicle 113-. (canceled)14. An oral pharmaceutical composition in the form of a capsule comprising a semisolid suspension or a solution of isotretinoin and at least a first and a second lipidic excipient , the composition exhibiting a dissolution of at least 40% within 4 hours as measured using USP paddle apparatus at 150 rpm in an aqueous dissolution medium constituted by buffer of pH 7.5 , sodium lauryl sulfate 2.5% and pancreatin 1 g/L at 37° C.15. The oral pharmaceutical composition of claim 14 , wherein the composition exhibits an isotretinoin release rate of at least 60% within 4 hours.16. The oral pharmaceutical composition of claim 14 , wherein isotretinoin comprises between 1% to 25% w/w of the composition claim 14 , the first lipidic excipient comprises between 20% to 80% w/w of the composition and the second lipidic excipient comprises between 5% to 70% w/w of the composition.17. The oral pharmaceutical composition of claim 14 , wherein the first lipidic excipient is selected from the group consisting of glyceroyl macrogolglycerides claim 14 , polyethylene glycol esters claim 14 , and mixtures thereof.18. The oral pharmaceutical composition of claim 14 , wherein the second lipidic excipient is selected from the group consisting of vegetable oils claim 14 , medium chain triglycerides claim 14 , fatty acid esters claim 14 , glycerol oleate and mixtures thereof.19. The oral pharmaceutical composition of claim 14 , wherein the first lipidic excipient has a HLB value of at least 12.20. The oral pharmaceutical composition of claim 14 , wherein the first lipidic excipient has a HLB value of at least 13.21. The oral pharmaceutical composition of claim 14 , wherein the composition is a semi-solid suspension.22. ...

Methods of treating hypertriglyceridemia

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof

STABLE PHARMACEUTICAL COMPOSITION AND METHODS OF USING SAME

The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases. 1. A method of treating mixed dyslipidemia in a subject on statin therapy comprising , administering to the subject a pharmaceutical composition comprising about 2500 mg to 5000 mg per day of ethyl eicosapentaenoate and not more than about 5% docosahexaenoic acid or its esters , by weight of all fatty acids , to effect a reduction in fasting triglycerides of at least 10% and a reduction in LDL-C compared to placebo control.2. The method of wherein upon 12 weeks of said administration the subject exhibits a reduction in LDL-C of at least 5% compared to placebo control.3. The method of wherein the subject exhibits a reduction in fasting triglycerides of at least 15% compared to placebo control.4. The method of wherein upon 12 weeks of said administration the subject exhibits a reduction in fasting triglycerides of at least 20% compared to placebo control.5. The method of wherein upon 12 weeks of said administration the subject exhibits a reduction in fasting triglycerides of at least 25% compared to placebo control6. The method of wherein the subject exhibits a reduction in fasting VLDL-C compared to placebo control.7. The method of wherein the subject exhibits a reduction in fasting VLDL-C of at least 5% compared to placebo control.8. The method of wherein the subject exhibits a reduction in hs-CRP compared to placebo control.9. The method of wherein the subject exhibits a reduction in non-HDL-C compared to placebo control.10. The method of wherein the subject exhibits a reduction in total cholesterol compared to placebo control.11. The method of wherein the subject exhibits a reduction in non-HDL-C claim 1 , total cholesterol and VLDL-C compared to placebo control.12. The method of wherein the subject exhibits a reduction in oxidized LDL-C compared to placebo control.13 ...

Orally administered composition and dietary composition having serum lipid improving effect

The present invention provides an orally administered composition and a dietary composition, which have a serum lipid improving effect. The orally administered composition and dietary composition, having a serum lipid improving effect, according to the present invention camp rise 2.0% by weight or less of a DHA ethyl ester composition comprising 75% by weight or more of DHA ethyl ester. It is preferable to comprise 1.2% by weight or less of the DHA ethyl ester composition. It is preferable not to substantially comprise a DHA ethyl ester composition comprising 30% by weight or less of DHA ethyl ester.

METHODS OF TREATING HYPERTRIGLYCERIDEMIA

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. 1. A method of reducing triglycerides in a subject having fasting triglycerides of at least 500 mg/dl comprising , orally administering to the subject a pharmaceutical composition comprising about 4 g of ethyl eicosapentaenoate and not more than about 4% docosahexaenoic acid or its esters , by weight of all fatty acids , wherein 12 weeks of daily administration is effective to reduce fasting triglyceride levels in subjects who have fasting triglycerides levels of at least 500 mg/dl.2. The method of claim 1 , wherein the subject has a fasting baseline LDL-C from about 50 mg/dl to about 300 mg/dl.3. The method of claim 1 , wherein the subject has one or more of: a baseline fasting non-HDL-C of about 200 mg/dl to about 300 mg/dl claim 1 , a baseline fasting total cholesterol of about 250 mg/dl to about 300 mg/dl claim 1 , a baseline fasting VLDL-C of about 140 mg/dl to about 200 mg/dl claim 1 , and/or a baseline fasting HDL-C of about 10 mg/dl to about 80 mg/dl.4. The method of claim 1 , wherein 12 weeks of said daily administration is effective to reduce triglycerides by at least about 30% without increasing LDL-C in subjects who have fasting triglycerides levels of at least 500 mg/dl.5. The method of claim 1 , wherein 12 weeks of said daily administration is effective to reduce apolipoprotein B in subjects who have fasting triglycerides levels of at least 500 mg/dl.6. The method of claim 1 , wherein 12 weeks of said daily administration is effective to reduce VLDL-C in subjects who have fasting triglycerides levels of at least 500 mg/dl.7. The method of claim 1 , wherein the subject has a fasting baseline triglyceride level of 500 mg/dl to 1500 mg/dl.8. ...

METHODS OF TREATING HYPERTRIGLYCERIDEMIA

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. 1. A method of reducing triglycerides comprising , identifying a group of subjects having a median triglyceride level of at least 500 mg/dl and orally administering daily to at least one subject in the group of subjects a pharmaceutical composition comprising about 4 g of ethyl eicosapentaenoate and not more than about 4% docosahexaenoic acid or its esters , by weight of all fatty acids , for a period of 12 weeks to reduce fasting triglycerides in the at least one subject.2. The method of claim 1 , wherein the group of subjects has a median fasting baseline LDL-C from about 50 mg/dl to about 300 mg/dl.3. The method of claim 1 , wherein the group of subjects has one or more of: a median baseline fasting non-HDL-C of about 200 mg/dl to about 300 mg/dl claim 1 , a median baseline fasting total cholesterol of about 250 mg/dl to about 300 mg/dl claim 1 , a median baseline fasting VLDL-C of about 140 mg/dl to about 200 mg/dl claim 1 , and/or a median baseline fasting HDL-C of about 10 mg/dl to about 80 mg/dl.4. The method of claim 1 , wherein 12 weeks of said administering is effective to reduce triglycerides by at least about 30% without increasing LDL-C in the at least one subject.512. The method of claim 1 , wherein weeks of said administering is effective to reduce apolipoprotein B in the at least one subject.612. The method of claim 1 , wherein weeks of said administering is effective to reduce VLDL-C in the at least one subject.7. The method of claim 1 , wherein the group of subjects has a median fasting baseline triglyceride level of 500 mg/dl to 1500 mg/dl.8. The method of claim 1 , wherein the composition is present in one or more dosage units.9. The ...

Methods for Improving Cognitive Function and Decreasing Heart Rate

The present invention is directed to methods of improving cognitive function in subjects having age related cognitive decline or mild cognitive impairment and to methods of decreasing heart rate in a subject by administering dosage forms comprising docosahexaenoic acid (DHA) substantially free of eicosapentaenoic acid (EPA). 1. A method of treating age related cognitive decline (ARCD) or mild cognitive impairment (MCI) , comprising administering to a subject in need thereof about 0.8 g to about 4 g of docosahexaenoic acid (DHA) per day in a dosage form substantially free of eicosapentaenoic acid (EPA) and substantially free of arachidonic acid (ARA).27-. (canceled)8. The method of claim 1 , wherein the DHA is derived from an algal source.911-. (canceled)12. The method of claim 1 , wherein about 0.84 g to about 1.0 g of DHA is administered per day to the subject.13. (canceled)14. The method of claim 1 , wherein the DHA is administered in at least one unit dose.1516-. (canceled)17. The method of claim 14 , wherein the DHA in the unit dose is about 30% to about 99.5% (w/w) of the total fatty acid content of the unit dose.1819-. (canceled)20. The method of claim 14 , wherein the DHA in the unit dose comprises 35% to 96% (w/w) of the total weight of the unit dose.2140-. (canceled)41. The method of claim 14 , wherein the unit dose comprises about 860 mg to about 950 mg of DHA ethyl ester.4247-. (canceled)48. The method of claim 1 , wherein the dosage form is an oral unit dose.4954-. (canceled)55. A method of reducing heart rate claim 1 , comprising administering docosahexaenoic acid to a subject in need thereof about 0.8 g to about 4 g of docosahexaenoic acid (DHA) per day in a dosage form substantially free of eicosapentaenoic acid (EPA) and substantially free of arachidonic acid (ARA).56. The method of claim 55 , wherein about 0.9 g to about 3.6 g of DHA is administered to the subject per day.57. (canceled)58. The method of claim 55 , wherein about 0.84 g to about 1.0 g ...

STABLE PHARMACEUTICAL COMPOSITION AND METHODS OF USING SAME

The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases. 1. A method of treating a subject with fasting triglycerides of at least 500 mg/dl comprising , orally administering to the subject daily for a period of 12 weeks about 2500 mg to 5000 mg of ethyl eicosapentaenoate to lower triglycerides in the subject by at least 25% without increasing LDL-C by more than 5%.2. The method of wherein the subject has a fasting baseline LDL-C from about 50 mg/dl to about 300 mg/dl.3. The method of claim 1 , wherein the subject has one or more of: a baseline fasting non-HDL-C of about 200 mg/dl to about 300 mg/dl claim 1 , a baseline fasting total cholesterol of about 250 mg/dl to about 300 mg/dl claim 1 , a baseline fasting VLDL-C of about 140 mg/dl to about 200 mg/dl claim 1 , and/or a baseline fasting HDL-C of about 10 mg/dl to about 80 mg/dl.4. The method of claim 1 , comprising administering to the subject the pharmaceutical composition daily for the period of 12 weeks to effect a reduction in triglycerides of at least about 30% without increasing LDL-C in the subject.5. The method of claim 1 , comprising administering to the subject the pharmaceutical composition daily for the period of 12 weeks to effect a reduction in apolipoprotein B in the subject.6. The method of claim 1 , comprising administering to the subject the pharmaceutical composition daily for the period of 12 weeks to effect a reduction in VLDL-C in the subject.7. The method of claim 1 , wherein the composition is present in one or more dosage units.8. The method of claim 7 , wherein the dosage units are capsules. This application claims priority from co-pending U.S. Application Ser. No. 13/685,291 filed on Nov. 26, 2012, which claims priority to U.S. application Ser. No. 13/614,111 filed Sep. 13, 2012, which claims priority to U.S. application Ser. No. 13/458,496 filed ...

DPA-ENRICHED COMPOSITIONS OF OMEGA-3 POLYUNSATURATED FATTY ACIDS IN FREE ACID FORM

DPA-enriched pharmaceutical compositions of polyunsaturated fatty acids in free acid form, therapeutic methods for their use, and processes for refining the compositions from fish oil are presented. 1. A pharmaceutical composition , comprising:EPA, substantially in free acid form, in an amount of at least about 50% (a/a);DHA, substantially in free acid form, in an amount of at least about 15% (a/a);DPA, substantially in free acid form, in an amount of at least about 1% (a/a).2. The pharmaceutical composition of claim 1 , wherein:DPA is present in an amount of at least about 2% (a/a).3. The pharmaceutical composition of claim 1 , wherein:DPA is present in an amount of at least about 2.5% (a/a).4. The pharmaceutical composition of claim 1 , wherein:DPA is present in an amount of at least about 3% (a/a).5. The pharmaceutical composition of claim 1 , wherein:DPA is present in an amount of at least about 3.5% (a/a).6. The pharmaceutical composition of claim 1 , wherein:EPA is present in an amount of at least about 51% (a/a).7. The pharmaceutical composition of claim 1 , wherein:EPA is present in an amount of at least about 52% (a/a).8. The pharmaceutical composition of claim 1 , wherein:EPA is present in an amount of at least about 53% (a/a).9. The pharmaceutical composition of claim 1 , wherein:EPA is present in an amount of at least about 54% (a/a).10. The pharmaceutical composition of claim 1 , wherein:DHA is present in an amount of at least about 16% (a/a).11. The pharmaceutical composition of claim 1 , wherein:DHA is present in an amount of at least about 17% (a/a).12. The pharmaceutical composition of claim 1 , wherein:EPA is present in an amount of about 55% (a/a) to about 56% (a/a);DHA is present in an amount of about 19% (a/a) to about 20% (a/a); andDPA is present in an amount of about 4% (a/a) to about 5% (a/a).13. A pharmaceutical composition claim 1 , comprising:EPA, substantially in free acid form, in an amount of about 50% (m/m) to about 60% (m/m);DHA, ...

Nutritional Compensation For Western-Type Diet

Disclosed is the use of a composition comprising docosahexaenoic acid (DHA) and/or arachidonic acid (ARA) in human subjects that are on the typical ‘Western-type” high-fat high-sugar diet. It was found, in a humanized animal model, that said composition is capable of compensating for one or more of the adverse health effects of said diet. Particularly, an effect was found in body weight reduction, without a lowering of food intake. The composition can be administered as an oral (pharmaceutical) dosage unit, as a nutritional supplement, or as a component in a food or drink. 1. A method for supplementing the diet of a human subject which comprises providing a composition comprising an LCPUFA selected from the group consisting of docosahexaenoic acid (DHA) , arachidonic acid (ARA) , metabolic precursors thereof , and combinations thereof , as a food supplement for a human subject , wherein the human subject is on a diet wherein more than 40% of the total calories is from fats , and more than 40% of the total calories is from carbohydrates.2. The method according to claim 1 , wherein the daily dosage of ARA is 50 to 750 mg and/or the daily dosage of DHA is 50 to 450 mg.3. The method according to claim 1 , wherein ARA and DHA are administered in a ratio of from 1:3 to 9:1.4. The method according to claim 3 , wherein said ratio is 1:2 to 4:1.5. The method according to claim 1 , wherein DHA and ARA are administered in a single composition claim 1 , preferably selected from the group of tablets claim 1 , pills claim 1 , capsules claim 1 , caplets claim 1 , gelcaps claim 1 , oil drops claim 1 , sachets claim 1 , effervescent formulations claim 1 , and powders.6. The method according to claim 1 , wherein the composition is provided in a food or drink product.7. The method according to claim 1 , wherein the diet contains on average 25-40 wt % fat claim 1 , 40-55 wt % carbohydrates and 10-20 wt % protein.8. The method according to claim 1 , wherein the human subject is a child ...

METHOD FOR INCREASING PERFORMANCE OF OFFSPRING

Methods and compositions for increasing intestinal transport of nutrients or growth performance in the offspring of an animal are described. More specifically, a feed composition comprising an omega-3 fatty acid-containing composition for increasing intestinal transport of nutrients or growth performance in the offspring of the animal, and methods therefor, are described. 1151.-. (canceled)152. A method of increasing intestinal transport of nutrients in an offspring of an animal , the method comprising the steps ofadministering to the animal a feed composition comprising an algal composition comprising omega-3 fatty acids or esters thereof, wherein the omega-3 fatty acids comprise docosahexaenoic acid and eicosapentaenoic acid, wherein the ratio of docosahexaenoic acid to eicosapentaenoic acid in the algal composition is about 60:1 to about 1:1, wherein the feed composition as a final mixture comprises about 0.01% to about 60% by weight of the algal composition, and wherein the animal is a species of poultry; andincreasing intestinal transport in the offspring of the animal.153. The method of wherein the feed composition as a final mixture comprises about 0.01% to about 4.0% by weight of the algal composition.154. The method of wherein the animal is a chicken.155. The method of further comprising the step of increasing the growth performance of the offspring of the animal.156. The method of wherein the growth performance is selected from a group consisting of an increased growth rate of the offspring and a reduced feed to weight gain ratio for the offspring.157. A method of increasing intestinal transport of nutrients in an offspring of an animal claim 155 , the method comprising the steps ofadministering to the animal a feed composition comprising a non-algal composition comprising omega-3 fatty acids or esters thereof wherein the docosahexaenoic acid to eicosapentaenoic acid ratio in the non-algal composition is about 30:1 to about 2:1 and wherein the animal is a ...

COMPOSITIONS AND METHODS FOR LOWERING LEVELS OF HIGH-SENSITIVITY (HS-CRP) IN A SUBJECT

The present disclosure provides methods for treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. In some embodiments, the method comprises lowering high sensitivity CRP (hs-CRP) levels in a subject including, for example, a subject with a HbAvalue of about 5.00%-8.50% or at least about 6.8%. 1. A method of lowering a high-sensitivity CRP (hs-CRP) level in a subject having a HbAlevel of at least about 6% , the method comprising administering to the subject daily a pharmaceutical composition comprising about 3.5 g to about 4 g of eicosapentaenoic acid or a derivative thereof for a period of time effective to lower the hs-CRP level in the subject.2. The method of claim 1 , wherein the subject has a baseline triglyceride level of about 150-499 mg/dl.3. The method of claim 2 , wherein the subject is on statin therapy or stable statin therapy.4. The method of claim 1 , wherein the pharmaceutical composition comprises at least 90% claim 1 , by weight of all fatty acids present claim 1 , ethyl eicosapentaenoate.5. The method of claim 1 , wherein the pharmaceutical composition is encapsulated in a capsule.6. The method of claim 5 , wherein the capsule comprises gelatin.7. The method of claim 6 , wherein 1 to 4 of said capsules are administered to the subject each day.8. The method of claim 1 , wherein the subject has a HbAlevel of at least about 6.8%.9. The method of claim 8 , wherein the period of time is about 12 weeks and the hs-CRP level is lowered in the subject by at least about 5% compared to a placebo controlled subject who is on stable statin therapy and has not received the pharmaceutical composition.10. The method of claim 9 , wherein the hs-CRP level is reduced by at least about 10% claim 9 , compared to the placebo controlled subject.11. A method of lowering high- ...

PHARMACEUTICAL COMPOSITIONS COMPRISING EPA AND A CARDIOVASCULAR AGENT AND METHODS OF USING THE SAME

The present invention relates to, inter alia, pharmaceutical compositions comprising EPA and one or more cardiovascular agents, and to therapeutic methods for treating various diseases and disorders using the same. 1. A method of treating a subject having baseline fasting triglycerides of at least 500 mg/dl comprising , administering to the subject an HMG-CoA reductase inhibitor and 4 g per day of a pharmaceutical composition comprising at least 96% by weight ethyl eicosapentaenoate for a period effective to reduce fasting triglycerides by at least 45% without substantially increasing LDL-C relative to a control subject taking a concomitant HMG-CoA reductase inhibitor without said pharmaceutical composition.2. The method of wherein said period is a period effective to reduce fasting triglycerides by at least 50% without substantially increasing LDL-C relative to a control subject taking a concomitant HMG-CoA reductase inhibitor without said pharmaceutical composition.3. The method of wherein said period is a period effective to reduce fasting triglycerides by at least 55% without substantially increasing LDL-C relative to a control subject taking a concomitant HMG-CoA reductase inhibitor without said pharmaceutical composition.4. The method of wherein said period is about 1 to about 12 weeks.5. The method of wherein said period is 12 weeks.6. The method of wherein the composition is administered to the subject 1 to 4 times per day.7. The method of wherein the composition is present in one or more capsules.8. The method of wherein the subject has a baseline fasting non-HDL-C of about 200 mg/dl to about 300 mg/dl claim 1 , a baseline fasting total cholesterol of about 250 mg/dl to about 300 mg/dl claim 1 , a baseline fasting VLDL-C of about 140 mg/dl to about 200 mg/dl claim 1 , a baseline fasting LDL-C of about 40 mg/dl to about 115 mg/dl and a baseline fasting HDL-C of about 10 mg/dl to about 80 mg/dl.9. The method of wherein upon administering to the subject about ...

COMPOSITION COMPRISING A COMBINATION OF DHA AND EPA FOR ADMINISTRATION PRIOR TO COMMENCEMENT OF CHEMOTHERAPY

The invention relates to a composition comprising a combination of the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). The composition can be used for enhancing the activity of chemotherapy or radiotherapy and/or in the prevention or reduction of side effects caused by the chemotherapy or radiotherapy in a patient ill with cancer, the composition being intended for administration to the patient prior to the commencement of a cycle of chemotherapy or radiotherapy. 1. A composition comprising a combination of the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) for use in the improvement of the efficacy of a chemotherapy or of a radiation therapy and/or in the prevention or reduction of adverse effects caused by the chemotherapy or the radiation therapy in a patient who has developed cancer , wherein the composition is to be administered to the patient not until from 48 to 24 hours prior to the start of a cycle of the chemotherapy or of the radiation therapy , wherein the composition contains from 1.0 g/100 mL to 7.0 g/100 mL EPA and from 1.0 g/100 mL to 7.0 g/100 mL DHA.2. The composition for use as claimed in claim 1 , wherein the adverse effects are selected from the group consisting of gastrointestinal adverse effects claim 1 , hematologic adverse effects claim 1 , reduction in liver weight claim 1 , neurotoxic adverse effects claim 1 , adverse effects affecting the heart claim 1 , inflammatory adverse effects claim 1 , weight loss claim 1 , limited function of the immune system claim 1 , reduction of inflammations or a combination thereof.3. The composition for use as claimed in claim 1 , wherein the cancer is selected from the group consisting of solid tumors and nonsolid tumors claim 1 , wherein the solid tumors are preferably selected from the group consisting of colorectal cancer claim 1 , breast cancer claim 1 , pancreatic cancer claim 1 , liver cancer claim 1 , lung cancer claim 1 , and stomach ...

DPA-ENRICHED COMPOSITIONS OF OMEGA-3 POLYUNSATURATED FATTY ACIDS IN FREE ACID FORM

DPA-enriched pharmaceutical compositions of polyunsaturated fatty acids in free acid form, therapeutic methods for their use, and processes for refining the compositions from fish oil are presented. 1. A pharmaceutical composition , comprising:EPA, substantially in free acid form, in an amount of at least about 50% (a/a);DHA, substantially in free acid form, in an amount of at least about 15% (a/a);DPA, substantially in free acid form, in an amount of at least about 1% (a/a).2. The pharmaceutical composition of claim 1 , wherein:DPA is present in an amount of at least about 2% (a/a).3. The pharmaceutical composition of claim 1 , wherein:DPA is present in an amount of at least about 2.5% (ala).4. The pharmaceutical composition of claim 1 , wherein:DPA is present in an amount of at least about 3% (a/a).5. The pharmaceutical composition of claim 1 , wherein:DPA is present in an amount of at least about 3.5% (a/a).6. The pharmaceutical composition of claim 1 , wherein:EPA is present in an amount of at least about 51% (a/a).7. The pharmaceutical composition of claim 1 , wherein:EPA is present in an amount of at least about 52% (a/a).8. The pharmaceutical composition of claim 1 , wherein:EPA is present in an amount of at least about 53% (a/a).9. The pharmaceutical composition of claim 1 , wherein:EPA is present in an amount of at least about 54% (a/a).10. The pharmaceutical composition of claim 1 , wherein:DHA is present in an amount of at least about 16% (a/a).11. The pharmaceutical composition of claim 1 , wherein:DHA is present in an amount of at least about 17% (a/a).1218-. (canceled)19. A unit dosage form suitable for oral administration claim 1 , comprising:a capsule,wherein the capsule encapsulates at least 500 mg of a pharmaceutical composition comprising:EPA, substantially in free acid form, in an amount of at least about 50% (a/a);DHA, substantially in free acid form, in an amount of at least about 15% (a/a);DPA, substantially in free acid form, in an amount of ...

Omega 3 fatty acid formulations

The present invention provides highly purified omega-3 fatty acid formulations. Certain formulations provided herein have greater than 85% omega-3 fatty acids by weight. Certain other formulations provided herein contain EPA and DHA in a ratio of from about 4.01:1 to about 5:1. The invention also provides methods of using the dosage forms to treat a variety of cardiovascular, autoimmune, inflammatory, and central nervous system disorders by administering a formulation of the invention to a patient in need thereof.

RESOLVINS: BIOEMPLATES FOR NOVEL THERAPEUTIC INTERVENTIONS

The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy EPA or DHA compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- or tri-hydroxy derivatives of EPA or DHA (resolvins) that diminish, prevent, or eliminate inflammation or PMN migration, for example. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification. 6. The method of claim 5 , wherein the carbon atom at C-17 has an R configuration.7. The method of claim 5 , wherein the C-10 carbon atom has an S configuration and the carbon atom at C-17 has an S configuration.8. The method of claim 5 , wherein the C-10 carbon atom has an R configuration and the carbon atom at C-17 has an S configuration.98. The method of any of - claims 4 , wherein Pand Peach are hydrogen atoms claims 4 , or a pharmaceutically acceptable salt thereof.10. The method of claim 9 , wherein Z is a carboxylic acid or a carboxylic ester claim 9 , or a pharmaceutically acceptable salt thereof.11. The method of claim 10 , wherein Z is a carboxylic acid salt.128. The method of any of - claims 4 , wherein Z is COOR claims 4 , wherein Ris hydrogen claims 4 , (C1-C6) alkyl claims 4 , (C3-C8) cycloalkyl claims 4 , (C4-C11) cycloalkylalkyl claims 4 , or (C6-C16) arylalkyl claims 4 , or a pharmaceutically acceptable salt thereof. This application is a Continuation patent application of U.S. Utility patent application Ser. No. 10/639,714, ...

COMBINATION COMPOSITION USEFUL FOR TREATING CARDIOVASCULAR DISEASES

It is described the use of a combination consisting of a microcapsule suspension comprising one or more statins in alkyl esters of n-3 PUFA in which the statins are isolated from contact with the alkyl ester of n-3 PUFA by means of a polymeric membrane that can be easily disintegrated in the gastrointestinal medium, for the treatment of cardiovascular diseases. 1. Method for the prevention and/or treatment of acute myocardial infarction and acute coronary syndrome with a combination composition consisting of a microcapsule suspension comprising one or more statins in alkyl esters of n-3 PUFA wherein the statins are isolated from contact with the alkyl ester of n-3 PUFA by means of a polymeric membrane disintegrateable in gastrointestinal medium.2. A medicament for the prevention and/or treatment of acute myocardial infarction and acute coronary syndrome with a combination composition consisting of a microcapsule suspension comprising one or more statins in alkyl esters of n-3 PUFA wherein the statins are isolated from contact with the alkyl ester of N-3PUFA by means of a polymeric membrane disintegrateable in gastrointestinal medium.3. The medicament according to claim 2 , for the prevention and/or treatment of atrial fibrillation.4. The medicament according to claim 2 , for reducing the day of hospitalization due to atrial fibrillation.5. The medicament according to claim 3 , in which the atrial fibrillation is associated with acute myocardial infarction and acute coronary syndrome.6. The medicament according to claim 2 , for reducing the number of deaths due to acute myocardial infarction and acute coronary syndrome.7. The medicament according to claim 2 , for reducing the day of re-hospitalization for any pre-existing or new non cardiovascular comorbidity associated with acute myocardial infarction and acute coronary syndrome.8. The method according to claim 1 , wherein the statin is selected from the group consisting of simvastatin claim 1 , lovastatin claim 1 , ...

SYNERGISTIC COMPOSITION AND METHOD OF RETARDING AND AMELIORATING PHOTO INDUCED RETINAL DAMAGE AND CATARACTS WHILE AMELIORATING DRY EYE SYNDROME USING OMEGA CHOLINE

A composition and method of retarding and ameliorating eye diseases and injuries is disclosed. The method comprises administering a synergistic mixture of certain carotenoids, including the carotenoid astaxanthin, with phospholipid and triglyceride bound EPA and DHA derived from omega choline, in which said omega choline contains at least 30% total phospholipids, in a therapeutically effective amount to prevent, retard or treat eye central nervous system diseases or injuries, such as age-related macular degeneration, cataract, dry eye syndrome due to glandular inflammation and other central nervous system degenerative diseases, photic injury, ischemic diseases, and inflammatory diseases. 1Haematococcus pluvialis. A composition comprising a therapeutically effective amount of a multi-ingredient composition of mixed carotenoids including at least S ,S′-astaxanthin derived from , and one or more of lutein and/or trans-zeaxanthin or meso-zeaxanthin admixed with a therapeutically effective amount of omega choline containing phospholipid bound and triglyceride bound EPA and DHA in which said omega choline contains at least 15% total phospholipids.2. The composition according to claim 1 , wherein the composition includes 50 to 1000 mg of omega choline claim 1 , 0.5 to 8 mg of astaxanthin claim 1 , 2 to 15 mg of lutein and 0.2 to 12 mg of trans-zeaxanthin.3. The composition according to claim 1 , wherein said omega choline comprises not less than (n.l.t.) 15 g/100 g of marine phospholipids.4. The composition according to claim 1 , wherein the omega choline comprises n.l.t. 22 g/100 g of Omega-3 and less than 3 g/100 g of Omega-6.540-. (canceled)41. The composition according to claim 1 , wherein the omega choline comprises n.l.t. 22 g/100 g of Omega-3 and less than 3 g/100 g of Omega-6.42. The composition according to claim 1 , further comprising a delivery vehicle for administrating the composition orally.43. The composition according to claim 1 , comprising 0.5 to 8.0 ...

COMPOSITIONS AND METHODS FOR THE DISRUPTION OF MYCOBACTERIUM BIOFILM

The present disclosure provides methods and compositions for the disruption of biofilms produced by . Methods and compositions related to the prevention and treatment of infections in which biofilm formation is implicated are also provided. 1. A compound having a formula:{'br': None, 'sub': 3', '2', 'n', '2', '2', '4', '3, 'CH—(CH)—CH(OR)—CH—CH(OR′)—(CH)—CH(CH)—CY(Z)—R″'}wherein R″ is a lower alkyl group;n is an integer from 10 to 32;{'sub': '3', 'Y is —H; Z is —OH or —OCH; or Y and Z together form a carbonyl group with the carbon atom to which they are attached;'}one of R and R′ is an unsaturated fatty acyl group; andone of R and R′ is a polymethyl substituted fatty acyl group.2. The compound of wherein said compound is represented by the formula:{'br': None, 'sub': 3', '2', 'n', '2', '2', '4', '3', '3, 'CH(CH)—CH(OR)—CH—CH(OR′)—(CH)—CH(CH)—CH(OH)—CH,'}{'br': None, 'sub': 3', '2', 'n', '2', '2', '4', '3', '2', '3, 'CH(CH)—CH(OR)—CH—CH(OR′)—(CH)—CH(CH)—CH(OH)—CH—CH,'}{'br': None, 'sub': 3', '2', 'n', '2', '2', '4', '3', '3', '3, 'CH(CH)—CH(OR)—CH—CH(OR′)—(CH)—CH(CH)—CH(OCH)—CH,'}{'br': None, 'sub': 3', '2', 'n', '2', '2', '4', '3', '3', '2', '3, 'CH(CH)—CH(OR)—CH—CH(OR′)—(CH)—CH(CH)—CH(OCH)—CH—CH,'}{'br': None, 'sub': 3', '2', 'n', '2', '2', '4', '3', '3, 'CH(CH)—CH(OR)—CH—CH(OR′)—(CH)—CH(CH)—C(O)—CH, or'}{'br': None, 'sub': 3', '2', 'n', '2', '2', '4', '3', '2', '3, 'CH(CH)—CH(OR)—CH—CH(OR′)—(CH)—CH(CH)—C(O)—CH—CH.'}3. The compound of wherein n is an integer from 20 to 30.4. The compound of wherein said compound has a formula:{'br': None, 'sub': 3', '2', 'n', '2', '2', '4', '3, 'CH—(CH)—CH(OR)—CH—CH(OR′)—(CH)—CH(CH)—CH(OH)—R″'}the unsaturated fatty acyl group is an polyunsaturated fatty acyl group; and [{'br': None, 'sub': 3', '2', 'm', '2', '3', 'x, 'CH—(CH)—(CH—CH(CH))—C(O)—'}, 'wherein m is an integer from 8 to 22; and x is 3 or 4., 'the polymethyl substituted fatty acyl group has a formula5. The compound of wherein the polyunsaturated fatty acyl group is a ...

Therapeutic or prophylactic agent for corneal epithelium disorders and/or conjunctival epithelium disorders

The present invention provides an effective and safe prophylactic and therapeutic pharmaceutical agent and supplement for corneal epithelium disorders and/or conjunctival epithelial disorders. This is a therapeutic and/or prophylactic agent for corneal epithelium disorders and/or conjunctival epithelial disorders comprising eicosapentaenoic acid and/or docosahexaenoic acid, a glycerin ester or phospholipid comprising these fatty acids as constituent fatty acids, or a lower alcohol ester of these fatty acids as active ingredients. These preferably comprise EPA and/or DHA in the form of a refined fish oil or refined krill oil. A total of at least approximately 50 to 5,000 mg of EPA and/or DHA or the esters thereof are taken daily, thereby easing corneal epithelium disorders and/or conjunctival epithelial disorders. In addition, the amount of tears may be recovered.

STABLE PHARMACEUTICAL COMPOSITION AND METHODS OF USING SAME

The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases. 1. A method of treating mixed dyslipidemia in a subject in need thereof comprising , administering to the subject daily a statin and 2500 mg to about 5000 mg of ethyl eicosapentaenoate to reduce fasting triglycerides and LDL-C relative to subjects having mixed dyslipidemia who are receiving a statin without said ethyl eicosapentaenoate.2. The method of wherein said administering step reduces fasting triglycerides by at least 10% relative to subjects with mixed dyslipidemia who are receiving a statin without said ethyl eicosapentaenoate.3. The method of wherein said administering step reduces fasting triglycerides by at least 15% relative to subjects with mixed dyslipidemia who are receiving a statin without said ethyl eicosapentaenoate.4. The method of wherein said administering step reduces fasting triglycerides by at least 20% relative to subjects with mixed dyslipidemia who are receiving a statin without said ethyl eicosapentaenoate.5. The method of wherein said administering step reduces fasting triglycerides by at least 25% and LDL-C by at least 5% relative to subjects with mixed dyslipidemia who are receiving a statin without said ethyl eicosapentaenoate.6. The method of wherein said administering step reduces fasting apolipoprotein B relative to subjects with mixed dyslipidemia who are receiving a statin without said ethyl eicosapentaenoate.7. The method of wherein said administering step reduces fasting apolipoprotein B by at least 5% relative to subjects with mixed dyslipidemia who are receiving a statin without said ethyl eicosapentaenoate.8. The method of wherein said administering step reduces fasting VLDL-C relative to subjects with mixed dyslipidemia who are receiving a statin without said ethyl eicosapentaenoate.9. The method of wherein said administering ...

STABLE PHARMACEUTICAL COMPOSITION AND METHODS OF USING SAME

The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases. 1. A method of treating hypertiglyceridemia in a subject in need thereof comprising , administering to the subject daily a statin and 2500 mg to about 5000 mg of ethyl eicosapentaenoate to reduce fasting triglycerides and LDL-C relative to subjects having hypertiglyceridemia who are receiving a statin without said ethyl eicosapentaenoate.2. The method of wherein said administering step reduces fasting triglycerides by at least 10% relative to subjects with hypertiglyceridemia who are receiving a statin without said ethyl eicosapentaenoate.3. The method of wherein said administering step reduces fasting triglycerides by at least 15% relative to subjects with hypertiglyceridemia who are receiving a statin without said ethyl eicosapentaenoate.4. The method of wherein said administering step reduces fasting triglycerides by at least 20% relative to subjects with mixed dyslipidemia who are receiving a statin without said ethyl eicosapentaenoate.5. The method of wherein said administering step reduces fasting triglycerides by at least 25% and LDL-C by at least 5% relative to subjects with hypertiglyceridemia who are receiving a statin without said ethyl eicosapentaenoate.6. The method of wherein said administering step reduces fasting apolipoprotein B relative to subjects with hypertiglyceridemia who are receiving a statin without said ethyl eicosapentaenoate.7. The method of wherein said administering step reduces fasting apolipoprotein B by at least 5% relative to subjects with hypertiglyceridemia who are receiving a statin without said ethyl eicosapentaenoate.8. The method of wherein said administering step reduces fasting VLDL-C relative to subjects with hypertiglyceridemia who are receiving a statin without said ethyl eicosapentaenoate.9. The method of wherein said ...

METHODS OF TREATING MIXED DYSLIPIDEMIA

The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate. 1. A method of treating mixed dyslipidemia in a subject comprising , administering to the subject daily a statin and about 4 g of ethyl eicosapentaenoate to effect a reduction in fasting triglycerides and LDL-C relative to subjects having mixed dyslipidemia who are receiving a statin without said ethyl eicosapentaenoate.2. The method of wherein said administering step reduces fasting triglycerides by at least 10% relative to subjects with mixed dyslipidemia who are receiving a statin without said ethyl eicosapentaenoate.3. The method of wherein said administering step reduces fasting triglycerides by at least 15% relative to subjects with mixed dyslipidemia who are receiving a statin without said ethyl eicosapentaenoate.4. The method of wherein said administering step reduces fasting triglycerides by at least 20% relative to subjects with mixed dyslipidemia who are receiving a statin without said ethyl eicosapentaenoate.5. The method of wherein said administering step reduces fasting triglycerides by at least 25% and LDL-C by at least 5% relative to subjects with mixed dyslipidemia who are receiving a statin without said ethyl eicosapentaenoate.6. The method of wherein said administering step reduces fasting apolipoprotein B relative to subjects with mixed dyslipidemia who are receiving a statin without said ethyl eicosapentaenoate.7. The method of wherein said administering step reduces fasting apolipoprotein B by at least 5% relative to subjects with mixed dyslipidemia who are receiving a statin without said ethyl eicosapentaenoate.8. The method of wherein said administering step reduces fasting VLDL-C relative to subjects with mixed dyslipidemia who are receiving a statin without said ethyl eicosapentaenoate.9. The method of wherein said administering step reduces fasting VLDL-C by at least 15% relative to subjects with mixed dyslipidemia who are ...

METHODS OF TREATING MIXED DYSLIPIDEMIA

The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate. 1. A method of treating hypertriglyceridemia in a subject comprising , administering to the subject daily a statin and about 4 g of ethyl eicosapentaenoate to effect a reduction in fasting triglycerides and LDL-C relative to subjects having hypertriglyceridemia who are receiving a statin without said ethyl eicosapentaenoate.2. The method of wherein said administering step reduces fasting triglycerides by at least 10% relative to subjects with mixed dyslipidemia who are receiving a statin without said ethyl eicosapentaenoate.3. The method of wherein said administering step reduces fasting triglycerides by at least 15% relative to subjects with mixed dyslipidemia who are receiving a statin without said ethyl eicosapentaenoate.4. The method of wherein said administering step reduces fasting triglycerides by at least 20% relative to subjects with mixed dyslipidemia who are receiving a statin without said ethyl eicosapentaenoate.5. The method of wherein said administering step reduces fasting triglycerides by at least 25% and LDL-C by at least 5% relative to subjects with mixed dyslipidemia who are receiving a statin without said ethyl eicosapentaenoate.6. The method of wherein said administering step reduces fasting apolipoprotein B relative to subjects with mixed dyslipidemia who are receiving a statin without said ethyl eicosapentaenoate.7. The method of wherein said administering step reduces fasting apolipoprotein B by at least 5% relative to subjects with mixed dyslipidemia who are receiving a statin without said ethyl eicosapentaenoate.8. The method of wherein said administering step reduces fasting VLDL-C relative to subjects with mixed dyslipidemia who are receiving a statin without said ethyl eicosapentaenoate.9. The method of wherein said administering step reduces fasting VLDL-C by at least 15% relative to subjects with mixed dyslipidemia who ...

OPTIMIZED NUTRITIONAL FORMULATIONS, METHODS FOR SELECTION OF TAILORED DIETS THEREFROM, AND METHODS OF USE THEREOF

Nutritional compositions and formulations that optimize nutritional contents are provided. Dietary compositions and methods for tailoring such compositions to optimize levels of nutrients that have beneficial effects within specific ranges are provided. Dietary plans, and formulations comprising dietary products that comprise optimized levels of nutrients derived from phytochemicals, antioxidants, vitamins, minerals, lipids, proteins, carbohydrates, probiotics, prebiotics, microorganisms and fiber. Diet plans and modular nutritional packages comprising food and drink items tailored according to consumer patterns typed by diet, age, size, gender, medical conditions, family history, climate and the like are provided. 152-. (canceled)53. A method for selecting a nutritional formulation or plan for an individual , comprising:determining for the individual a diet cohort, the cohort being high plant food, high meat, or high seafood; andsupplementing the individual's diet with one or more nutritional modules comprising one or more of natural oils, butters, margarines, nuts, seeds, herbs, lipids, phytochemicals, antioxidants, vitamins, and minerals, so as to balance the individual's nutritional state.54. The method of claim 53 , which involves use of a kit comprising the formulation or modules claim 53 , wherein one or more of the following apply:(i) the kit comprises individual portions of food items for daily consumption;(ii) the kit comprises individual portions of food items for supplementation of daily diet of a subject;(iii) the kit comprises a label comprising at least one indication of the suitability of the modules or packages for a consumer with a specific dietary profile or cohort;(iv) the kit comprises an indication of the upper limit of average daily consumption of items in the kit or module; or(v) a label is attached to the packaging of the kit or module.55. The method of claim 53 , wherein the individual has signs or symptoms of a chronic disease.56. A ...

USE OF DHA, EPA OR DHA-DERIVED EPA FOR TREATING A PATHOLOGY ASSOCIATED WITH CELLULAR OXIDATIVE DAMAGE

The present invention relates to the use of an acid enriched in docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) or DHA-derived EPA for manufacturing a drug for the treatment of processes that involve associated oxidative damage. In particular, it is for the treatment of processes associated with neurodegenerative, ocular, ischaemic and inflammatory pathology, atherosclerosis, with oxidative damage to DNA and with physical exercise. 147-. (canceled)48. A method comprising administering a foodstuff comprising docosahexaenoic acid (DHA) , eicosapentaenoic acid (EPA) , or DHA-derived EPA to a subject affected by cellular oxidative damage , wherein said DHA , EPA , or DHA-derived EPA is incorporated into a glyceride , andwherein said DHA, EPA, or DHA-derived EPA is in a percentage by weight between 40 and 100% in relation to the total fatty acids or said DHA, EPA or DHA-derived EPA is incorporated into a sn-2 position of the glyceride.49. The method according to claim 48 , wherein the cellular oxidative damage comprises production of a reactive oxygen species.50. The method according to claim 49 , wherein the reactive oxygen species comprises a superoxide anion.51. The method according to claim 48 , wherein the cellular oxidative damage comprises a shortening of DNA telomeres.52. The method according to claim 48 , wherein the cellular oxidative damage comprises a premature cellular senescence.53. The method according to claim 48 , wherein the cellular oxidative damage is associated with a physiological condition selected from ageing claim 48 , physical exercise claim 48 , or hypoglycemia during or after physical exercise.54. The method according to wherein the cellular oxidative damage is associated with a disease selected from a neurodegenerative pathology claim 48 , an ischaemic pathology claim 48 , an inflammatory process claim 48 , or atherosclerosis.55. The method according to wherein said neurodegenerative pathology is selected from multiple sclerosis ...

PHARMACEUTICAL COMPOSITIONS COMPRISING DGLA, 15-OHEPA, AND/OR 15-HETRE AND METHODS OF REDUCING SEBUM PRODUCTION USING SAME

The present disclosure provides compositions comprising fatty acids, or derivatives thereof (e.g., C1-C4 esters) including, for example, DGLA, 15-OHEPA and/or 15-HETrE, used singly or in combination with anti-bacterial agents for the inhibition of sebum production. 1. A pharmaceutical composition comprising 15-HETrE and a retinoid analogue.2. The pharmaceutical composition of wherein the retinoid analogue is adapalene.3. A topically deliverable pharmaceutical composition comprising a therapeutically effective amount of 15-HETrE and a retinoid analogue.4. The topically deliverable composition of wherein the retinoid analogue is adapalene.5. The pharmaceutical composition of claim 2 , wherein the pharmaceutical composition comprises about 0.05 wt. % to about 0.3 wt. % of adapalene.6. The pharmaceutical composition of claim 2 , wherein the pharmaceutical composition comprises about 0.01 wt. % to about 20 wt. % of 15-HETrE.7. The pharmaceutical composition of claim 1 , wherein the composition is a cream.8. A method of treating or inhibiting development of acne in a subject in need thereof claim 1 , the method comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of .9. The method of claim 8 , wherein the step of administering comprises applying the pharmaceutical composition to an area of skin of the subject afflicted with acne lesions.10Propionibacterium acnes.. The method of claim 8 , wherein the acne is associated with11. The method of claim 8 , wherein the pharmaceutical composition is administered to the subject once a day claim 8 , twice a day claim 8 , or three times a day.12. The method of claim 8 , wherein the pharmaceutical composition is a cream.13. The method of claim 8 , wherein the pharmaceutical composition comprises about 0.1 wt. % to about 20 wt. % of 15-HETrE.14. The method of claim 8 , wherein the pharmaceutical composition comprises about 0.05 wt. % to about 0.3 wt. % of adapalene. This ...

COMPOSITIONS AND METHODS FOR LOWERING TRIGLYCERIDES WITHOUT RAISING LDL-C LEVELS IN A SUBJECT ON CONCOMITANT STATIN THERAPY

In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof. 114-. (canceled)15. A method of lowering triglycerides in a subject having mixed dyslipidemia on stable statin therapy having baseline fasting triglycerides of about 200 mg/dl to about 500 mg/dl , the method comprising orally administering to the subject daily a pharmaceutical composition comprising about 4 g of ethyl eicosapentaenoate and not more than about 4% docosahexaenoic acid or its esters , by weight of all fatty acids , for a period of at least about 4 weeks.16. The method of claim 15 , wherein the subject has coronary heart disease or a coronary heart disease risk equivalent.17. The method of claim 16 , wherein the subject has an LDL-C level of 40 mg/dl to 100 mg/dl prior to the administering step.18. The method of claim 15 , wherein LDL-C is reduced in the subject upon 4 weeks of said administering.19. The method of claim 18 , wherein the subject exhibits a reduction in one or more of: non-HDL-C claim 18 , VLDL-C claim 18 , Lp-PLA2 claim 18 , apolipoprotein B claim 18 , total cholesterol claim 18 , HDL-C or VLDL-TG.20. The method of claim 15 , wherein the subject exhibits a reduction in one or more of: non-HDL-C claim 15 , VLDL-C claim 15 , Lp-PLA2 claim 15 , apolipoprotein B claim 15 , total cholesterol claim 15 , HDL-C or VLDL-TG.21. The method of claim 15 , wherein the composition is present in one or more dosage units claim 15 ,22. A method of lowering triglycerides in a subject on stable statin therapy having baseline fasting triglycerides of about 200 mg/dl to about 500 mg/dl and an LDL-C level of 40 mg/dl to 100 mg/dl claim 15 , the method comprising orally administering to the subject daily a pharmaceutical composition claim 15 , present more than one dosage unit claim 15 , comprising about 4 g of ethyl eicosapentaenoate and not more than about 4% docosahexaenoic acid or its ...

LIPID-LOWERING ANTIDIABETIC AGENT

A composition which includes a salt of metformin and the use of the composition for treatment of or use in prediabetes, diabetes, lowering triglycerides and/or other conditions in mammals. 119-. (canceled)2344-. (canceled) The present application claims priority from U.S. provisional patent application 61/461,113 filed on Jan. 12, 2011, the contents of which arc herein incorporated by reference.1. Field of the InventionThe present invention relates to salts of poly unsaturated fatty acids with biguanides.2. Technical BackgroundDiabetes mellitus has become pandemic and according to a forecast by the World Health Organization, there will be a sharp increase in the number of diabetic patients by the year 2030. This is an ominous forecast, because managing the long-term complications of diabetes, which include nephropathy, neuropathy, retinopathy, and cardiovascular complications, will have a serious impact on public health budgets. The hallmark of diabetes is chronically elevated blood glucose levels. It is also known that abnormally elevated glucose levels have an adverse impact on glutathione levels in key diabetic tissues. Furthermore, increased oxidative stress and increased production of reactive oxygen species are implicated under hyperglycemic conditions.In spite of the early discovery of insulin and its subsequent widespread use in the treatment of diabetes, and the later discovery of and use of sulfonylureas, and thiazolidenediones, such as troglitazone, rosiglitazone or pioglitazone, as oral hypoglycemic agents, the treatment of diabetes remains less than satisfactory.The use of insulin requires multiple daily doses, usually by self-injection. Determination of the proper dosage of insulin requires frequent estimations of the sugar in urine or blood. Treatment of non-insulin dependent diabetes mellitus (type 2 diabetes, NIDDM) usually consists of a combination of diet, exercise, oral hypoglycemic agents, e.g., thiazolidenediones, and, in more severe cases, ...

Composition for Improving Membrane Composition and Functioning of Cells

It has now been found that after administration to a diseased person or person that is at risk for developing such disease of a neutraceutical or pharmaceutical composition that comprises: 2. The use according to claim 1 , characterized in that the composition further comprises a nucleotide fraction claim 1 , selected from the group consisting of nucleobases like uridine claim 1 , cytidine claim 1 , adenine claim 1 , guanidine claim 1 , thymidine claim 1 , their phosphorylated forms claim 1 , in particular the mono-phosphorylated forms such as uridine monophosphate claim 1 , but also adenosine and guanosine claim 1 , nucleotides and nucleosides.3. The use according to claim 1 , wherein the composition further comprises a digestible carbohydrate fraction claim 1 , preferably a source of galactose and/or ribose.4. The use according to claim 1 , wherein the composition comprises a lipid fraction from originating from a dairy product claim 1 , from eggs or from the endosperm of plant seeds or beans.5. The use according to claim 1 , wherein the lipid fraction comprises fat globules having a size of 0 claim 1 ,001-10 μm.6. The use according to claim 1 , characterized in that the composition comprises a protein fraction which provides cysteine and/or taurine and a lipid fraction claim 1 , and wherein the composition provides per daily dose:d) 400 to 3300 mg of DHA+DPA+EPA;e) a Uridine source which provides 0.08-3/324 Mol uridine,f) and wherein the product provides per 100 kJ 2-40 ug molybdenum and more than 0.0238 mg manganese.7. A composition for improving cognitive function in elderly subjects claim 1 , the composition having an energy content of 50-120 kcal claim 1 , a protein content of 1-10 g claim 1 , a lipids content of lipids 1-5 g claim 1 , and a content of digestible carbohydrates of 4-20 g claim 1 , which composition comprises:g) 1000-2000 mg DHA+DPA+EPAh) 30-280 mg cysteine or taurinei) 100-1000 mg phospholipidsj) 0.5-3 mg vitamin B6k) 50-500 ug folic acidl) 1- ...

METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS

Methods and compositions are disclosed to treat neuropsychiatric disorders based upon a new framework of diagnosis. Axis I biomarkers include genes related to prefrontal dopamine synthesis and/or dopamine degradation. Axis II includes genes related to re uptake of dopamine, norepinephrine and serotonin and autonomic hyperactivity. Axis III includes genes relates to impairments in inflammatory pathways, glutamate neurotransmission and/or neurotrophic factors. Axis IV includes genes related to glutamate reuptake and predisposition to addictive behavior, and obsessive compulsions. 1. A method of treating a patient having a disruption in a prefrontal dopamine axis (Axis I) with a medical food , the method comprising providing the patient with a medical food composition comprising a first compound that reduces degradation of dopamine and a second compound that increases synthesis of dopamine.2. The method of claim 1 , further comprising determining that the patient has a disruption in the prefrontal dopamine axis.3. The method of claim 1 , further comprising determining that the patient has a disruption in the prefrontal dopamine axis based by identifying one or more biomarkers indicating a disruption in the prefrontal dopamine axis.4. The method of claim 1 , further comprising determining that the patient has a disruption in the prefrontal dopamine axis based by identifying a disruption in the patient's catechol methyltransferase pathway(s).5. The method of claim 1 , further comprising determining that the patient has a disruption in the prefrontal dopamine axis based by identifying a polymorphism in the patient's COMT gene claim 1 , MTHFR gene or both COMT and MTHFR genes leading to a decrease in dopamine.6. The method of claim 1 , wherein providing the first compound that reduces degradation of dopamine comprises phosphatidylserine.7. The method of claim 1 , wherein providing the second compound that increases synthesis of dopamine comprises methylfolate.8. The method ...

REDUCTION OF RISK OF OBESITY

A nutritional composition comprising a significant amount of arachidonic acid (ARA) is described. Such nutritional composition is particularly suitable for infants below the age of 3 years, preferably between birth and 12 months of life. The composition can be used to reduce the risk of developing overweight/obesity and/or insulin resistance later in life. 1. A method for reducing the risk of development of obesity and/or insulin resistance , later in life comprising the step of administering a nutritional composition comprising a protein source , a lipid source and a carbohydrate source , the lipid source comprises arachidonic acid in an amount so as to provide between 5 and 100 mg of arachidonic acid per kg per day to an infant in the first 3 years of the infant.2. The method of claim 1 , wherein the infants have a predisposition to obesity and/or predisposition to insulin resistance. This application is a divisional of U.S. application Ser. No. 13/260,842, filed Sep. 28, 2011, which is a National Stage of International Application No. PCT/EP2010/054025, filed on Mar. 26, 2010, which claims priority to European Patent Application No. 09157086.1, filed on Apr. 1, 2009, the entire contents of which are incorporated herein by reference.This invention relates to the use of a nutritional composition such as an infant formula or a baby food, comprising an n-6 long chain polyunsaturated fatty acid to reduce the risk of the infant developing obesity and insulin resistance later in life.Mother's milk is recommended for all infants. However, in some cases breast feeding is inadequate or unsuccessful or inadvisable for medical reasons or the mother chooses not to breast feed either at all or for a period of more than a few weeks. Infant formulas have been developed for these situations. Similarly, the infant's nutritional needs remain specific until early childhood. There are situations where the nutritional needs cannot be adequately covered by family foods. Therefore, ...

AGENT FOR INHIBITING ELEVATION IN BLOOD GLUCOSE LEVEL

The present invention relates to a suppressor for increase in postprandial blood glucose level, which contains an ester of EPA or DHA as an active ingredient and is characterized by being administered between meals. The present invention provides a suppressor for increase in blood glucose level which is highly safe and has desired properties including storage stability, particularly a means for preventing postprandial hyperglycemia. 1. A method for inhibiting elevation in blood glucose level , which comprises administration of effective amount of an eicosapentaenoic acid ester or a docosahexaenoic acid ester between meals.2. The method according to claim 1 , wherein the administration is conducted between 2 hours after a meal and 1 hour before the next meal.3. The method according to claim 1 , wherein the eicosapentaenoic acid ester or the docosahexaenoic acid ester is a triglyceride comprising eicosapentaenoic acid or docosahexaenoic acid as a constituent fatty acid or is a Calkyl ester of eicosapentaenoic acid or docosahexaenoic acid.4. The method according to claim 1 , comprising administration of a purified fish oil whose total content of eicosapentaenoic acid and docosahexaenoic acid in all fatty acids is at least 20% by weight. The present invention relates to a composition for oral ingestion having an inhibitory action on elevation in blood glucose level, in particular a composition having an inhibitory action on elevation in postprandial blood glucose level.For the purpose of treatment or prevention of diseases such as diabetes, hyperglycemia and obesity, many studies have been made on means for inhibiting elevation in blood glucose level.Pharmaceutical preparations in which an ethyl ester of the polyunsaturated fatty acid eicosapentaenoic acid (the ester is hereinafter referred to as EPA-E) is contained as an active ingredient (which are exemplified by Epadel®) are used as pharmaceutical products for treating or preventing arteriosclerosis obliterans and ...

Compositions for improving mental performance

The present invention provides formulas for producing compositions for the structural/functional nutritional support for those who struggle with poor focus, concentration and/or memory. In addition, the present invention provides compositions comprising nutritional/botanical factors helpful to those who subjectively experience transient mental fatigue or poor cognitive function. The compositions of this invention consist primarily of the following ingredients B-complex vitamins, antioxidants, minerals, phosphatidyl serine (PS), choline, dimenthyl-aminoethanol (DMAE), docosahexaenoic acid (DHA), L-pyroglutamic acid, as well as herbal extracts from Bacopa monniera, Vinca minor , and Huperzia serrata . The present invention also relates to the administration of these compounds to alleviate mental fatigue or poor cognitive function.

Methods of treating hypercholesterolemia

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of treating hypercholesterolemia, comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.

METHODS OF TREATING HYPERTRIGLYCERIDEMIA

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. 1. A method of lowering high-sensitivity C-reactive protein in a subject in need thereof comprising , administering to the subject daily (a) about 4 g of a pharmaceutical composition comprising at least 96% pure ethyl-EPA and (b) a statin.2. The method of wherein the pharmaceutical composition contains substantially no DHA or derivative thereof.3. The method of wherein the subject has a triglyceride level of 500 mg/dl to about 2000 mg/dl.4. The method of wherein the subject has a triglyceride level of 750 mg/dl to about 2000 mg/dl.5. The method of wherein the subject is diabetic.6. The method of wherein said administration is continued for a period of at least 12 weeks.7. The method of wherein the subject exhibits at least a 20% reduction in high-sensitivity C-reactive protein after the period of at least 12 weeks compared to baseline.8. The method of wherein the subject exhibits at least a 35% reduction in fasting triglycerides compared to baseline and no statistically significant increase in LDL9. A pharmaceutical composition comprising an effective amount of at least 96% pure E-EPA and an HMG-CoA inhibitor for use in reducing hsCRP in patients with TGs above 500 mg/dl. This application is a continuation of U.S. application Ser. No. 13/198,221, filed Aug. 4, 2011, which is a continuation of U.S. application Ser. No. 12/702,889, filed Feb. 9, 2010, which claims priority to U.S. provisional application Ser. No. 61/151,291 filed Feb. 10, 2009, and U.S. provisional application Ser. No. 61/173,755 filed Apr. 29, 2009, each of which are incorporated by reference herein in their entireties.Cardiovascular disease is one of the leading causes of death in the ...

SUPPLEMENT COMPOSITION AND METHOD OF USE TO TREAT ANHIDROSIS

The present invention relates to a dietary supplement composition made of: linolenic expeller pressed soybean oil in the range of 65%-85%, Omega 3 (18/12) fish oil 15%-35%, and 1%-20% alpha-tocopherol and a method to use this composition to supplement the diet of a domestic animal, such as a canine or an equine. 1. A method for alleviating anhidrosis in an equine , the method comprising administering a nutritional supplement to said equine , the nutritional supplement consisting essentially of linolenic expeller pressed soybean oil to Omega 3 fish oil is ratio of 3:1 and alpha-tocopherol (natural vitamin E).2. The method of claim 1 , wherein 1 oz. of said nutritional supplement is administered per 300 lbs of said equine per day.3. The method of claim 2 , wherein the concentration of alpha-tocopherol is 12 claim 2 ,000 IU per day. This application is a continuation of U.S. application Ser. No. 13/012,255 filed on Jan. 24, 2011 and now U.S. Pat. No. ______, which is hereby incorporated by reference in its entirety.This application is related to U.S. provisional patent application Ser. No. 61/298,260 (hereby incorporated by reference in its entirety) filed Jan. 26, 2010 through U.S. application Ser. No. 13/012,255. This application is related to U.S. application Ser. Nos. ______and ______, filed concurrently with this application.The present invention is related to an animal nutritional supplement and, more particularly to a method of using an equine nutritional supplement to alleviate chronic or acute conditions in domestic animals such as equines and canines.Equines are known to suffer from a number of conditions related to vitamin and minerals deficiencies due to poor quality forage or hay, chronic colic, chronic diarrhea, or anorexia resulting from dental disease. In addition, there may also be disturbances in absorption as the result of liver or biliary tract disease, hypothyroidism, anemia and other pathological conditions of the digestive system and related ...

SUPPLEMENT COMPOSITION AND METHOD OF USE

The present invention relates to a dietary supplement composition made of: linolenic expeller pressed soybean oil in the range of 65%-85%, Omega 3 (18/12) fish oil 15%-35%, and 1%-20% alpha-tocopherol and a method to use this composition to supplement the diet of a domestic animal, such as a canine or an equine. 1. A method for alleviating chronic or acute conditions in a domestic animal , the method comprising administering a nutritional supplement to said domestic animal , the nutritional supplement consisting of linolenic expeller pressed soybean oil in the volume range of 65%-85% , Omega 3 fish oil 15%-35% , and 1%-20% alpha tocopherol (natural vitamin E) , as the only active ingredients in the nutritional supplement , wherein the chronic or acute conditions are selected from the group consisting of colic , joint swelling , joint pain , muscle soreness , poor muscle tone , inflammation associated with muscle injuries , and stifle locking.2. The method of claim 1 , wherein the domestic animal is an equine.3. The method of claim 2 , wherein 1 oz. of said nutritional supplement is administered per 300 lbs of said equine per day.4. The method of claim 3 , wherein the concentration of alpha-tocopherol ranges from 3 claim 3 ,000-28 claim 3 ,000 IU per day.5. A method for alleviating stifle locking in an equine claim 3 , the method comprising administering a nutritional supplement to said domestic animal claim 3 , the nutritional supplement consisting of linolenic expeller pressed soybean oil claim 3 , in the volume range of 65%-85% claim 3 , Omega 3 fish oil 15%-35% claim 3 , and 1%-20% alpha tocopherol (natural vitamin E) claim 3 , as the only active ingredients in the nutritional supplement claim 3 , wherein the Omega 3 fish oil has EPA and DHA of 18% EPA and 12% DHA.6. The method of claim 5 , wherein 1-3 oz. of said nutritional supplement is administered per 300 lbs of said equine per day.7. The method of claim 6 , wherein the concentration of alpha-tocopherol ...

POWDER EMULSIFIER

The present invention relates to an emulsifier comprising vegetable fibrous material with natural or artificial cavities and comprising at least cellulose, hemicellulose, soluble fibrous material and starch. The vegetable fibrous material is based on e.g. potato. The emulsifier also comprises a lipophilic phase constituting a maximum of 75% by weight of the total weight, wherein the emulsifier is in the form of a powder or a paste. The vegetable fibrous material constitutes a support phase in the emulsifier, and the emulsifier also comprises some form of dextrose, dextrose polymer, dextrin or dextrin polymer or a derivate thereof. 1. An emulsifier comprising vegetable fibrous material with natural or artificial cavities and comprising at least cellulose , hemicellulose , soluble fibrous material and starch , wherein the emulsifier also comprises a lipophilic phase constituting a maximum of 75% by weight of the total weight , wherein the emulsifier is in the form of a powder or a paste , wherein the vegetable fibrous material constitutes a support phase in the emulsifier and wherein the emulsifier also comprises some form of dextrose , dextrose polymer , dextrin or dextrin polymer or a derivative thereof.2. The emulsifier according to claim 1 , wherein the emulsifier is of the type oil-in-water-emulsifier.3. The emulsifier according to claim 1 , wherein the emulsifier has a HLB-value corresponding to at least 8.4. The emulsifier according to claim 3 , wherein the emulsifier has a HLB-value in an interval corresponding to from 12 to 18.5. The emulsifier according to claim 1 , wherein the vegetable fibrous material is based on potato claim 1 , beetroot claim 1 , pea claim 1 , tapioca claim 1 , carrot or parsnip claim 1 , or a combination thereof.6. The emulsifier according to claim 5 , wherein the vegetable fibrous material is based on potato raw material.7. A product comprising an emulsifier according to claim 1 , wherein the product is a pharmaceutical preparation ...

METHODS FOR TREATING CARDIOVASCULAR DISEASE IN STATIN-TOLERANT SUBJECTS

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease in a statin-intolerant subject in need thereof and, in particular, a method of blood lipid therapy in a statin-intolerant subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. 1. A method of treating a cardiovascular disease or disorder in a statin-intolerant subject in need thereof , the method comprising:(a) identifying a subject as intolerant to one or more statins; and(b) administering to the subject about 1 g to about 4 g per day of ethyl eicosapentaenoate.2. The method of claim 1 , wherein the ethyl eicosapentaenoate is administered to the subject 1 to 4 times per day.3. The method of claim 1 , wherein the ethyl eicosapentaenoate is present in a capsule.4. The method of claim 1 , wherein the subject is not on concomitant lipid-altering therapy.5. The method of claim 1 , wherein the subject is intolerant to one or more of: amlodipine claim 1 , atorvastatin claim 1 , fluvastatin claim 1 , lovastatin claim 1 , pitavastatin claim 1 , pravastatin claim 1 , rosuvastatin claim 1 , simvastatin and/or sitagliptin.6. The method of claim 1 , further comprising a step of measuring a baseline lipid profile in the subject prior to administering the ethyl eicosapentaenoate to said subject.7. The method of claim 6 , wherein the subject has one or more of: a fasting baseline triglyceride level of about 135 mg/dL to about 1500 mg/dL claim 6 , a baseline non-HDL-C value of about 200 mg/dL to about 300 mg/dL; a baseline total cholesterol value of about 250 mg/dL to about 300 mg/dL; a baseline VLDL-C value of about 140 mg/dL to about 200 mg/dL; and/or a baseline HDL-C value of about 10 to about 80 mg/dL.8. The method of wherein after administering to the subject said ethyl eicosapentaenoate daily for about 12 weeks claim 7 , the subject exhibits one or more of: ( ...

METHODS OF TREATING PEDIATRIC METABOLIC SYNDROME

In various embodiments, the present invention provides methods of treating and/or preventing pediatric metabolic syndrome comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. 1. A method of treating a pediatric metabolic syndrome in a subject in need thereof , the method comprising: '(b) administering to the subject about 1 g to about 4 g of ethyl eicosapentaenoate per day.', '(a) identifying a subject as having pediatric metabolic syndrome; and'}2. The method of claim 1 , wherein the subject has one or more of: excessive belly fat claim 1 , hypertension claim 1 , hyperlipidemia claim 1 , and/or hyperglycemia.3. The method of claim 1 , wherein the subject has three or more of: (a) a fasting glucose level of at least 110 mg/dL; (b) a waist circumference value in at least the 90th percentile based on an age and a gender associated with the subject; (c) a triglyceride level of at least 110 mg/dL; (d) an HDL-C level of no more than about 40 mg/dL; and (e) a blood pressure level in at least the 90th percentile based on the age claim 1 , gender and height associated with the subject.4. The method of claim 1 , wherein the subject has three or more of: (a) a fasting glucose level of at least 110 mg/dL; (b) a waist circumference value in at least the 75th percentile; (c) a triglyceride level of at least 100 mg/dL; (d) an HDL-C level of no more than about 50 mg/dL; and (e) a blood pressure level in at least the 90th percentile.5. The method of claim 1 , wherein the subject has three or more of: (a) an impaired glucose tolerance as determined by having two-hour glucose levels of 140 mg/dL to 199 mg/dL on the 75-gram oral glucose tolerance test; (b) a waist circumference value in at least the 90th percentile based on an age claim 1 , a gender claim 1 , and a race associated with the subject; (c) a triglyceride level in at least the 90th percentile based on the age and gender associated with ...

METHODS FOR TREATING HYPERTRIGLYCERIDEMIA

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy, comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof, wherein the subject is not on concomitant omega-3 fatty acid therapy. 1. A method of treating a cardiovascular disease or disorder in a subject in need thereof , the method comprising administering to the subject about 1 g to about 4 g per day of ethyl eicosapentaenoate , wherein the subject is not on concomitant omega-3 fatty acid therapy.2. The method of claim 1 , wherein the omega-3 fatty acid therapy comprises: prescribed pharmaceutical compositions which include an omega-3 fatty acid component claim 1 , over-the-counter compositions which include an omega-3 fatty acid component claim 1 , and dietary supplements which include an omega-3 fatty acid component.3. The method of claim 1 , wherein the omega-3 fatty acid therapy includes Lovaza® claim 1 , Max EPA® claim 1 , SuperEPA claim 1 , Super MaxEPA claim 1 , fish oil supplements claim 1 , and krill oil supplements.4. The method of claim 1 , wherein the subject ingests no more than about 1 g claim 1 , no more than about 0.9 g claim 1 , no more than about 0.8 g claim 1 , no more than about 0.7 g claim 1 , no more than about 0.6 g claim 1 , no more than about 0.5 g claim 1 , no more than about 0.4 g claim 1 , no more than about 0.3 g claim 1 , no more than about 0.2 g claim 1 , or no more than about 0.1 grams of omega-3 fatty acids per day claim 1 , excluding administration of the ethyl eicosapentaenoate.5. The method of claim 1 , wherein the ethyl eicosapentaenoate is administered to the subject 1 to 4 times per day.6. The method of claim 1 , wherein the subject is not on concomitant lipid-altering therapy.7. The method of claim 1 , further comprising a step of measuring a baseline lipid profile in the ...

STABLE PHARMACEUTICAL COMPOSITION AND METHODS OF USING SAME

The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases. 1. A pharmaceutical composition , comprising: fatty acids including (a) eicosapantaenoic acid in an amount selected from 1000 mg , 1650 mg and 2200 mg; (b) docosahexaenoic acid in an amount of about 20% , by weight of total fatty acids; and docosapentaenoic acid in an amount of about 5% , by weight of total fatty acids.2. The pharmaceutical composition of wherein the eicosapantaenoic acid is present in an amount of about 1000 mg.3. The pharmaceutical composition of wherein the eicosapantaenoic acid is present in an amount of about 1650 mg.4. The pharmaceutical composition of wherein the eicosapantaenoic acid is present in an amount of about 2200 mg.5. The composition of wherein the composition is present in one or more dosage units.6. The composition of wherein the dosage units comprise capsules.7. A method of reducing triglycerides in a subject in need thereof comprising claim 6 , administering to the subject daily a composition of .8. The method of wherein the subject has very high serum triglycerides and is at risk of pancreatitis. This application claims priority from co-pending U.S. application Ser. No. 13/685,281 filed Nov. 26, 2012, which claims priority to U.S. patent Ser. No. 13/614,146 filed Sep. 13, 2012, now U.S. Pat. No. 8,501,225, which claims priority to U.S. application Ser. No. 13/458,496 filed Apr. 27, 2012, now U.S. Pat. No. 8,445,003, which claims priority from U.S. application Ser. No. 12/769,885 filed Apr. 29, 2010, now U.S. Pat. No. 8,298,554 which claims priority to U.S. provisional patent application 61/173,763, filed Apr. 29, 2009, the entireties of each of which are hereby Incorporated by reference herein.Mixed omega-3 fatty acid esters are typically encapsulated in type 2a gelatin capsules containing gelatin (˜43.4%), glycerol (˜20%) and ...

Compositions and methods for using same for improving the quality of the meibum composition of meibomiam glands

This invention relates to methods for improving changing the quality of the meibum composition of the meibomian glands to enhance or improve the lipid layer of the tear and increase tear breakup time by way of elevating the omega-3 index in patients suffering from symptoms of dry eye, posterior blepharitis, and/or meibomian gland dysfunction. The methods comprise administering a supplementation of omega-3 fatty acids to a patient having an inflamed meibomian gland so as to facilitate an increase in the amount of omega-3's acting as an anti-inflammatory and, respectively, decrease the amount of omega-6′s (arachidonic acid) acting as an inflammatory in the composition of the meibum, thereby normalizing the lipid layer of the tear and effectively reducing the associated symptoms. In certain embodiments, the supplementation of omega-3's comprises the esterified or re-esterified triglyceride form. 1. A method for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands , comprising the steps of administering an effective amount of omega-3 fatty acids to a mammal having inflamed or dysfunctional meibomian glands , wherein said effective amount includes between 600 mg and 5 ,000 mg delivered on a daily dosage basis;increasing levels of anti-inflammatory omega-3's in a composition of meibum of said treated meibomian glands; anddecreasing levels of inflammatory omega-6's in said composition of meibum.2. The method for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands as defined in claim 1 , wherein said effective amount claim 1 , of omega-3. fatty acids comprises between. 2 claim 1 ,000 mg and 3 claim 1 ,000 mg on a daily dosage basis.3. The method for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands as defined in claim 1 , wherein said omega-3 fatty acids comprise the re-esterified triglyceride form.4. The method for improving the quality of the ...

SN-1(3) MONOACYLGLYCERIDES AND LIPID ABSORPTION

The present invention relates generally to the field of lipids and in particular aims at improving lipid absorption, for example under conditions of lipid maldigestion or malabsorption. One embodiment of the present invention relates to a composition comprising sn-1(3) monoacylglycerols, wherein the sn-1 or sn-3 position is occupied by an acyl group such as a fatty acid and the sn-2 position remains unoccupied. The fatty acid may be one with anti-inflammatory properties. 1. A method for the treatment or prevention of inflammatory disorders comprising the step of administering to a subject suffering from a lipid maldigestion or malabsorption condition a composition comprising a sn-1(3)-monoacylglycerol , wherein the acyl group is a fatty acid having anti-inflammatory properties.2. The method in accordance with claim 1 , wherein the fatty acid having anti-inflammatory properties is selected from the group consisting of eicosapentaenoic acid (EPA) claim 1 , docosahexaenoic acid (DHA) claim 1 , α-linolenic acid (ALA) claim 1 , stearidonic acid claim 1 , γ-linolenic acid (GLA) claim 1 , dihomo-γ-linolenic acid (DGLA) claim 1 , n-3 docosapentanenoic acid (DPA) claim 1 , sciadonic acid and juniperonic acid.3. The method in accordance with claim 1 , wherein the sn-1(3)-monoacylglycerol is selected from the group consisting of sn-1(3)-monoeicosapentaenoylglycerol claim 1 , sn-1(3)-mono docosahexaenoylglycerol claim 1 , sn-1(3)-monooctadecatrienoylglycerol claim 1 , sn-1(3)-monooctadecatetraenoylglycerol claim 1 , sn-1(3)-monoeicosatrienoylglycerol claim 1 , sn-1(3)-monodocosapentaenoylglycerol claim 1 , sn-1(3)-monosciadonylglycerol claim 1 , sn-1(3)-monojuniperonylglycerol or combinations thereof.4. The method in accordance with claim 1 , wherein the sn-1(3)-monoacylglycerol is sn-1(3) monoeicosapentaenoylglycerol.5. The method in accordance with claim 1 , wherein no more than 25 weight-% of the total monoacylglycerols are sn-2 monoacylglycerols.6. The method in accordance ...

FORMULATIONS OF LIPOPHILIC BIOACTIVE MOLECULES

This invention provides aqueous and non-aqueous clear formulations including at least one lipophilic bioactive molecules and an amphiphilic solubilizing agent. Exemplary aqueous formulations include a water-soluble reducing agent, which diminishes or prevents chemical degradation of the lipophilic bioactive molecule. The invention also provides methods of using the formulations of the invention. For example, the invention provides beverages including the formulations of the invention. The invention further provides methods of making the formulations and beverages. 181.-. (canceled)83. The method of claim 82 , wherein the ratio of said omega-fatty acid to said water-soluble reducing agent is between about 100:1 (w/w) and about 1:10 (w/w).84. The method of claim 82 , wherein the ratio of said omega-fatty acid to said water-soluble reducing agent is between about 10:1 (w/w) and about 1:10 (w/w).85. The method of claim 82 , wherein said omega-fatty acid is stable with respect to chemical degradation for at least 90 days when said formulation is stored at about 4° C.86. The method of claim 82 , wherein said omega-fatty acid is an omega-3-fatty acid.87. The method of claim 86 , wherein said omega-3-fatty acid is a member selected from docosahexaenoic acid (DHA) claim 86 , eicosapentaenoic acid (EPA) and alpha-linolenic acid (ALA).8889.-. (canceled)90. The method of claim 82 , wherein said water-soluble reducing agent is vitamin C claim 82 , a vitamin C derivative claim 82 , or a combination thereof.91. The method of claim 82 , wherein said solubilizing agent is a member selected from polyoxyethanyl-tocopheryl-sebacate (PTS) claim 82 , polyoxyethanyl-sitosterol-sebacate (PSS) claim 82 , polyoxyethanyl-cholesterol-sebacate (PCS) claim 82 , and combinations thereof.92. The method of claim 82 , wherein said omega-fatty acid is an omega-3-fatty acid; said water-soluble reducing agent is vitamin C; and said solubilizing agent is PTS.94. The composition of claim 93 , wherein the ...

OIL BODY EXTRACTION AND USES

The present invention provides a method of extracting naturally occurring oil bodies comprising obtaining material containing naturally occurring oil bodies, recovering the oil bodies in a wet preparation and drying the oil bodies; and dried oil bodies obtained by the method and uses thereof. 1. A method of extracting naturally occurring oil bodies comprising:(i) obtaining material containing naturally occurring oil bodies;(ii) recovering the oil bodies in a wet preparation;(iii) drying the oil bodies.2. The method of wherein the dried oil bodies have a water activity of less than 0.3.3Euglena.. The method of wherein the material containing the naturally occurring oil bodies is selected from one or more of seeds claim 1 , pollen claim 1 , flowers claim 1 , roots and stems of flowering plants claim 1 , the spores and vegetative organs of non-flowering plants claim 1 , algae claim 1 , microalgae claim 1 , animal cells claim 1 , fungi and protists such as4echium. The method of wherein the seeds are seeds or kernels from one or more of the following plants claim 3 , sunflower claim 3 , soybean claim 3 , oil palm claim 3 , safflower claim 3 , almond claim 3 , macadamia claim 3 , cotton seed claim 3 , ground nut claim 3 , coconut claim 3 , oil seed rape claim 3 , claim 3 , borage claim 3 , linseed/flax/hemp claim 3 , evening primrose claim 3 , rice claim 3 , wheat claim 3 , oat claim 3 , maize and barley.5. The method of wherein the oil bodies contain triacylglycerol molecules enriched in unsaturated fatty acids6. The method of wherein the oil bodies contain omega-3 or other essential fatty acids7. The method of wherein the oil bodies are spray dried.8. The method of wherein before drying the oil bodies a carrier is added to the wet preparation.9. The method of wherein the carrier is a protein or a sugar.10. The method of wherein the carrier is maltodextrin.11. The method of wherein the dried oil bodies are in a powder form.12. The method of wherein the dried oil bodies ...

PLANT DERIVED SEED EXTRACT RICH IN ESSENTIALLY FATTY ACIDS DERIVED FROM SALVIA HISPANICA L. SEED: COMPOSITION OF MATTER, MANUFACTURING PROCESS AND USE

A L. derived seed oil extract composition of matter containing from 60-88% PUFAs in a ratio of from 3.1:1-3.3:1 of ALA to LA, 4-10% of C-18 mono-unsaturated fatty acid, 1-5% of C-18 saturated fatty acid and 4-8% of C-16 saturated fatty acid in a mixed triglyceride form stable at room temperature of 12-24 months containing a mixture of selected antioxidants. 121-. (canceled)22Salvia hispanica. A method of manufacturing a L. derived seed oil comprising from 60-88% PUFAs in a ratio of from 3.1:1-3.3:1 of alpha-linolenic acid (ALA) to linoleic acid (LA) , 4-10% of C-18 mono-unsaturated fatty acid , 1-5% of C-18 saturated fatty acid and 4-8% of C-16 saturated fatty acid in a mixed triglyceride form , comprising:{'i': 'Salvia hispanica', 'sub': '2', 'extracting seed oil from a cracked seed biomass of L. seed using supercritical fluid COextraction;'}fractionating the resulting seed oil extract into light and heavy fractions; andseparating the heavy fraction from the light fraction to form the final seed oil.23. The method according to claim 22 , and further comprising treating the heavy fraction of the seed oil extract with antioxidants to impart a desired room temperature stability.24. The method according to claim 23 , and further comprising adding lipophilic antioxidants to increase the room temperature stability of the resulting seed oil extract.25. The method according to claim 24 , and further comprising adding lipophilic antioxidants either alone or in combination with a) phenolic antioxidants including at least one of sage claim 24 , oregano claim 24 , and rosemary; b) tocopherol; c) tocotrienol(s); d) carotenoids including at least one of astaxanthin claim 24 , lutein claim 24 , and zeaxanthin; e) ascorbylacetate; f) ascorbylpalmitate; g) Butylated hydroxytoluene (BHT); h) Docosapentaenoic Acid (BHA); and i) Tertiary Butyl hydroquinone (TBHQ).26. The method according to claim 22 , and further comprising treating the heavy fraction of the seed oil extract with ...

COMPOSITIONS CONTAINING OMEGA-3 OIL WITH AN ANTI-INFLAMMATORY AGENT AND USES THEREOF

The invention provides compositions containing omega-3 oil and at least one anti-inflammatory agent and/or at least one gastrotoxic, nephrotoxic, or hepatotoxic pharmaceutical agent. The invention further provides kits containing these compositions and methods for decreasing pain or inflammation, decreasing the symptoms of an allergic condition, and/or the gastrotoxicity, nephrotoxicity, and hepatotoxicity of a pharmaceutical agent in a subject (e.g., a human) or companion animal requiring the administration of at least one composition containing omega-3 oil. The invention also provides methods for formulating an anti-inflammatory agent to increase its absorption rate requiring the mixing of omega-3 oil with the anti-inflammatory agent and methods of concentrating an omega-3 oil. 1. A composition comprising an omega-3 oil and at least one anti-inflammatory agent.2. The composition of claim 1 , wherein said composition is formulated as a liquid.3. The composition of claim 1 , further comprising at least one absorption enhancer.4. The composition of claim 1 , wherein the omega-3 oil is from a natural source.5. The composition of claim 4 , wherein the natural source is selected from the group consisting of: salmon claim 4 , herring claim 4 , mackerel claim 4 , and sardines.6. The composition of claim 1 , wherein the omega-3 oil is an alkyl ester of a fatty acid.7. The composition of claim 1 , wherein the omega-3 oil is an alkyl ester of eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA) claim 1 , or a mixture of EPA and DHA.8. The composition of claim 1 , wherein the omega-3 oils are in the form of triglycerides.9. The composition of claim 1 , wherein the omega-3 oils are a mixture of triglycerides and free fatty acids.10. The composition of claim 1 , wherein the omega-3 oil is high grade.11. The composition of claim 10 , wherein the high grade omega-3 oil is OmegaMaine omega-3 oils.12. The composition of claim 2 , wherein said composition is formulated in a ...

SELF-EMULSIFYING COMPOSITION OF OMEGA3 FATTY ACID

This invention provides a self-emulsifying composition comprising 50 to 95% by weight in total of at least one compound selected from the group consisting of ω3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters; and 5 to 50% by weight of an emulsifier having a hydrophilic lipophilic balance of at least 10. The composition has no or reduced ethanol content, and exhibits excellent self-emulsifying property, dispersibility in the composition, emulsion stability, and absorption property. The composition is adapted for use as a drug. 1. A self-emulsifying composition comprising:a) 50 to 95% by weight in total amount of the composition of at least one compound selected from the group consisting of eicosapentaenoic acid, docosahexaenoic acid and their pharmaceutically acceptable salts and esters;b) 1 to 20% by weight in total amount of the composition of a sucrose fatty acid ester as an emulsifier;c) 3 to 40 parts by weight of a glycerin based on 100 parts by weight of said component a); andd) up to 4% by weight of ethanol in total amount of the composition.2. The self-emulsifying composition according to claim 1 , wherein said 1 to 20% by weight of component b) of the sucrose fatty acid ester is at least one member selected from the group consisting of sucrose laurate claim 1 , sucrose myristate claim 1 , sucrose palmitate claim 1 , sucrose stearate claim 1 , and sucrose oleate.3. The self-emulsifying composition according to claim 1 , wherein said 50 to 95% of component a) is icosapentate claim 1 , docosahexaenoate claim 1 , or both icosapentate and docosahexaenoate.4. The self-emulsifying composition according to claim 1 , wherein said 50 to 95% of component a) is ethyl icosapentate claim 1 , ethyl docosahexaenoate claim 1 , or both ethyl icosapentate and ethyl docosahexaenoate. This application is a 37 C.F.R. §1.53(b) divisional of U.S. application Ser. No. 13/321,801, filed Nov. 21, 2011, which is the National Phase of PCT ...

HIGHLY PURIFIED ETHYL EPA AND OTHER EPA DERIVATIVES

A pharmaceutical preparation comprising EPA in an appropriately assimilable form where of all the fatty acids present in the preparation at least 90%, and preferably at least 95%, is in the form of EPA and where less than 5%, and preferably less than 3%, is in the form of DHA is provided. 1. A composition comprising eicosapentaenoic acid , wherein the composition contains no docosahexaenoic acid and the composition is present in a capsule.2. The composition of wherein the composition contains less than 5% of any fatty acid other than eicosapentaenoic acid.3. The composition of wherein the composition contains less than 3% of any fatty acid other than eicosapentaenoic acid.4. The composition of wherein the eicosapentaenoic acid comprises ethyl-eicosapentaenoic acid claim 2 , lithium-eicosapentaenoic acid claim 2 , mono- claim 2 , di- or triglyceride eicosapentaenoic acid claim 2 , or an ester claim 2 , salt or free acid of eicosapentaenoic acid.5. The composition of wherein the eicosapentaenoic acid comprises ethyl-eicosapentaenoic acid or an ester thereof.6. The composition of wherein the capsule is a gelatin capsule.7. The composition of where the composition comprises at least 90% wt/wt ethyl-eicosapentaenoic acid or an ester thereof.8. The composition of where the composition comprises at least 95% wt/wt ethyl-eicosapentaenoic acid or an ester thereof.98. The composition of any one of - wherein the eicosapentaenoic acid is present in the composition in an amount of 250 mg to 1000 mg.10. A composition comprising 250 mg to 1000 mg of eicosapentaenoic acid claims 1 , wherein the composition contains no docosahexaenoic acid claims 1 , less than 5% of any fatty acid other than eicosapentaenoic acid claims 1 , and the composition is present in a capsule.11. A composition comprising 250 mg to 1000 mg of ethyl-eicosapentaenoic acid or an ester thereof claims 1 , wherein the composition contains no docosahexaenoic acid claims 1 , less than 5% of any fatty acid other than ...

Statin and Omega-3 Fatty Acids for Lipid Therapy

A method and composition for lipid therapy. In some embodiments, the method comprises providing a subject group having a baseline triglyceride level of 200 to 499 mg/dl and being at or near its low-density lipoprotein cholesterol (LDL-C) level goal, and reducing the triglyceride level and the non-high-density lipoprotein cholesterol (non-HDL-C) level of the subject group as compared to treatment with a 3-hydroxy-3-methyl glutaryl coenzyme A (HMG CoA) inhibitor alone, by administering to the subject group an effective amount of an HMG CoA inhibitor and a composition comprising omega-3 fatty acids. 1. A composition for lipid therapy in a subject comprising a fixed dosage form comprising an HMG CoA inhibitor and natural or synthetic omega-3 fatty acids or pharmaceutically acceptable esters , derivatives , conjugates , precursors or salts thereof , or mixtures thereof.2. The composition of claim 1 , wherein the composition comprises a solvent system including solubilizers in amounts of less than 25% w/w based on the total weight of the solvent system.3. The composition of claim 1 , wherein the composition comprises a solvent system including solubilizers in amounts of less than 10% w/w based on the total weight of the solvent system.4. The composition of claim 1 , wherein the composition comprises a solvent system including no solubilizers other than the omega-3 fatty acids.5. The composition of claim 1 , wherein omega-3 fatty acids comprise omega-3 polyunsaturated claim 1 , long-chain fatty acids claim 1 , esters of omega-3 fatty acids with glycerol claim 1 , esters of omega-3 fatty acids and a primary claim 1 , secondary or tertiary alcohol claim 1 , or mixtures thereof.6. The composition of claim 1 , wherein the omega-3 fatty acids are present in a concentration of at least 40% by weight as compared to the total fatty acid content of the composition.7. The composition of claim 1 , wherein the omega-3 fatty acids are present in a concentration of at least 80% by ...

STABLE PHARMACEUTICAL COMPOSITION AND METHODS OF USING SAME

The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases. 1. A method of treating high triglycerides in a subject receiving statin therapy comprising , administering to the subject daily for a period effective to reduce triglycerides in the subject a pharmaceutical composition comprising omega-3 fatty acids including: (a) about 1100 mg to about 1200 mg of eicosapentaenoic acid; (b) docosahexaenoic acid , and (c) docosapentaenoic acid , wherein the docosahexaenoic acid comprises not more than about 20% by weight of fatty acids in the composition and the docosapentaenoic acid comprises not more than about 7% by weight of fatty acids present in the composition.2. The method of wherein the composition is present in one or more dosage units.3. The method of wherein the dosage units comprise capsules.4. A method of treating high triglycerides in a subject receiving statin therapy comprising claim 2 , administering to the subject daily for a period effective to reduce triglycerides in the subject a pharmaceutical composition comprising omega-3 fatty acids including: (a) about 1700 mg to about 1800 mg of eicosapentaenoic acid; (b) docosahexaenoic acid claim 2 , and (c) docosapentaenoic acid claim 2 , wherein the docosahexaenoic acid comprises not more than about 20% by weight of fatty acids in the composition and the docosapentaenoic acid comprises not more than about 7% by weight of fatty acids in the composition.5. The method of wherein the composition is present in one or more dosage units.6. The method of wherein the one or more dosage units comprise capsules.7. A method of treating high triglycerides in a subject receiving statin therapy comprising claim 5 , administering to the subject daily for a period effective to reduce triglycerides in the subject a pharmaceutical composition comprising omega-3 fatty acids including: (a) ...

STABLE PHARMACEUTICAL COMPOSITION AND METHODS OF USING SAME

The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases. 1. A method of lowering triglycerides in a subject with triglycerides of at least 500 mg/dl comprising , administering to the subject daily for a period effective to reduce triglycerides in the subject a pharmaceutical composition comprising omega-3 fatty acids including: (a) about 1100 mg to about 1200 mg of eicosapentaenoic acid; (b) docosahexaenoic acid , and (c) docosapentaenoic acid , wherein the docosahexaenoic acid comprises not more than about 20% by weight of fatty acids in the composition and the docosapentaenoic acid comprises not more than about 7% by weight of fatty acids present in the composition.2. The method of wherein the composition is present in one or more dosage units.3. The method of wherein the dosage units comprise capsules.4. A method of lowering triglycerides in a subject with triglycerides of at least 500 mg/dl comprising claim 2 , administering to the subject daily for a period effective to reduce triglycerides in the subject a pharmaceutical composition comprising omega-3 fatty acids including: (a) about 1700 mg to about 1800 mg of eicosapentaenoic acid; (b) docosahexaenoic acid claim 2 , and (c) docosapentaenoic acid claim 2 , wherein the docosahexaenoic acid comprises not more than about 20% by weight of fatty acids in the composition and the docosapentaenoic acid comprises not more than about 7% by weight of fatty acids in the composition.5. The method of wherein the composition is present in one or more dosage units.6. The method of wherein the one or more dosage units comprise capsules.7. A method of lowering triglycerides in a subject with triglycerides of at least 500 mg/dl comprising claim 5 , administering to the subject daily for a period effective to reduce triglycerides in the subject a pharmaceutical composition comprising ...

OMEGA-3 PENTAENOIC ACID COMPOSITIONS AND METHODS OF USE

Orally administrable composition comprising fatty acids, wherein at least 50% by weight of the fatty acids comprise omega-3-fatty acids, salts or derivatives thereof, wherein the omega-3 fatty acids comprise eicosapentaenoic acid (EPA; C20:5-n3), docosapentaenoic acid (DPA; C22:5-n3), and docosahexaenoic acid (DHA; C22:6-n3), wherein the ratio of DHA to EPA (DHA:EPA) is less than 1:20, and wherein the ratio of DHA to DPA (DHA:DPA) is less than 2:1 are provided. These compositions can be used for the treatment or prophylaxis of dyslipidemic, cardiovascular, CNS, inflammatory, and other diseases/conditions or risk factors therefore. 1. A method of reducing triglyceride levels in a subject from a baseline triglyceride level , comprising administering to the subject a composition comprising fatty acids , wherein at least 50% by weight of the fatty acids comprise omega-3 fatty acids , salts , esters , or derivatives thereof , wherein the omega-3 fatty acids comprise eicosapentaenoic acid (EPA) and docosapentaenoic acid (DPA) and wherein the ratio of docosahexaenoic acid to DHA to EPA (DHA:EPA) is less than 1:10 , and wherein the ratio of DHA to DPA (DHA:DPA) is less than 2:1.2. The method of claim 1 , wherein the ratio of DHA:EPA is less than 1:20.3. The method of claim 1 , wherein the ratio of DHA:DPA is less than 1:1.4. The method of claim 1 , wherein the ratio of EPA to DPA (EPA:DPA) is between 30:1 and 1:1.5. The method of claim 1 , wherein the composition comprises DHA in an amount less than 5% of the total amount of fatty acids.6. The method of claim 1 , wherein the composition comprises EPA in an amount between about 80% and about 90% of the total amount of fatty acids.7. The method of claim 1 , wherein the composition comprises DPA in an amount between about 5% and about 15% of the total amount of fatty acids.8. The method of claim 1 , wherein the composition comprises DPA free fatty acid or a salt claim 1 , ester or derivative of DPA.9. The method of claim 1 , ...

METHODS OF ADMINISTERING COMPOSITIONS COMPRISING DOCOSAPENTAENOIC ACID

The present invention relates to compositions comprising docosapentaenoic acid and methods of reducing lipid parameters, such as triglycerides, total cholesterol, low density lipoprotein (LDL) cholesterol, non-HDL cholesterol, free fatty acids, and other lipids, comprising administration of omega-3 docosapentaenoic acid. 1. A pharmaceutical composition comprising eicosapentaenoic acid (EPA) and docosapentaenoic acid (DPA) , wherein the amount of EPA and DPA is about 55% or more by weight of the total amount of fatty acids , and wherein the ratio of DHA:DPA is no more than 1:1.2. The composition of claim 1 , wherein the amount of EPA and DPA is selected from the group consisting of about 60% or more claim 1 , about 65% or more claim 1 , about 70% or more claim 1 , about 75% or more claim 1 , about 80% or more claim 1 , about 85% or more claim 1 , and about 90% or more by weight of the total amount of fatty acids.3. The composition of claim 1 , wherein the composition comprises omega-6 fatty acids in an amount of no more than 6% of total amount of fatty acids.4. The composition of claim 1 , wherein the composition comprises a daily dosage of DPA of about 120 mg/day to about 150 mg/day.5. The composition of claim 1 , wherein the composition comprises a daily dosage of DPA of about 150 mg/day to about 200 mg/day.6. The composition of claim 1 , wherein the composition comprises a daily dosage of DPA of about 200 mg/day to about 250 mg/day.7. The composition of claim 1 , wherein the composition comprises a daily dosage of DPA of about 250 mg/day to about 300 mg/day.8. The composition of claim 1 , wherein the composition comprises a daily dosage of DPA of about 300 mg/day to about 400 mg/day.9. The composition of claim 1 , wherein the composition comprises a daily dosage of DPA of about 400 mg/day to about 600 mg/day.10. The composition of claim 1 , wherein the composition comprises a daily dosage of DPA of about 600 mg/day to about 1000 mg/day.11. The composition of claim ...

METHODS OF ADMINISTERING COMPOSITIONS COMPRISING DOCOSAPENTAENOIC ACID

The present invention relates to compositions comprising docosapentaenoic acid and methods of reducing lipid parameters, such as triglycerides, total cholesterol, low density lipoprotein (LDL) cholesterol, non-HDL cholesterol, free fatty acids, and other lipids, comprising administration of omega-3 docosapentaenoic acid. 1. A method of reducing triglyceride levels in a subject from a baseline triglyceride level , comprising administering to the subject a composition comprising a daily dosage of docosapentaeoic acid (DPA) of about 120 mg/day to about 150 mg/day.2. The method of claim 1 , wherein the composition comprises a daily dosage of DPA of about 150 mg/day to about 200 mg/day.3. The method of claim 1 , wherein the composition comprises a daily dosage of DPA of about 200 mg/day to about 250 mg/day.4. The method of claim 1 , wherein the composition comprises a daily dosage of DPA of about 250 mg/day to about 300 mg/day.5. The method of claim 1 , wherein the composition comprises a daily dosage of DPA of about 300 mg/day to about 400 mg/day.6. The method of claim 1 , wherein the composition comprises a daily dosage of DPA of about 400 mg/day to about 600 mg/day.7. The method of claim 1 , wherein the composition comprises a daily dosage of DPA of about 600 mg/day to about 1000 mg/day.8. The method of claim 1 , wherein the composition further comprises eicosapentaenoic acid (EPA) and claim 1 , wherein the amount of EPA and DPA is about 55% or more by weight of the total amount of fatty acids claim 1 , and wherein the ratio of DHA:DPA is no more than 1:1.9. The method of claim 8 , wherein the amount of EPA and DPA is selected from the group consisting of about 60% or more claim 8 , about 65% or more claim 8 , about 70% or more claim 8 , about 75% or more claim 8 , about 80% or more claim 8 , about 85% or more claim 8 , and about 90% or more by weight of the total amount of fatty acids.10. The method of claim 1 , wherein the composition comprises further omega-6 fatty ...

METHODS OF ADMINISTERING COMPOSITIONS COMPRISING DOCOSAPENTAENOIC ACID

The present invention relates to compositions comprising docosapentaenoic acid and methods of reducing lipid parameters, such as triglycerides, total cholesterol, low density lipoprotein (LDL) cholesterol, non-HDL cholesterol, free fatty acids, and other lipids, comprising administration of omega-3 docosapentaenoic acid. 1. A method of reducing non-HDL cholesterol levels in a subject from a baseline non-HDL cholesterol level , comprising administering to the subject a composition comprising a daily dosage of docosapentaeoic acid (DPA) of about 120 mg/day to about 150 mg/day.2. The method of claim 1 , wherein the composition comprises a daily dosage of DPA of about 150 mg/day to about 200 mg/day.3. The method of claim 1 , wherein the composition comprises a daily dosage of DPA of about 200 mg/day to about 250 mg/day.4. The method of claim 1 , wherein the composition comprises a daily dosage of DPA of about 250 mg/day to about 300 mg/day.5. The method of claim 1 , wherein the composition comprises a daily dosage of DPA of about 300 mg/day to about 400 mg/day.6. The method of claim 1 , wherein the composition comprises a daily dosage of DPA of about 400 mg/day to about 600 mg/day.7. The method of claim 1 , wherein the composition comprises a daily dosage of DPA of about 600 mg/day to about 1000 mg/day.8. The method of claim 1 , wherein the composition further comprises eicosapentaenoic acid (EPA) and claim 1 , wherein the amount of EPA and DPA is about 55% or more by weight of the total amount of fatty acids claim 1 , and wherein the ratio of DHA:DPA is no more than 2:1.9. The method of claim 8 , wherein the amount of EPA and DPA is selected from the group consisting of about 60% or more claim 8 , about 65% or more claim 8 , about 70% or more claim 8 , about 75% or more claim 8 , about 80% or more claim 8 , about 85% or more claim 8 , and about 90% or more by weight of the total amount of fatty acids.10. The method of claim 1 , wherein the composition comprises further ...

METHODS OF ADMINISTERING COMPOSITIONS COMPRISING DOCOSAPENTAENOIC ACID

The present invention relates to compositions comprising docosapentaenoic acid and methods of reducing lipid parameters, such as triglycerides, total cholesterol, low density lipoprotein (LDL) cholesterol, non-HDL cholesterol, free fatty acids, and other lipids, comprising administration of omega-3 docosapentaenoic acid. 1. A method of increasing a lipid parameter level in a subject from a baseline lipid parameter level , wherein the lipid parameter is selected from the group consisting of HDL cholesterol and apolipoprotein A-I (apo A-I) , comprising administering to the subject a composition comprising a daily dosage of docosapentaenoic acid (DPA) of about 120 mg/day to about 150 mg/day.2. The method of claim 1 , wherein the composition comprises a daily dosage of DPA of about 150 mg/day to about 200 mg/day.3. The method of claim 1 , wherein the composition comprises a daily dosage of DPA of about 200 mg/day to about 250 mg/day.4. The method of claim 1 , wherein the composition comprises a daily dosage of DPA of about 250 mg/day to about 300 mg/day.5. The method of claim 1 , wherein the composition comprises a daily dosage of DPA of about 300 mg/day to about 400 mg/day.6. The method of claim 1 , wherein the composition comprises a daily dosage of DPA of about 400 mg/day to about 600 mg/day.7. The method of claim 1 , wherein the composition comprises a daily dosage of DPA of about 600 mg/day to about 1000 mg/day.8. The method of claim 1 , wherein the composition further comprises eicosapentaenoic acid (EPA) and claim 1 , wherein the amount of EPA and DPA is about 55% or more by weight of the total amount of fatty acids claim 1 , and wherein the ratio of DHA:DPA is no more than 2:1.9. The method of claim 8 , wherein the amount of EPA and DPA is selected from the group consisting of about 60% or more claim 8 , about 65% or more claim 8 , about 70% or more claim 8 , about 75% or more claim 8 , about 80% or more claim 8 , about 85% or more claim 8 , and about 90% or ...

OMEGA-3 PENTAENOIC ACID COMPOSITIONS AND METHODS OF USE

Orally administrable composition comprising fatty acids, wherein at least 50% by weight of the fatty acids comprise omega-3-fatty acids, salts or derivatives thereof, wherein the omega-3 fatty acids comprise eicosapentaenoic acid (EPA; C20:5-n3), docosapentaenoic acid (DPA; C22:5-n3), and docosahexaenoic acid (DHA; C22:6-n3), wherein the ratio of DHA to EPA (DHA:EPA) is less than 1:20, and wherein the ratio of DHA to DPA (DHA:DPA) is less than 2:1 are provided. These compositions can be used for the treatment or prophylaxis of dyslipidemic, cardiovascular, CNS, inflammatory, and other diseases/conditions or risk factors therefore. 1. A pharmaceutical composition comprising fatty acids , wherein at least 50% by weight of the fatty acids comprise omega-3 fatty acids , salts , esters , or derivatives thereof , wherein the omega-3 fatty acids comprise eicosapentaenoic acid (EPA) and docosapentaenoic acid (DPA) and wherein the ratio of docosahexaenoic acid to DHA to EPA (DHA:EPA) is less than 1:10 , and wherein the ratio of DHA to DPA (DHA:DPA) is less than 2:1.2. The pharmaceutical composition of claim 1 , wherein the ratio of DHA:EPA is less than 1:20.3. The pharmaceutical composition of claim 1 , wherein the ratio of DHA:DPA is less than 1:1.4. The pharmaceutical composition of claim 1 , wherein the ratio of EPA to DPA (EPA:DPA) is between 30:1 and 1:1.5. The pharmaceutical composition of claim 1 , wherein the composition comprises DHA in an amount less than 5% of the total amount of fatty acids.6. The pharmaceutical composition of claim 1 , wherein the composition comprises EPA in an amount between about 80% and about 90% of the total amount of fatty acids.7. The pharmaceutical composition of claim 1 , wherein the composition comprises DPA in an amount between about 5% and about 15% of the total amount of fatty acids.8. The pharmaceutical composition of claim 1 , wherein the composition comprises DPA free fatty acid or a salt claim 1 , ester or derivative of DPA.9. ...

Reperfusion with Omega-3 Glycerides Promotes Donor Organ Protection for Transplantation

It has been discovered that isolated organs and tissues perfused/reperfused in perfusion buffer to which omega-3 glyceride oil had been added retain higher levels of function than if perfused/reperfused without the omega-3 glycerides. Isolated hearts reperfused ex vivo after induced ischemia in n-3 triglyceride perfusion emulsion maintained a normal heart rate and normal LVDP and showed a dramatically reduced frequency of arrhythmias compared to control hearts. Further, test hearts reperfused with n-3 oil triglyceride emulsion showed a decrease in creatine kinase and upregulation of certain beneficial proteins including the anti-apoptotic gene marker Bcl-2. 119-. (canceled)20. An omega-3 oil in water emulsion application for perfusion of an organ or tissue ex vivo , wherein the emulsion comprises(a) a perfusion buffer suitable for organ or tissue preservation and transplantation, (i) comprises from about 10% to about 99% omega-3 diglyceride, omega-3 triglyceride or combinations thereof by weight per total weight of the omega-3 oil, and at least about 20% to about 99% of the total acyl groups of the diglycerides and triglycerides comprise EPA or DHA or combinations thereof, and', '(ii) comprises less than 10% omega-6 fatty acids by weight per total weight of the omega-3 oil,, '(b) from about 0.05% to about 0.5% of an omega-3 oil by weight in grams per 100 ml of perfusion buffer, wherein the omega-3 oil'}(c) less than 10% omega-6 oil by weight in grams per 100 ml of perfusion buffer, and(d) the mean diameter of lipid droplets in the emulsion is from about 100 nm to less than about 5 microns.21. The omega-3 oil in water emulsion of claim 20 , wherein the emulsion comprises from about 0.05% to about 0.3% claim 20 , or from about 0.3% to about 1% omega-3 oil by weight in grams per 100 ml of perfusion buffer.22. The omega-3 oil in water emulsion of claim 20 , wherein the emulsion comprises from about 1% to about 5% omega-3 oil by weight in grams per 100 ml of perfusion ...

Method for Increasing Performance of Offspring

Methods and compositions for increasing intestinal transport of nutrients or growth performance in the offspring of an animal are described. More specifically, a feed composition comprising an omega-3 fatty acid-containing composition for increasing intestinal transport of nutrients or growth performance in the offspring of the animal, and methods therefor, are described. 1151.-. (canceled)152. A method of increasing the performance of an animal , the method comprising the steps ofadministering to the animal a feed composition comprising an algal composition comprising omega-3 fatty acids or esters thereof, wherein the omega-3 fatty acids comprise docosahexaenoic acid and eicosapentaenoic acid, wherein the ratio of docosahexaenoic acid to eicosapentaenoic acid in the algal composition is about 60:1 to about 1:1, wherein the feed composition as a final mixture comprises about 0.01% to about 60% by weight of the algal composition, and wherein the animal is a species of poultry; andincreasing the performance of the animal.153. The method of wherein the feed composition as a final mixture comprises about 0.01% to about 4.0% by weight of the algal composition.154. The method of wherein the feed composition as a final mixture comprises about 0.01% to about 3.0% by weight of the algal composition.155. The method of wherein the feed composition as a final mixture comprises about 0.01% to about 1.5% by weight of the algal composition.156. The method of wherein the animal is a chicken.157. The method of wherein the feed composition as a final mixture further comprises omega-6 fatty acids or esters thereof.158. The method of wherein the feed composition is administered daily to the animal.159. The method of wherein the feed composition as a final mixture further comprises an antioxidant.160. The method of wherein the ratio of docosahexaenoic acid to eicosapentaenoic acid is about 10:1.161. The method of wherein the ratio of docosahexaenoic acid to eicosapentaenoic acid is ...

METHODS OF REDUCING THE RISK OF CARDIOVASCULAR EVENTS IN A SUBJECT

In various embodiments, the present disclosure provides methods reducing the risk of cardiovascular events in a subject on statin therapy by administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof. 1. A method of reducing a cardiovascular event in a subject , the method comprising administering daily 4 g of ethyl icosapentate to the subject , wherein the subject is receiving a high intensity statin regimen , has elevated triglyceride levels and (1) established cardiovascular disease , or (2) diabetes and at least two additional risk factors for cardiovascular disease , wherein the high intensity statin regimen comprises about 40 mg to about 80 mg per day of atorvastatin or about 20 mg to about 40 mg per day of rosuvastatin.2. The method of claim 1 , wherein the cardiovascular event is one or more of: myocardial infarction claim 1 , stroke claim 1 , cardiovascular death claim 1 , unstable angina claim 1 , coronary revascularization procedures and/or hospitalizations for unstable angina.3. The method of claim 1 , wherein the subject has a fasting baseline triglyceride level of about 135 mg/dL to about 500 mg/dL.4. The method of claim 1 , wherein the subject has a fasting baseline triglyceride level of at least about 135 mg/dL.5. The method of claim 1 , wherein the administering occurs for at least about 2 years.6. The method of claim 1 , wherein the subject exhibits at least about a 30% reduction in risk for the cardiovascular event.7. The method of claim 1 , wherein the ethyl icosapentate is present in a pharmaceutical composition and the ethyl icosapentate comprises at least about 90 wt. % of all omega-3 fatty acids in the pharmaceutical composition.8. The method of claim 7 , wherein the ethyl icosapentate comprises at least about 96 wt. % of all omega-3 fatty acids in the pharmaceutical composition.9. The method of claim 1 , wherein the at least two additional risk ...

ENHANCED BIOAVAILABILITY OF POLYUNSATURATED FATTY ACIDS

Described herein are pharmaceutical compositions providing enhanced bioavailability of polyunsaturated fatty acids and methods of manufacturing the same. In particular, described herein are pharmaceutical compositions comprising soft enteric capsules that provide enhanced bioavailability of omega-3 polyunsaturated fatty acids. The oral pharmaceutical compositions described herein are useful as nutritional supplements or for the treatment of cardiovascular-related diseases, such as hyper dyslipidemia and moderate to high triglyceride levels. 1. An oral controlled release pharmaceutical composition providing enhanced bioavailability comprising an enteric soft capsule shell encapsulating a matrix fill comprising an omega-3 polyunsaturated fatty acid having enhanced bioavailability.2. The composition of claim 1 , wherein the matrix fill comprises eicosapentaenoic acid (EPA).3. The composition of claim 1 , wherein the matrix fill comprises about 94% EPA free fatty acid.4. The composition of claim 1 , wherein the matrix fill comprises about 250 mg to about 1000 mg of EPA.5. The composition of claim 1 , wherein the omega-3 polyunsaturated fatty acid does not substantially contain docosahexaenoic acid (DHA).6. The composition of claim 1 , wherein upon administration to a subject claim 1 , in vivo absorption and bioavailability of the omega-3 polyunsaturated fatty acid is uneffected by the presence of food in the subject's gastrointestinal tract.7. The composition of claim 1 , wherein the composition reduces the onset or ameliorates the symptoms of any gastrointestinal side effects including claim 1 , but not limited to claim 1 , eructation claim 1 , abdominal discomfort claim 1 , nausea claim 1 , diarrhea claim 1 , fishy aftertaste claim 1 , or fishy odor.8. The composition of claim 1 , wherein the capsule shell and matrix fill composition are stable for at least 1 year at 25° C. claim 1 , 60% relative humidity.9. The composition of claim 1 , wherein the capsule shell does ...

METHODS OF TREATING OTOTOXICITY

The present invention relates to use of DHA analogs and their pharmaceutical compositions for treating ototoxicity, by administering these compounds or pharmaceutical compositions to subjects in need thereof. Ototoxicity is defined as damage to the structures of the ear, such as the cochlea and vestibular system, by drugs or toxins. Ototoxicity can result in irreversible hearing loss, tinnitus, dysequilibrium, Meniere's disease, or vertigo. 2. The method of wherein said compound of Formula I claim 1 , II claim 1 , III claim 1 , or IV claim 1 , or a pharmaceutically acceptable salt claim 1 , ester claim 1 , hydrate claim 1 , solvate claim 1 , prodrug claim 1 , metabolite claim 1 , analog or derivative thereof is in combination with a pharmaceutically acceptable excipient.3. The method of claim 1 , wherein treating ototoxicity comprises delaying the onset or progression of ototoxicity.4. The method of wherein treating ototoxicity comprises alleviating at least one symptom or sign of otoxicity.5. The method of claim 4 , wherein the symptom or sign of ototoxicity is selected from:hearing loss, tinnitus, disequilibrium, Meniere's disease, vertigo, motion sickness, nausea, vomiting, ataxia, labyrinthitis, oscillopsia, dizziness, difficulty walking, difficulty in visual tracking and processing, and reduction of the high frequency range.6. The method of claim 1 , wherein treating ototoxicity comprises prolonging or increasing the survival of the subject suffering from ototoxicity.7. The method of claim 1 , wherein treating ototoxicity comprises reducing cell death or increasing cell survival of a cell from the subject suffering from ototoxicity.8. The method of claim 7 , wherein the cell is a hair cell of the cochlea claim 7 , a cell of the vestibular system claim 7 , a cell of the stria vascularis claim 7 , or an auditory neuron.9. The method of claim 1 , wherein the compound is any one of the compounds listed in Table 1.10. The method of claim 1 , wherein the compound is ...

METHODS OF TREATING MIXED DYSLIPIDEMIA

The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate. 1. A method of reducing triglyceride levels in a subject on an anticoagulant/antiplatelet/thrombolytic therapy , having triglyceride levels of at least about 500 mg/dl , and having atrial fibrillation , the method comprising to the subject about 4 g of ethyl icosapentate per day.2. The method of claim 1 , wherein the subject is on statin therapy.3. The method of claim 1 , wherein the subject has a baseline LDL-C level of about 40 mg/dL to about 100 mg/dL.4. The method of claim 1 , wherein the ethyl icosapentate is present in a pharmaceutical composition and the ethyl icosapentate comprises at least about 96 wt. % of all omega-3 fatty acids in the pharmaceutical composition.5. The method of claim 4 , wherein about 1 g of the pharmaceutical composition is present in each of 4 capsules.6. The method of claim 1 , wherein the subject is administered the icosapent ethyl for a period of at least about 2 years. This application is a continuation of U.S. patent application Ser. No. 16/709,492 filed Dec. 10, 2019, which is a continuation of U.S. patent application Ser. No. 16/179,763 filed Nov. 2, 2018, which is a continuation of U.S. patent application Ser. No. 15/273,430 filed on Sep. 22, 2016 (now U.S. Pat. No. 10,220,013), which is a continuation of U.S. patent application Ser. No. 14/704,329 filed on May 5, 2015 (now U.S. Pat. No. 9,855,237), which is a continuation of U.S. patent application Ser. No. 14/175,602 filed Feb. 7, 2014 (now U.S. Pat. No. 9,056,088), which is a continuation of U.S. patent application Ser. No. 13/898,447 filed on May 20, 2013 (now U.S. Pat. No. 8,691,871), which is a continuation of U.S. patent application Ser. No. 13/540,319 filed on Jul. 2, 2012 (now U.S. Pat. No. 8,618,166), which is a continuation of U.S. patent application Ser. No. 13/417,899 filed on Mar. 12, 2012 (now U.S. Pat. No. 8,563,608), which is a continuation of U.S ...

STABLE PHARMACEUTICAL COMPOSITION AND METHODS OF USING SAME

The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases. 1. A pharmaceutical composition , comprising: omega-3 fatty acids in free acid form including (a) eicosapentaenoic acid in an amount selected from about 925 mg , about 950 mg and about 975 mg; (b) docosapentaenoic acid in an amount of about 5% , by weight of total fatty acids.2. The pharmaceutical composition of claim 1 , wherein the eicosapentaenoic acid is present in an amount of about 925 mg.3. The pharmaceutical composition of claim 1 , wherein the eicosapentaenoic acid is present in an amount of about 950 mg.4. The pharmaceutical composition of claim 1 , wherein the eicosapentaenoic acid is present in an amount of about 975 mg.5. The composition of claim 3 , wherein the composition is present in one or more dosage units.6. The composition of claim 5 , wherein the dosage units comprise capsules.7. A method of reducing triglycerides in a subject in need thereof comprising claim 6 , administering to the subject daily a composition of .8. The method of claim 7 , wherein the subject has very high serum triglycerides. This application is a continuation of U.S. application Ser. No. 15/996,901 filed Jun. 4, 2018 (now allowed), which is a continuation of U.S. application Ser. No. 15/415,468 filed Jan. 25, 2017 (now U.S. Pat. No. 10,010,517), which is a continuation of U.S. application Ser. No. 15/092,391 filed Apr. 6, 2016 (now U.S. Pat. No. 9,585,856), which is a continuation of U.S. application Ser. No. 14/709,937 filed May 12, 2015, which is a continuation of Ser. No. 14/259,724 filed Apr. 23, 2014 (now U.S. Pat. No. 9,072,715), which is a continuation of U.S. application Ser. No. 14/084,887 filed Nov. 20, 2013 (now U.S. Pat. No. 9,060,982), which is a continuation of U.S. application Ser. No. 13/685,291 filed Nov. 26, 2012 (now U.S. Pat. No. 8,613,945), which is a ...

NANOPARTICLES COMPRISING A VEGETABLE HYDROPHOBIC PROTEIN AND A WATER MISCIBLE NON-VOLATILE ORGANIC SOLVENT AND USES THEREOF

The present invention relates to nanoparticles for encapsulating compounds, the preparation and uses thereof, said nanoparticles being based on a vegetable hydrophobic protein, particularly zein, and a water miscible non-volatile organic solvent, particularly propylene glycol. Said nanoparticles can encapsulate or incorporate a product of interest for use in the agricultural, cosmetic, food or pharmaceutical fields. 120-. (canceled)22. The nanoparticle according to claim 21 , further comprising a product of interest.23. The nanoparticle according to claim 21 , wherein the prolamine is zein.24. A process for producing a nanoparticle selected from the group consisting of:(i) a matrix nanosphere, wherein said matrix nanosphere comprises a matrix, said matrix comprising a vegetable hydrophobic protein and at least a water miscible non-volatile organic solvent,said process comprising contacting a solution of the vegetable hydrophobic protein in at least a water miscible non-volatile organic solvent with a vegetable hydrophobic protein non-solvent in order to form said nanoparticle andwherein the solution of the vegetable hydrophobic protein does not comprise a volatile organic solvent,wherein the vegetable hydrophobic protein is a prolamine and,wherein the water miscible non-volatile organic solvent is propylene glycol or a mixture of propylene glycol and other primary and/or secondary solvents;(ii) a matrix nanosphere comprising a product of interest, wherein said matrix nanosphere comprises a matrix, said matrix comprising a vegetable hydrophobic protein and at least a water miscible non-volatile organic solventsaid process comprising contacting a solution, suspension or emulsion comprising the vegetable hydrophobic protein and the product of interest in at least a water miscible non-volatile organic solvent with a vegetable hydrophobic protein non-solvent in order to form said nanoparticle andwherein the solution, suspension or emulsion comprising the vegetable ...

TOPICAL COMPOSITIONS FOR TREATMENT OF SKIN CONDITIONS

The invention provides a topical formulation adapted for treatment of a skin condition comprising (i) at least one retinoid; and (ii) salicylic acid or an ester, amide, salt, or solvate thereof. The invention also includes a kit for treatment of skin conditions comprising a retinoid and salicylic acid, as well as a method of treating skin conditions utilizing the inventive formulation and kit. 131-. (canceled)33. The method according to claim 32 , wherein the one or more C12-C16 alcohols comprises cetyl alcohol.34. The method according to claim 32 , wherein the one or more polyols comprises one or both of glycerin and ethoxydiglycol.35. The method according to claim 32 , wherein the composition further comprises one or both of polyethylene glycol (PEG) and xanthan gum.36. The method according to claim 32 , wherein the skin condition is selected from the group consisting of acne vulgaris claim 32 , cystic acne claim 32 , hyper-pigmentation claim 32 , hypo-pigmentation claim 32 , dermal hypoplasia claim 32 , epidermal hypoplasia claim 32 , dermal keratosis claim 32 , epidermal keratoses claim 32 , wrinkles of the skin as an incident of aging claim 32 , enlarged pores claim 32 , surface roughness claim 32 , ichthyoses claim 32 , follicular disorders claim 32 , benign epithelial tumors claim 32 , perforated dematoses claim 32 , disorders of keratinization claim 32 , and combinations thereof.38. The method according to claim 37 , wherein said co-administration comprises sequential administration in any order.39. The method according to claim 37 , wherein the second composition comprises a cleanser.40. The method according to claim 37 , wherein the second composition comprises a moisturizer.42. The composition according to claim 41 , wherein the one or more C12-C16 alcohols comprises cetyl alcohol.43. The composition according to claim 41 , wherein the one or more polyols comprises one or both of glycerin and ethoxydiglycol.44. A kit comprising at least two containers ...

COMPOSITION FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASES, CONTAINING DITERPENE-BASED COMPOUND

The present invention relates to a pharmaceutical composition for preventing or treating neurodegenerative diseases comprising a diterpene, or a pharmaceutically acceptable salt thereof. 2. The pharmaceutical composition for the prevention or treatment of neurodegenerative diseases according to claim 1 , wherein the diterpenes is one of the compounds represented by Formulas 2 claim 1 , 8 claim 1 , 13 claim 1 , 14 or 16.3. The pharmaceutical composition for the prevention or treatment of neurodegenerative diseases according to claim 1 , wherein the diterpene is the compound represented by Formula 2.4. The pharmaceutical composition for the prevention or treatment of neurodegenerative diseases according to claim 1 , wherein the diterpene is the compound represented by Formula 14.5. The pharmaceutical composition for the prevention or treatment of neurodegenerative diseases according to claim 1 , wherein the neurodegenerative diseases may be any one selected from the group consisting of Parkinson's disease (PD) claim 1 , Alzheimer's disease (AD) claim 1 , amyotrophic lateral sclerosis (ALS) claim 1 , Huntington's disease (HD) claim 1 , Fronto-Temporal Dementia claim 1 , Cortico Basal Degeneration claim 1 , and Progressive supranuclear palsy (PSP).6. The pharmaceutical composition for the prevention or treatment of neurodegenerative diseases according to claim 1 , wherein the neurodegenerative disease is Parkinson's disease (PD).7Daphne genkwa.. The pharmaceutical composition for the prevention or treatment of neurodegenerative diseases according to claim 1 , wherein the diterpene is separated from the extract of flower of9. A dietary supplement for preventing or improving of neurodegenerative diseases according to claim 8 , wherein the neurodegenerative diseases may be any one selected from the group consisting of Parkinson's disease (PD) claim 8 , Alzheimer's disease (AD) claim 8 , amyotrophic lateral sclerosis (ALS) claim 8 , Huntington's disease (HD) claim 8 , ...

METABOLISM-IMPROVING AGENT COMPRISING RARE FATTY ACID

The present invention provides a metabolism improving agent containing a rare fatty acid such as hydroxylated fatty acid, oxo fatty acid and the like, and further, food, pharmaceutical product and the like containing the metabolism improving agent. 115.-. (canceled)16. A method for the prophylaxis or treatment of a disease relating to metabolism , comprising administering to a patient an effective amount of a fatty acid that is(1) a fatty acid having 18 carbon atoms and a hydroxyl group or carbonyl group at the 13-position,(2) a fatty acid having 20 carbon atoms and a hydroxyl group or carbonyl group at the 15-position,(3) a fatty acid having 20 carbon atoms and a hydroxyl group or carbonyl group at the 12-position, or(4) a fatty acid having 16 carbon atoms and a hydroxyl group or carbonyl group at the 10-position.17. The method according to claim 16 , wherein the disease relating to metabolism is at least one kind selected from the group consisting of obesity claim 16 , diabetes claim 16 , lipid metabolism abnormality claim 16 , hyperlipidemia claim 16 , and fatty liver.1821.-. (canceled)22. The method according to claim 16 , wherein the fatty acid is(1) a saturated fatty acid or an unsaturated fatty acid having at least one cis double bond at the 6-position, the 9-position, the 15-position, which has 18 carbon atoms and a hydroxyl group or carbonyl group at the 13-position,(2) an unsaturated fatty acid having at least one cis double bond at the 5-position, the 8-position, the 11-position, the 17-position, which has 20 carbon atoms and a hydroxyl group or carbonyl group at the 15-position,(3) a saturated fatty acid or an unsaturated fatty acid having at least one cis double bond at the 5-position, the 8-position, the 14-position, the 17-position, which has 20 carbon atoms and a hydroxyl group or carbonyl group at the 12-position, or(4) a saturated fatty acid having 16 carbon atoms and a hydroxyl group or carbonyl group at the 10-position.23. The method according to ...

Compositions and Methods for Treating Non-Alcoholic Steatohepatitis

Compositions and method are disclosed comprising ethyl icosapentate for use in treatment of non-alcoholic steatohepatis (NASH).

A COMPOSITION FOR ENHANCING NEWBORN INFANT COGNITIVE, BRAIN AND/OR CNS DEVELOPMENT AND METHOD OF USING SAME

Disclosed are nutritional compositions generally, and infant formulas specifically, that include a combination of RRR-alpha tocopherol, fat, and protein. The amount of non-RRR alpha tocopherol stereoisomers in the nutritional compositions is limited Also disclosed are methods of using the compositions to improve cognitive, brain and/or central nervous system development in an individual. 1. A nutritional composition comprising:i) from about 20 to about 50 g/L fat;ii) from about 10 to about 15 g/L protein;iii) from about 5 mg/L to about 100 mg/L RRR-alpha tocopherol;iv) less than about 8 mg/L of non-RRR alpha tocopherol isomers;v) from about 60 mg/L to about 180 mg/L of DHA;vi) from about 120 mg/L to about 360 mg/L of ARA; andvii) at least about 130 mg/L of ascorbic acid;wherein the DHA to RRR-alpha tocopherol ratio is from about 7.5:1 to about 20:1 and the ARA to RRR-alpha tocopherol ratio is from about 15:1 to about 40:1.2. The nutritional composition of claim 1 , wherein the nutritional composition is substantially free of the non-RRR alpha tocopherol isomers.3. The nutritional composition of claim 1 , wherein the nutritional composition comprises less than about 0.5 mg/L of the non-RRR alpha tocopherol isomers.4. The nutritional composition of claim 1 , wherein the nutritional composition comprises less than about 5 mg/L of the non-RRR alpha tocopherol isomers.5. The nutritional composition of claim 1 , wherein the nutritional composition further comprises a carotenoid.6. The nutritional composition of claim 5 , wherein the carotenoid comprises all trans-lutein.7. The nutritional composition of claim 1 , wherein the nutritional composition is a liquid nutritional product.8. The nutritional composition of claim 1 , wherein the nutritional composition is a powdered nutritional product.9. The nutritional composition of claim 1 , wherein the nutritional composition is an infant formula.10. A method for enhancing central nervous system development in an individual ...

COMPOSITIONS COMPRISING 15-HEPE AND METHODS OF USING THE SAME

The present disclosure relates to the compositions, formulations and methods of treating or preventing diseases mediated by peroxisome proliferator-activated receptors (PPARs) by administration of 15-HEPE. 1. A method for treating or preventing a disease mediated by peroxisome proliferator-activated receptors (PPARs) in a subject comprising , administering to the subject pharmaceutical composition comprising 15-HEPE to treat or prevent the disease in the subject.2. The method of claim 1 , wherein the disease is selected from impaired insulin sensitivity claim 1 , psoriasis claim 1 , cancer claim 1 , fibrosis claim 1 , melanoma claim 1 , neurodegenerative disorders claim 1 , Huntington's disease claim 1 , inflammatory diseases claim 1 , adipocyte differentiation claim 1 , fertility or reproduction diseases claim 1 , pain claim 1 , and obesity.3. The method of claim 1 , wherein the 15-HEPE is present in the composition in an amount from about 50 mg to about 1000 mg.4. The method of claim 1 , wherein the 15-HEPE represents at least about 90% of all fatty acids present in the composition.5. The method of claim 1 , wherein the 15-HEPE represents substantially all fatty acids present in the composition.6. The method of claim 1 , wherein the 15-HEPE represents all fatty acids present in the composition.7. The method of wherein the composition is free of any other omega-3 fatty acids.8. The method of claim 1 , wherein the administering step includes administering the pharmaceutical composition to the human subject about 1 to about 4 times per day.9. The method of claim 1 , wherein the pharmaceutical composition comprises an orally deliverable capsule.10. The method of claim 1 , wherein the human subject has a predisposition to and/or a diagnosis of the liver disease.11. A method for treating or preventing a disease mediated by peroxisome proliferator-activated receptors (PPARs) in a subject comprising claim 1 , administering to the subject pharmaceutical composition ...